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SUMMARY
V-acetyl transferase 1 and 2 are metabolic enzymes involved in the detoxification 
or bioactivation of aromatic amines. The development of transitional cell carcinoma of 
the bladder is associated with exposure to chemical carcinogens, either from 
occupational exposure or through smoking, and many chemical carcinogens are aromatic 
amines. The genes that encode the V-acetyl transferase enzymes are polymorphic, and 
particular alleles are associated with an increased incidence of bladder cancer.
Transitional cell carcinoma of the bladder is the fourth commonest cancer in the 
UK and USA. Repeated recurrences (in up to 80% of patients), place an individual at 
increased risk of developing muscle invasion. However it is not possible to predict, 
from clinical and pathological data, which index (primary) carcinomas will recur. Due 
to the increased risk of recurrence and progression of non-muscle-invasive transitional 
cell carcinoma, patient management involves prolonged clinical follow-up as at present 
there are no reliable markers to predict the biological behaviour of an index, non- 
invasive transitional cell carcinoma.
Intensive scientific research over the past decade into genetic mechanisms 
involved in transitional cell carcinoma has established two distinct genetic pathways to 
progression, and recently markers of recurrence have also begun to emerge.
The aim of this study was to use a DNA probe for the A-acetyl transferase 2 gene 
{NAT2) and to investigate whether genetic abnormalities at this locus contribute to 
recurrence or progression in an index, non-muscle-invasive transitional cell carcinoma, 
and whether patients who present with muscle-invasive transitional cell carcinoma (stage 
pT2 and above) have an abnormal genotype. NAT2 is on chromosome 8p, a region 
commonly aberrent in many carcinomas including bladder. In order to achieve this aim, 
it was necessary to obtain a cosmid containing the NAT2 sequence, label the cosmid to 
produce a probe for fluorescence in situ hybridisation, and then to apply the technique to 
formalin fixed paraffin processed sections of transitional cell carcinomas. This process 
proved technically challenging, but once the methodology was working consistently well 
on formalin fixed paraffin processed control material, sections of transitional cell 
carcinomas were assessed in a dual labelling technique with the NAT2 probe and an 
alpha centromeric probe for chromosome 8.
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Nineteen patients were assessed, with full clinical follow-up (median=55 
months), in eight of whom carcinomas recurred. Fluorescence in situ hybridisation was 
also applied to the recurrences, and a total of 37 carcinomas were assessed.
Of the 19 primary carcinomas assessed, five were muscle-invasive at 
presentation (stage pT2 or above), the remainder were stage pTa or pTl. All five 
muscle-invasive carcinomas had polysomy of chromosome 8, four of whom also had 
abnormal NAT2 copy number. Another six primary carcinomas (all stage pTa or pTl) 
had abnormal chromosome 8 and/or NAT2 copy number. Of the 18 recurrences, 9 were 
abnormal for chromosome 8 and/or NAT2 copy number, eight of which were in patients 
who progressed at recurrence to muscle invasion (pT2 or above).
Overall, a high proportion of carcinomas 54% (20/37) when assessed by mean 
chromosome or gene copy number, were abnormal for either gene or chromosome copy 
number or both, and this was significantly associated with high grade, p=0.014 and stage 
pT2 or above, p=0.039. There were more abnormalities in patients with detrusor muscle 
-  invasive disease.
Few studies of abnormalities of gene and/or chromosome copy number in 
transitional cell carcinoma of the bladder achieve full clinical follow-up, and are unable 
to relate their findings to the clinical course of the disease. The abnormalities of NAT2 
demonstrated in this study were more common in patients with muscle-invasion at some 
point in their disease history, linking abnormal function of A-acetyl transferase 2 with 
aggressive disease course. Polysomy 8 was also common, and abnormalities of 
chromosome 8 have been previously been associated with late stage progression in 
transitional cell carcinoma.
In conclusion, by studying the gene and chromosome copy number of NAT2 and 
chromosome 8 in index transitional cell carcinomas and any subsequent recurrences 
further understanding of the role of metabolic enzymes in transitional cell carcinoma has 
been realised. For molecular biology to have any impact on patient management, studies 
such as this one, recapitulated with larger numbers, will begin to become a much needed 
additional tool in the accurate diagnosis and management of this complex cancer.
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ABBREVIATIONS
TCC = transitional cell carcinoma of the urinary bladder
NR = non-recurrer, individual who presented with a single episode of non-detrusor- 
muscle-invasive TCC and no further recurrence, median follow-up 79 months (range 24- 
106 months).
RNP = recurrer-non-progressor, an individual who, following an initial presentation with 
non-detrusor-muscle-invasive TCC, subsequently recurred, but did not progress to 
detrusor-muscle-invasion, median follow-up 40.5 months (range 18-135 months).
RP = recurrer progressor, an individual who following an initial presentation with non­
detrusor-muscle-invasive TCC, subsequently developed detrusor-muscle-invasion, 
median follow-up 37 months (range 14-152 months).
PP = progressed at presentation, an individual with detrusor-muscle-invasion at first
presentation.
pTa = superficial TCC
pTl = TCC locally invasive to the sub mucosa (lamina propria) 
pT2 = TCC invasive to detrusor-muscle layers 
NAT2 = the gene for the metabolic enzyme N- acetyl transferase 2 
FISH = fluorescence in situ hybridisation
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CHAPTER 1 INTRODUCTION & STUDY AIMS
1.1 Bladder Cancer
Bladder cancer is the fourth commonest neoplasm in the UK. The incidence of 
bladder cancer has risen 3-fold over the last 30 years (Office of Population Censuses and 
Studies, 1969-1987; 1971-1984), as illustrated in Figure 1. The causes of bladder cancer 
are multifactorial but exposure to chemical carcinogens, for example from smoking or as 
an occupational hazard, is thought to be particularly important (Sandberg & Berger
1994). Bladder cancer is the fifth commonest cause of deaths in the UK, 5800 die 
annually in England and Wales (Abdel-Fattah et al, 1998), 450 annually in Scotland 
(Scottish Cancer Registry, 1995).
1.1.1 Clinical Presentation
The bladder is a reservoir for urine and lies in the pelvic cavity; its size and 
position vary depending on the amount of urine it contains. The bladder wall is 
composed of three layers (illustrated in Figure 2). The outer layer, of loose connective 
tissue containing nerves, blood and lymphatic vessels, is covered on the upper surface by 
peritoneum. The middle layer of interlacing smooth muscle fibres and elastic tissue 
loosely arranged in three layers forms the detrusor muscle which empties the bladder 
when it contracts. The inner layer is a lining of transitional epithelium and subjacent 
connective tissue. When 300-400ml of urine have accumulated afferent autonomic 
nerve fibres in the bladder wall sensitive to stretch are stimulated. Micturition occurs 
when the detrusor muscle contracts, there is a reflex relaxation of the internal sphincter 
and voluntary relaxation of the external sphincter (Wilson & Waugh 1996).
The majority of bladder cancers (90%, Raghavan et al, 1990, Soloway, 1992) are 
transitional cell carcinomas. Much less commonly, squamous cell carcinomas (Cotran, 
1987), adenocarcinomas (2.5%), sarcomas, melanomas, small-cell undifferentiated 
carcinomas or métastasés from other primary tumours may occur in the bladder 
(Raghavan et al, 1990). Clinical appearance of transitional cell carcinoma varies from a 
single superficial, non-invasive low-grade papillary lesion to numerous or extensive 
highly malignant anaplastic tumours (Raghavan et al, 1990). The latter account for 20% 
of transitional cell carcinomas and have a poor prognosis (5 year survival 35%) 
(Knowles, 1995) as they tend to be detrusor-muscle-invasive. Fifty to 70% of non- 
invasive transitional cell carcinomas will develop recurrence (van der Meijden, 1998)
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about 20% of which will progress to muscle-invasion (reviewed by Adshead et al, 
1998),
1.1.2 Clinical Staging
Although the histogenesis of transitional cell carcinoma is unclear (Raghavan et 
al, 1990) a classification of urothelial tumours has emerged following TNM guidelines 
which gives a clinical and a pathological basis to the diagnosis (Sobin and Wittekind,
1997). The classification system is summarised in Figure 3 (van der Meijden, 1998).
This system of classification came about after repeated observations that survival 
and recovery rates were higher for patients with localised disease compared to those with 
invasive disease. Using the TNM classification, conformity between clinicians is 
achieved and appropriate treatment can be planned (Pavone-Macaluso, 1984, Droller, 
1985), although T2 and T3 transitional cell carcinoma cannot be distinguished in 
cystoscopic biopsies. The T stages of bladder tumours are illustrated in Figure 4 
(Cotran, 1987).
1.1.3 Pathological Staging
Pathological examination of a diagnostic bladder tumour biopsy covers three 
stages. First it must be established that the lesion is truly neoplastic, and the cell type 
identified. As indicated above, the commonest bladder tumours are transitional cell 
carcinoma, with occasional metaplastic squamous or glandular areas. True squamous 
carcinomas are rare in the West but are the commonest bladder cancers in Egypt due to 
urinary schistosomiasis (Bedwani et al, 1998).
Secondly, the lesion is graded using TNM guidelines i.e. grade 1, well 
differentiated; grade 2, moderately differentiated; grade 3/4, poorly/undifferentiated 
(Sobin and Wittekind, 1997).
Finally, the stage is assessed as far as possible based on observations of the 
overall growth pattern and the presence or absence of invasion by the lesion i.e. in situ 
pTis, papillary non invasive pTa, papillary invasive pTl, papillary and solid pT2 and, 
where the true extent of invasion cannot be assessed, pTx. The prefix “p” is used to 
denote a pathological diagnosis, as opposed to the “T” classification, without the “p” 
denoting the clinical diagnosis.
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Figure 1: Incidence of Bladder Cancer in Scotland
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This graph illustrates the increasing incidence of bladder cancer in Scotland
Figure 2 The Structure of the Bladder Wall
IL = inner longitudinal smooth muscle layer; OC = outer circular smooth muscle layer 
OL = outer longitudinal smooth muscle layer; A = adventitia
Figure 3 Tumour Staging According to the TNM System, 1997. 
(reproduced from van der Meijden, 1998).
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Prostate gland
Urethra
A method of classification o f urothelial tumours which involves staging, depending on 
the degree of invasion Ta=non invasive papillary; Tis=flat carcinoma in situ, 
Tl=locally invasive to the submucosa (lamina propria); T2=invasive o f the muscularis; 
T3a=beyond muscularis microscopically; T3b=extra vesicular mass; T4a=infiltration of 
prostate, uterus or vagina; T4b-fixation to the pelvis or abdominal wall (Sobin & 
Wittekend, 1997).
Figure 4: The Four Morphological Patterns of Bladder Cancer
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This diagram illustrates the main features of the four commonest forms of bladder cancer
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1.1.4 Treatment and Patient Management
Eighty-five percent of transitional cell carcinoma patients present with gross or 
microscopic haematuria at some point but this is intermittent, even when caused by 
muscle invasive transitional cell carcinoma (Goldstein & Messing, 1998). But because 
of the low specificity and pick-up rate, despite the high sensitivity, haematuria is not 
used as a screening test for the presence of transitional cell carcinoma. Repeated tests 
would need to be carried out to enable a diagnosis of transitional cell cai'cinoma to be 
made (Goldstein & Messing, 1998). Urgency and frequency may also reflect the 
presence of carcinoma in situ (Droller, 1985).
Bladder cancer is commoner with advancing age, and older patients have more 
poorly differentiated, invasive tumours than younger patients (Anderson, 1982). 
Increasing incidence with age is well established but not fully understood, although 
several genetic aberrations are required for a tumour to become fully malignant (Nowell, 
1976). The latency associated with exposure to environmental carcinogens and the 
development of cancers, for example >15 years for asbestos and the development of 
mesothelioma (Attanoos & Gibbs, 1997) and up to 40 years for bladder cancer (Risch et 
al, 1995) supports this paradigm.
Three times as many men as women develop bladder cancer, a phenomenon that 
has been known for many years (Case et al, 1954, Raghavan et al, 1990). The reasons 
for this are unclear, although the majority of cases have been attributed to environmental 
exposure in industries predominantly occupied by men. In addition, the exposure to 
many carcinogens in developed countries is now strictly limited by industrial health and 
safety legislation.
Urine cytology, the simplest and least invasive diagnostic procedure, has a poor 
record for detecting malignant cells. Low grade carcinomas are less likely to to shed 
cells, due to the low rate of cell turnover. A higher percentage of positive samples are 
observed with grades 2 and 3 transitional cell carcinoma. Despite its poor sensitivity, 
urine cytology is used in occupational screening of workers at high risk of occupational 
bladder cancer. Results have been encouraging with a higher pick-up rate of positive 
cytology than in the general population (Droller, 1985).
Bladder washings increase the diagnostic yield possibly because low-grade 
tumours may shed papillary fronds through this procedure (Droller, 1985), increasing the
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detection rate for low-grade carcinomas. Cystoscopy is the gold standard for diagnosis, 
allowing a direct view and biopsy of the mucosa (Steiner et al, 1997).
1.1.5 Treatment and Follow-up of Superficial Transitional Cell Carcinoma
Initial treatment of superficial and superficially locally invasive carcinomas (pTa, 
pTl and carcinoma in situ) is usually by transurethral resection (Holmang et al 1995), 
diathermy or both (Raghavan et al, 1990). This is followed by surveillance 
cystoscopies, usually 3 monthly for the first year, 6 monthly for the second year and then 
annually (Tolley et al, 1996), unless there is a recurrence in which case the above 
sequence is repeated. After several recurrences, especially if the tumours become 
muscle invasive, cystectomy may eventually be performed. Cystectomy may be 
required earlier in cases of carcinoma in situ, a high grade lesion entirely different to 
non-invasive papillary transitional cell carcinoma.
Reducing the recurrence of transitional cell carcinoma and thus the number of 
cystoscopies due to its high prevalence is the aim of several researchers, who 
acknowledge that this would reduce patient trauma and cut down the resources allocated 
to management of transitional cell carcinoma. Holmang and co-workers(1995) argue 
that patients with low-grade superficial carcinomas i.e. pTaGl treated by transurethral 
resection of the tumour are at low risk of recurrence and are effectively cured by this 
procedure. But in patients with frequent recurrences of multifocal carcinomas, which 
carry an increased risk of progression to muscle invasion relative to patients with non­
recurrent disease, Holmang and co-workers (1995) suggested earlier and more 
aggressive treatment, i.e. with intravesical chemotherapy or cystectomy. With the 
conventional management of superficial transitional cell carcinoma, i.e. transurethral 
resection of the tumour and/or diathermy or cystectomy, long-term survival of patients 
with superficial transitional cell carcinoma has been achieved in 80% of cases, but 
complete cure rate remains at less than 50% of all cases diagnosed (Raghavan et al 
1990). These statistics have remained constant over the past ten years (van der Meijden,
1998).
Chemotherapy of superficial transitional cell carcinoma has included intravesical 
chemotherapy, in which cytotoxic agents are instilled by a urinary catheter directly into 
the bladder, has been more widely applied over the past 20 years than previously 
(Raghavan et al, 1990, Holmang et al, 1995, Tolley et al, 1996). Prolonged disease-free
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interval after transurethral resection of the tumour was observed if agents such as 
thiotepa, eoglucid, doxorubicin or mytomycin C were administered (Raghavan et al, 
1990). A large randomised trial (Tolley et al, 1996) demonstrated decreased reeurrence 
rates and increased disease free intervals (decreased recurrence risk of 15%) after 
intravesical mytomycin C was administered for newly diagnosed superficial bladder 
cancer, with follow-up over seven years. There appeared to be no significant benefit to 
giving repeated instillations.
In a separate trial, by the Genito-Urinary Group of the European Organization for 
Research and Treatment of Cancer, a single instillation of epirubiein was effective at 
decreasing recurrence (nearly 71% of treated patients were free of recurrence after 2 
years compared to the 59% in the control group), and that recurrence rate was 
approximately halved by use of a single installation of epirubiein (Oosterlinck et al, 
1993).
An alternative treatment involves the administration of the BCG (bacillus 
Calmette-Guerin) vaccine. This form of immunotherapy appears to be most effective in 
carcinoma in situ (Raghavan et al, 1990). A comparison between BCG and doxorubicin 
for carcinoma in situ showed remission in 74% of cases treated with BCG as opposed to 
42% treated with doxorubicin, with a median disease free interval of 48 months for BCG 
treated patients, 5.9 months for doxorubicin, (Hudson & Herr, 1995). Immunotherapy 
rather than cystectomy has been recommended as the initial treatment for CIS (Hudson 
& Herr, 1995).
At present clinical management of either superficial transitional cell carcinoma 
or carcinoma in situ involves repeat cystoscopies with transurethral resection of the 
tumour that may incorporate diathermy followed by instillation chemotherapy or 
immunotherapy and/or cystectomy.
1.1.6 Treatment and Follow-up of Muscle-invasive Transitional Cell 
Carcinoma:
The two classic ways to treat muscle invasive disease are surgery and/or 
radiotherapy. Radical cystectomy (involving excision of the bladder and contiguous 
organs and tissues as a block) is associated with improved survival rates over simple 
cystectomy (where only the bladder is removed). Actuarial five year survival rates of 
35% to 75% have been reported following cystectomy and lymphadenectomy (Raghavan
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et al, 1990). The higher survival rates were observed in patients with disease confined to 
the bladder and contiguous organs. Radiotherapy has been less widely used in the past 
30 years compared to in previous years, but with the recent development o f precise 
delivery of radiation through computerised tomography scans, this treatment modality 
has been revived.
Despite improvements in surgical and radiotherapy techniques, survival of 
patients has not changed. Up to 50% develop métastasés and die within 5 years 
(reviewed by van der Meijden, 1998), and consequently other approaches in the 
management of advanced TCC have been investigated. Neoadjuvant chemotherapy 
whereby the chemotherapeutic agent is administered before surgery or radiotherapy may 
confer benefits such as reducing tumour bulk and minimising micrometastatic disease, 
although patients must be in good health otherwise before beginning this type of 
treatment. With this approach, 5 year actuarial survival rates of 35%-70% have been 
reported (reviewed in Raghavan et al, 1990) and quality of life has been improved.
1.1.7 Pathology
Disparities exist in the pathological reporting of bladder carcinomas, with high 
inter- and intra-observer variability and inconsistency in the assessment of clinically 
important data. When bladder tumours were reassessed seven months later by the same 
group of pathologists who had made the original diagnosis, there was inconsistency of 
reporting WHO grade in almost 50% of cases (Ooms et al, 1982). Potentially important 
considerations are raised as grade 1 and grade 3 carcinomas will be treated differently. 
Although there does appear to be wide variation in the consistency of reporting of 
bladder tumours, a higher percentage of conformity was observed by Witjes and co­
workers (1994) than the study by Ooms and co-workers (1982) with figures of 79.3% for 
stage and 70.2% for grade. They claimed that although review of pathology caused 
considerable changes in the results, there was no change to treatment and virtually no 
difference in the results of a prognostic factor analysis. There remains controversy over 
these inconsistencies and additional work is required to address this problem.
1.1.8 Summary
Bladder cancer, in particular its commonest form, transitional cell carcinoma is a 
dichotomous disease which can present as a superficial lesion or an aggressive high 
grade lesion. There are strong links to environmental factors. The rising incidence and
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high prevalence of transitional cell carcinoma mandate early and accurate diagnosis. 
The development of new techniques of management such as intravesical chemotherapy 
in tandem with the pathological diagnosis is improving the disease free interval and 
possibly rates of cure. However, it is well known that two morphologically similar 
tumours can behave differently, implying that the biology of transitional cell carcinoma 
remains poorly understood.
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1.2 The Genetics of Cancer
Observations were made in the early 1900’s linking cancer with cellular 
abnormalities. In his only theoretical paper, published in English in 1929, Theodore 
Boveri proposed that cancers arose from abnormalities that occur in chromosomes 
during faulty cell division. But it was not until the 1950’s, when the technique of 
karyotyping was developed, that chromosomes could be identified, and another 20 years 
before the connection between abnormal chromosomes and cancer was made (reviewed 
by Bodmer & McKie, 1995).
Cancer has many causes. Biological, chemical and physical agents initiate or 
promote neoplastic processes. However, almost all carcinogens are genotoxic and cause 
somatic derangements (Cordon-Cardo & Sheinfeld, 1997). Several genetic aberrations 
are required for cells to develop full malignant potential (Nowell, 1976). Inherited 
(germline) and acquired (somatic) mutations can be implicated in this process. Genes 
involved in carcinogensis have been categorised as tumour suppressors or oncogenes. 
Recently a new type of carcinogenic mutation has been described, the mutator genotype 
(Loeb, 1997).
1.2.1 Genes involved in Carcinogenesis
1.2.1.1 Tumour Suppressor Genes
Tumour suppressor genes encode a diverse group of proteins which, through a 
variety of mechanisms, function to negatively regulate cell growth and development 
(Brown, 1997). Tumour suppressor genes have been recognised since the 1970’s as a 
result of studying the patterns of inheritance of the childhood tumour retinoblastoma. 
Alfred G. Knudson (1978) in his “two hit” theory stated that genetic susceptibility to 
cancer could be explained by inactivation of one allele in the germ line of affected 
patients with the other allele then deleted or mutated in a somatic cell (reviewed by 
Brewster et al, 1992). This concept as applied to sporadic cancers involves a loss of 
function mutation of one allele followed by a somatic mutation affecting the other allele.
Genetic aberrations may occur by point mutation, rearrangement or deletion. 
Allelic loss, determined by loss of heterozygosity (LOH) analysis, is a hallmark of 
tumour suppressor loci. For example, the p i6 protein plays a critical role in cell-cycle 
regulation via binding and inhibition of cyclin dependent kinases. The gene has been 
mapped to 9p21, a region which shows LOH in many carcinomas including those of
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breast, lung, prostate and bladder (Foresman & Messing, 1997). The retinoblastoma 
(Rb) gene, also mutated in many cancers, encodes a nuclear phosphoprotein that 
functions as a cell cycle regulator (Romkes et al, 1996). Many tumour suppressor genes 
have key roles in cell cycle control, disruption of which can undermine genome stability.
1.2.1.2 Oncogenes
There are cellular genes (proto-oncogenes) that in another form (oncogenes) can 
cause neoplastic growth (Bishop, 1987). Specific alterations to these genes promote 
tumour growth in a dominant manner. A single “hit” may therefore activate these genes, 
usually by point mutation, amplification or gene rearrangement. Studies with 
retroviruses have shown that viral DNA can be integrated into host DNA, and the viral 
genes can then be expressed via the cell’s own machinery (Bishop, 1987). Most proto­
oncogenes, when expressed at high levels experimentally, can transform established cell 
lines. At least 40 oncogenes have been identified, with functions as varied as c~myc, 
which encodes a nuclear phosphoprotein involved in transcriptional regulation (Sauter et 
al, 1995c) and c~erhB2 which encodes a transmembrane receptor-like protein with 
sequence homology to epithelial growth factor receptor (Coussens et al, 1985).
The action of tumour suppressor genes is in general opposite to that of 
oncogenes. Tumour suppressor genes are inactivated in cancer cells, and the 
introduction of functional tumour suppressor genes from normal cells into cancer cells 
may result in loss of tumourigenicity. In contrast, oncogenes are activated in cancer 
cells, and their introduction into normal cells leads to tumour formation (Sidransky,
1995).
1.2.1.3 Mutator Genes
A new class of recessive cancer genes (mutator genes) has recently been 
described. The expansion and contraction of tandem repetitive nucleotide sequences 
(microsatellites) in many human tumours, but not in non-malignant cells, provided the 
first strong evidence for a mutator phenotype in cancers. Tumours with microsatellite 
instability frequently contain mutations in mismatch repair genes (reviewed by Loeb, 
1997). For example, the genes MSHl and MLHl encode proteins for DNA mismatch 
repair, loss of which would make cells replication-error prone, (reviewed in Reznikoff et 
al, 1996). Microsatellite instability has been investigated in many cancers although so 
far there has only been one heritable cancer syndrome causally linked to defective 
mismatch repair genes (including MSH2 and MLHl), hereditary non-polyposis 
colorectal cancer (Lynch syndrome) (reviewed in Knowles, 1998). However, in sporadic
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cancers such as bladder cancer there have also been reports of microsatellite instability 
(reviewed by Reznikoff et al, 1996).
1.2.2 A Genetic Model for Cancer Progression
The model of tumour formation and progression proposed by Fearon and 
Vogelstein (1990) for colorectal cancer has become a paradigm for the study of many 
other cancer types (see Figure 5, Sidransky, 1995). This hypothesis proposes that 
progression from adenoma to carcinoma is based on specific genetic events that drive the 
carcinogenic process. For example, activation of the proto-oncogene K-ras, and 
inactivation of a TSG {FAP) on chromosome 5, occur early. Screening for these specific 
mutations, for example in stool specimens, in families with a history of colorectal 
cancer, could lead to early detection and treatment of pre-neoplastic lesions before they 
become malignant.
1.2.3 Genetic Models for Bladder Carcinogenesis
Transitional cell carcinoma of the bladder, as with many other solid tumours, is 
though to arise through the multistep accumulation of genetic aberrations (Saran et al,
1996). The model of urothelial tumourigenesis proposed by Reznikoff et al, (1996) 
illustrates this hypothesis (Figure 6). Reznikoff et al, (1996) suggest that at least three 
different genetic events that have been identified early in bladder cancer pathogenesis 
can be regarded as initiating events. This concept is partly based on research by Spruck 
et al, (1994), who demonstrated LOH of chromosome 9 in 34% of pTa lesions compared 
to 12% in carcinoma in situ (CIS) and flat dysplasia. In contrast, only 3% of pTa lesions 
contained a mutation while 65% of CIS and flat dysplastic lesions had such 
mutations. They suggested that the frequency of p53 mutations could explain the 
propensity of flat dysplasia and CIS to progress, as p53 mutations are known to 
destabilise the genome.
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Figure 5: Genetic progression of colorectal cancer
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Figure 6: Model of different genetic pathways of urothelial 
tumourigenesis in vivo
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This proposes pathways by which the variant forms o f bladder cancer are initiated and 
progress to muscle invasion.
1.2.4 Molecular Genetics of Bladder Cancer
The commonest genetic and/or chromosomal aberrations are in p53 (up to 70%), 
partial or complete loss of chromosome 9 (up to 60%), in Rb (30-40%) and loss of 
heterozygosity on chromosome 8 (approximately 23%). These are discussed in more 
detail below.
1.2.4.1 Chromosome 17
Currently the TSG p53, located at 17pl3, represents the most frequently mutated 
gene in human cancers (Jones et al, 1991, Reznikoff et al, 1996). This crucial gene 
encodes a nuclear phosphoprotein, involved in cell cycle control and preservation of 
genomic integrity. It coordinates the cellular response to DNA damage and other 
cellular stresses by inducing cell cycle arrest (Lane, 1992). Deletion frequencies o fp53 
can be as high as 70% in bladder tumours of high grade and/or stage. This gene has been 
widely studied (Spruck et al, 1994, Reznikoff et al, 1996, Popov et al, 1997), and 
mutations show a close correlation with progression to muscle-invasion and poor clinical 
outcome.
The gene c-erbB2 is located at 17q21 (Coussens et al, 1985). Amplification and 
overexpression has been shown to correlate with poor clinical outcome in breast cancers 
(Ozen, 1996). Correlation with outcome in bladder cancer has also been investigated. 
Gene amplification was seen only after progression had occurred and may be a potential 
diagnostic marker of progression (Underwood et al, 1995).
1.2.4.4 Chromosome 9
Partial or complete loss of chromosome 9 is a common early change with 
frequencies of up to 60% in all grades and stages of TCC (Knowles, 1995, Cordon- 
Cardo & Sheinfeld, 1997). In most low grade TCC’s this is the only identified genetic 
aberration (Knowles, 1995). More extensive analysis has shown there are distinct 
deletion targets on 9p and 9q (Knowles, 1995). Four candidate TSG’s have been 
mapped to chromosome 9; 9p21 is a common region of deletion shared by many 
carcinomas including bladder and this region contains the genes p i  5, p i  6 and p i 9 ^ ^ ^ .  
High frequency homozygous deletion has implicated p i  6, also known as CDKN2 or 
M TSl (Knowles, 1995) as the target tumour suppressor gene, but this remains 
controversial (Cairns et al, 1995, Dorkin et al, 1997). At least one candidate TSG has 
been proposed at 9q32-33, within the region 9ql3-33 that contains at least two common
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regions of deletion (Habuchi et al 1997). The proposed region at 9q32-33 has been 
designated DBCl, for deleted in bladder cancer gene 1 and a novel gene, DBCCRl has 
been identified (Habuchi et al, 1998).
An additional candidate region is at 9q34. The ABO gene locus has been 
mapped to 9q34.2, (Meldgaard et al, 1995). There is also a TSCl (for the congenital 
disorder tuberous sclerosis) candidate region at 9q34 (Wolfe et al, 1997). In addition, 
this region contains the oncogene ABL associated with the 9;22 translocation, which 
creates the Philadelphia chromosome in 95% of adults with chronic myelogenous 
leukaemia (Rowley, 1973). In conclusion, the high frequency of partial or complete loss 
of chromosome 9 appears to be an early event in bladder carcinogenesis and in particular 
in the initiation of transitional cell carcinoma (Figure 6).
1.2.4.3 Chromosome 13
Loss of function of the tumour suppressor gene, Rb, located at 13ql4 (Cavanee et 
al, 1983), is associated with the development of 30-40% of human bladder cancers, 
especially high grade cancers with poor clinical outcome. However loss can also occur 
early in bladder cancer pathogenesis (see Figure 6, Reznikoff et al, 1996), thus this gene 
may be a potential marker of recurrence or progression risk.
1.2.4.4 Chromosome 8
Approximately 23% of TOCs have deletion of the short arm of cliromosome 8. 
Loss of heterozygosity (LOH) has been associated with the development of an invasive 
phenotype in bladder cancer (Knowles et al, 1993, Wagner et al, 1997). LOH of 8p has 
been related to several other cancers, including breast (Ambrosone et al, 1996), 
colorectal (Farrington et al, 1996) and prostate (Matas et al, 1997) and may play an 
important role in the progression of prostatic and colorectal carcinomas (Takle & 
Knowles, 1996).
Regions of deletion have been mapped to 8p23.2-22 and 8p21.3-8pll.22 
(Eydmann & Knowles, 1997). A candidate TSG homologous to the extracellular 
domain of the PDGF (platelet derived growth factor) receptor gene has been isolated 
from the region 8p21.3-22 (Takle & Knowles, 1996) and the genes for n-acetyl 
transferase 1 and 2 assigned to 8p22 (Hickman et al, 1994). These enzymes detoxify 
compounds such as aromatic amines. Exposure to these chemicals increases the risk of 
bladder cancer. A more proximal region of deletion, at 8p 12-11.2 has also been 
identified. The candidate TSGs POLB and PPP2CB have been mapped to this region. 
Mutations in POLB, a DNA repair gene, have been described in both colorectal and
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pro static cancers, but POLB and PPP2CB are thought unlikely to be tumour suppressor 
genes in bladder cancer. Single strand conformation polymorphism analysis and direct 
sequencing of bladder tumours and bladder cancer cell lines failed to show tumour 
specific sequence variants (Eydmann & Knowles, 1997).
Amplification of chromosome 8 at 8pl2, postulated to contain an oncogene, has 
been associated with breast and ovarian cancers (Theillet et al, 1993). This region 
contains the PLAT  gene, which encodes the tissue-type plasminogen activator. 
Amplification at 8pl2 has also been observed in bladder caneer (Wagner et al, 1997).
In conclusion, partial or complete loss of 8p is associated with the progression of 
several carcinoma types; to a lesser extent amplification of 8pl2 is also implicated in 
carcinogenesis. The cliromosomal region 8p thus has potential as a marker of 
progression.
1.2.4.5 Other Chromosomal Abnormalities
Many other chromosomal abnormalities have been described in TCC. Common 
regions of deletion exist on 4p, l ip  and 14q (Knowles et al, 1994); frequent LOH on 
chromosomes 3p and 18q (Knowles, 1995, Reznikoff et al, 1996), and loss of 
cliromosome Y (Sauter et al, 1995a). Other observations include abnormalities of 
chromosomes 1, isochromosomes of 5p and trisomy 7 (Waldman et al, 1991, 
Kallioniemi et al, 1995), overrepresentation of lq31, lp22, 3q24, high level 
amplifications on 20q (reviewed in Reznikoff et al, 1996) and polysomy X (Sauter et al, 
1995a). Other potential tumour suppressor genes involved in bladder cancer are in the 
region 4pl6.3 (Bell et al, 1996), 5pl3-12 (Bohm et al, 1997), 3pl3-14.3 (Knowles, 
1995).
1.2.5 Molecular Diagnostic Markers
Deletion of 9q was demonstrated in all grade pTa and almost all grade pTl TCC, 
whilst deletions of 3p, 5q and 17p are generally absent in pTa/pTl carcinomas but are 
seen in muscle invasion (Dalbagni et al, 1993, Saran et al, 1996). LOH of 8p has been 
associated with both high tumour grade and stage (Knowles et al, 1994). Gains at 8q24 
(containing o-myc) were observed at a higher frequency from pTl to pT2-4 bladder 
cancers than from pTa to pTl tumours (Wagner et al, 1997).
Higher tumour grade is correlated with deletion of 3p and 17p (Dalbagni et al, 
1993) and increased copy number of chromosome 7 (Waldman et al, 1991). The
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abnormal expression of retinoblastoma gene product (Rb) (Wright et al, 1995), p53 and 
the proliferative marker Ki67 (Popov et al, 1997) have been linked to factors such as 
shorter disease-free interval, higher grade and poorer outcome for patients diagnosed 
with transitional cell carcinoma.
The observation that many human cancers express the enzyme telomerase, 
normally found only in germ cells, has prompted research into this area of molecular 
biology. The telomeric repeats amplification protocol (TRAP) assay to confirm the 
presence of the enzyme has produced promising results. For example in voided urine 
samples, all grade 1, 92% of grade 2 and 83% of grade 3 tumours were positive for 
telomerase activity in one study (Landman et al, 1997), suggesting that this may show a 
higher degree of sensitivity and specificity than previously reported with for example 
urine cytology. Réintroduction of a normal chromosome 3 to the human renal cell 
carcinoma line, RCC23, can restore the programme of cellular senescence. The loss of 
indefinite growth potential was associated with the loss of telomerase activity. This 
suggests that genes on chromosome 3 can repress telomerase activity as loss of 
chromosome 3, frequently observed in renal cell caicinoma, may allow a cell to divide 
indefinitely (Landman et al, 1997).
1.2.6 Summary
As with many other cancers, development of bladder eancer involves an 
accumulation of genetic aberrations. As understanding of the genetics of bladder cancer 
increases, the potential for molecular markers is becoming apparent as an adjunct to the 
existing clinical and pathological diagnoses.
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1.3. Chemical Carcinogens and Bladder Cancer
The first link with environmental chemical exposure and the development of 
cancer was recorded by Percival Pott who, in 1775, noted the high risk of scrotal cancer 
in chimney sweeps and its association with prolonged contact to soot (Hill & Tamiock, 
1987, Jones et al, 1991).
1.3.1 Industrial Exposure
Rehn in 1895 reported “an undue incidence of bladder tumours in a group of 
workers employed in the manufacture of fuchsine (magenta)” and concluded that aniline 
was the most suspicious of the substances used in this process. From this stemmed the 
term “aniline tumour of the bladder” (Case et al, 1954). Rehn first linked urothelial 
cancer to occupational exposure (Hanssen et al, 1985). Throughout the first half of this 
century several animal studies using dogs substantiated these links (Case et al, 1954). 
Industrial exposure to a  napthylamine, p napthylamine and benzidine are now generally 
accepted as causative agents in bladder carcinogenesis (Case et al, 1954). Industries 
such as the manufacture of aniline dyes, rubber and gasworks have been associated with 
occupational bladder cancer but p napthylamine manufacture was abandoned by the 
British chemical industry in 1952, and synthesis of other Icnown carcinogens is now 
severely limited (Risch et al, 1995).
1.3.2 Environmental Exposure
Rachel Carson highlighted awareness of the effect of enviromnental pollutants in 
1962 with the publication of her book “Silent Spring”, and indeed prompted 
governments in many countries to restrict the use of pesticides (Carey, 1995). Most 
cancers are now thought to arise as a result of interaction of genetic factors, such as 
genetic polymorphisms, with environmental carcinogens (Perera, 1997). Up to 80% of 
cancers have been attributed to environmental factors (Smith et al, 1995).
Another potentially important source of exposure to bladder earcinogens is from 
benzo(a)pyrene, p napthylamine and other carcinogens found in cigarette smoke. In 
developed countries 40-70% of bladder cancers in men are causally linked to tobacco 
exposure (Sorlie et al, 1998). p53 mutations occur in many human cancers, and links 
between smoking, p53  mutations and the development of bladder cancer have been
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investigated (Jones et al, 1991, Vineis & Martone, 1996, Sorlie et al, 1998), A current 
paradigm is that chemical carcinogens cause DNA adducts with resultant specific p53 
mutations, usually transversions (Reznikoff et al, 1996). Experimental studies have 
shown that after activation to electrophilic metabolites, potential carcinogens such as 
aromatic amines and benzo(a)pyrene may bind covalently to DNA, preferentially at the 
C8 position of guanine. This binding specificity is consistent with a mutation 
mechanism affecting primarily G:C base pairs (Sorlie et al, 1998).
To confuse the picture further, it appears that formation of DNA adducts and p53 
mutations in response to chemical exposure is strongly modulated by polymoiphisms in 
genes responsible for metabolising aromatic amines, some of which are expressed on 
bladder epithelium (Perera, 1997). This is further discussed in Section 1.3.3.
1.3.3 Drug Metabolising Enzymes and Cancer Susceptibility
The ability to metabolise and thus detoxify xenobiotic toxins is one of the 
primary strategies that higher animals have developed to protect themselves against 
environmental insult. A number o f enzyme superfamilies, such as the cytoclirome P450s 
(P450s) and the glutathione S-transferases (GSTs) together with the two n-acetyl 
transferases (NATs), are thought to have evolved as adaptive responses to xenobiotic 
toxins. Thus variation in the activity of these enzymes could alter an individual’s 
susceptibility to developing a toxin-induced cancer. It is now well established that the 
expression of many of these enzymes is genetically polymorphic and many published 
studies have attempted to relate the presence or absence of a particular allele to disease 
susceptibility (reviewed by Smith et al, 1995).
Drug metabolism in humans occurs in two distinct phases, as illustrated in 
simplified form in Figure 7 (Smith et al, 1995). Phase I catalyses the oxidation, 
reduction and hydrolysis of functional groups on drug and chemical molecules (Grant, 
1991). The P450s are involved in at least 95% of this activity (Nebert, 1996). Phase II 
enzymes such as the GSTs and the NATs then increase the water solubility of the 
product sufficiently to permit excretion of the xenobiotic. Differences in activities of the 
enzymes involved in Phase I and II metabolism will affect the way the chemical is 
processed. Any abnormality in a Phase I enzyme, which could result in metabolic 
activation, has the potential to increase susceptibility to DNA damage and mutation.
37
rather than detoxification, and will have a more marked effect than a Phase II enzyme 
further down the metabolic pathway.
However minor metabolites of a parent compound which are particularly toxic 
may have significant phenotypic consequences if a Phase II enzyme is affected. In this 
case, the Phase II enzyme may not efficiently facilitate excretion of the metabolic 
products of Phase I activity, as will be further discussed in Section 1.3.4.
Differences in allele frequencies of metabolic enzymes have been observed 
between ethnic populations, for example the CYPD2D6 PM genotype from the 
cytochrome P450 family is present in 5 to 7% of the Caucasian population but is 
relatively rare in Orientals (Smith et al, 1995). The NATs also show etlmic variation 
between slow and fast acetylator phenotypes. For example, most populations in Europe 
and North America have 40-70% slow acetylators but in Asian populations only 10-20% 
are slow acetylators (Meyer, 1994). Low levels of either NAT or GSTMl activity may 
influence the formation of p53 point mutations. A proportion o f bladder cancer patients 
who were carriers o f these mutations were either homozygously deficient for GSTMl 
(60%) or homozygous for the slow acetylator genotype in NATs (65%), (Broclonoller et 
al, 1996).
1.3.4 Metabolic Activity
Metabolic activation of aromatic amines is crucial for their carcinogenic potential 
(Frederickson et al, 1994). Figure 8 (Meyer, 1994) illustrates the pathways to 
bioactivation of an aromatic amine. There are competing pathways to bioactivation (via 
cytochrome P450 A2) step 1 or deactivation (via hepatic NAT2)-see step 2. The rate of 
deactivation is partly determined by the activity of NAT2, influenced by genetic 
polymorphisms. Further down the pathway, if the metabolite has not been successfully 
deactivated by n-acetylation and excreted, one of two activation pathways will be 
initiated. Either N-hydroxylation via P4501 A2 (step 3) followed by N ,0  
transacetylation by cytosolic NATs (step 4) will occur or, following step 1, the toxic 
metabolite will be frirther bioactivated by NATl, again influenced by genetic 
polymorphisms, expressed by the bladder epithelium (step 5).
The end result is the arylnitrenium ion [aryl-NH^], the so-called ultimate 
carcinogen or mutagen, which forms covalent adducts by binding to and reacting with 
DNA. These DNA adducts can increase the rate of somatic mutation which if it occurs
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in genes controlling cellular proliferation can lead to a malignant phenotype (Grant 
1993).
In addition, individuals with the slow acetylator phenotype who develop bladder 
carcinoma have higher circulating levels of 4 aminobiphenyl (ABP) haemoglobin DNA 
adducts, reflecting decreased clearance of reactive aromatic amine metabolites 
(Ambrosone et al, 1996). Vineis & Martone, (1996), reported that when investigating 
the relationship between ABP adducts and NAT  polymorphisms, a combination o f slow 
acetylator/fast oxidiser phenotype was associated with the highest level of ABP adduct. 
Studies measuring DNA adducts in workers exposed to benzidine, (DeMarini et al, 
1997) are becoming more commonplace, and there may be a role for this type of assay to 
be used as a screen for cancer risk.
1.3.5 Summary
The development of bladder cancer has been linked with exposure to chemical 
carcinogens. The metabolic enzymes involved in detoxification or bioactivation, 
cytochrome P450s, NATs and GSTs, are genetically polymorphic and thus an alteration 
in their activity may result in a DNA binding mutation and subsequent increased cancer 
risk.
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Figure 7: Pathways of drug metabolism
Toxin Metabolism
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Phase 1 
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S-TransferaseGlutathione 
N-Acetyl Transferase
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^  Mutation 
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Phase II Metabolism
Glutathione S-Transferase 
N-Acetyl Transferase
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Excretion
This diagram outlines the mechanisms whereby a potential carcinogen can be 
metabolised. Either activation or detoxification of the parent compound will occur, and 
the metabolic activities are dependent on phenotypic variations o f the relevant enzymes.
Figure 8: Metabolism of Arylamines by Hydroxylation and Acétylation 
to Electrophilic Arylnitrenium Ions
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This diagram illustrates the pathways involved in metabolic processes resulting in DNA 
damaging agents. This is a dynamic process dependent on the polymorphisms in the 
drug metabolising enzymes involved in these activities.
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1.4 The N-acetyl Transferases
1.4.1 Phenotypic Analysis
Bonicke & Reif discovered the NAT acétylation polymorphism in 1953, 
following the advent of isoniazid therapy for the treatment of tuberculosis. The 
incidence of neurological side effects during therapy was related to elevated plasma 
concentrations of the unchanged drug. Impaired elimination was found to be related to a 
reduction in the rate at which isoniazid was enzymatically n-acetylated in the liver 
(reviewed by Grant, 1993).
From the early 1980’s, the association with the acétylation polymorphism and 
individual susceptibility to the development of caneer was investigated. Compounds 
such as monoacetyldapsone/dapsone (Cartwright et al, 1982), sulphamethazine 
(Hielonan & Sim, 1991) and caffeine (Kadlubar et al, 1992) were used to investigate 
phenotypic variation. Following oral ingestion of the drugs, the ratio of acetylated to 
non-acetylated metabolites was measured in urine (Hickman & Sim, 1991, Kadlubar et 
al, 1992), or plasma (Cartwright et al, 1982). These studies confirmed that inter­
individual phenotypic variation existed. The drugs p-aminobenzoic acid and p- 
aminosalicylic acid were metabolised identically by slow and fast acetylators and termed 
“monomorphic” substrates, whereas isoniazid and procainamide were termed 
“polymorphic” substrates because the rate of acétylation correlated with distinct 
phenotypic variations. The existence of two different NAT enzymes was thus proposed.
Jenne (1965) suggested that the observed genetic variation was related to 
differences in the quantity of the enzymes rather than to altered kinetic characteristics of 
a structural variant and that the two different N-acetyItransferase enzymes were 
responsible for the metabolism of these distinct classes of arylamines (Grant, 1991, 
Meyer, 1994).
Experiments to elucidate biochemical and molecular mechanisms in humans 
showed that the majority of slow aeetylators have less immunodetectable NAT2 protein 
in their liver cytosol relative to fast acetylators (Grant, 1993), supporting Jenne’s 
hypothesis. The results of expression studies (reviewed by Grant, 1993) provided the 
first evidence that the human acétylation polymorphism was regulated at the NAT2 
locus, although it is now known that NATl is also polymorphic (Bell et al, 1995).
The link between the slow acetylator NAT2 phenotype and bladder cancer is well 
documented (Cartwright et al, 1982, Grant, 1993, Risch et al, 1995, Badawi et al, 1995,
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Ambrosone et al, 1996). Cartwright and co-workers, (1982), studied patients with 
bladder cancer and investigated their acétylation phenotype in response to previous 
research that suggested that the slow aeetylator phenotype was a susceptibility factor in 
the development of bladder cancer. Twenty-three patients were dye workers and of 
these 22 had a slow acetylator phenotype, linking the metabolism of potential 
carcinogens with bladder cancer. This first strong association with acetylator phenotype 
and carcinogenesis was recapitulated by Risch and co-workers, (1995), using a similar 
cohort of patients to those in Cartwi'ight’s study. A greater proportion of patients with 
bladder cancer and previous occupational exposure to carcinogenic aromatic amines 
(71.0%) were slow-slow homozygotes for NAT2 than in the control group (44.1%) 
(attending the urology clinic for non-malignant urological complaints with no previous 
exposure to carcinogenic aromatic amines). Interestingly, the proportion o f bladder 
cancer patients with the slow-slow genotype without known previous occupational 
exposure to carcinogenic aromatic amines was also higher than the control group 
(65.4%).
In addition, the incidence of bladder cancer in smokers has shown a small but 
significant link with slow NAT2 acétylation phenotype (Golka et al, 1996, Oklcels et al,
1997). In an analysis of the same patient eohorts, this time comparing smokers versus 
non-smokers in the control and bladder cancer patients, the proportion of slow 
acetylators of the patients with bladder cancer who smoked was 71.6% compared to 
39.3% of smokers in the control group, as shown in Figure 9 (Risch et al, 1995). Slow 
acétylation phenotype has also been recently linked to the development of breast cancer 
(Ambrosone et al, 1996).
Less research has been carried out on an association with cancer risk and NATl. 
However, NATl acetylates heterocyclic amines, associated with cooking of red meat 
and the consequent increased risk of colon cancer (Bell et al, 1995, Hubbard et al, 1998). 
NATl has also been linked with bladder carcinogenesis (Badawi et al, 1995, Bell et al, 
1995).
In conclusion, interindividual phenotypic variation o f the NAT’s has been shown 
experimentally to be associated with differences in the rate of drug acétylation. Further 
research has substantiated the link between bladder carcinogenesis and the slow NAT2 
phenotype. There also appears to be a relationship with colon carcinogenesis and N A T l.
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Figure 9: Distribution of fast and slow NAT2 acetylator phenotypes 
amongst patient groups and controls, comparing smokers and non 
smokers.
NAT2 in Bladder Cancer
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A comparison of genotype with occupational exposure to chemical carcinogens, 
demonstrating a higher incidence of slow acetylators in bladder cancer patients that 
smoked (Risch etal,  1997).
1.4.2 Genetics
There are 3 distinct iV/fT genes; two loci encode the functional NATs, also known 
as AACl and AAC2, characterised by their distinct but overlapping substrate specificities 
(Hickman et al, 1994). A third isolated region contains the related pseudo gene NATP. 
Both the AAC l locus, also known as NATl, and the AAC2 locus, also known as NAT2, 
contain intronless genes that produce 290 amino acid proteins (Hein et al 1994). NAT2 
has been mapped centromeric to NATl in the region 8p22 (Matas et al, 1997). This 
region is frequently deleted in bladder cancers of high stage and grade (Knowles et al,
1993).
1.4.2.1 Genotypic Analysis
Phenotypic analysis of an individual’s drug metabolising capability cannot 
account for external factors such as smoking and alcohol consumption, and other factors 
such as impaired renal function may also affect drug clearance. It is now possible to 
genotype an individual and determine the relevance to disease susceptibility using DNA 
based techniques such as the polymerase chain reaction (PCR) and restriction fragment 
length polymorphism (RFLP) analysis (Smith et al, 1995).
1A.2.2NAT1
N ATl was initially believed to be monomorphic (Smith et al, 1995) but recent 
studies have shown that it is indeed highly polymorphic and 9 allelic variants have been 
detected in humans (Hubbard et al, 1998). Polymorphisms in the polyadenylation signal 
have also been identified (Bell et al, 1995). Polyadenylation promotes RNA stability 
and it has been suggested that certain isoforms of NATl {NATl "^ 10) are linlced with a 
higher cancer risk because they are more stable resulting in an increase in NATl activity 
(Bell et al, 1995). NATl^^lO contains a single base substitution in the polyadenylation 
signal in the 3’ untranslated region of the gene. Bell et al, (1995) demonstrated that this 
allelotype conferred a 2.9-fold to 26-fold increase in the incidence of bladder cancers. 
\A ,2 3 N A T 2
Functional activity of NAT2 is related to the inlieritance of particular alleles 
(Matas et al 1997). Genetic variants have been cloned and sequenced. One major and 
two minor alleles confer the fast acétylation phenotype, other alleles are associated with 
slow acétylation at frequencies varying between different etlmic groups. Seventeen 
allelic variants have been identified in a Caucasian population (Agundez et al, 1996).
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Slow acétylation has been linked with cancer, particularly bladder (Cartwright at al, 
1982, Risch et al, 1995,) and breast (Ambrosone et al, 1996). This may be due to LOH 
of 8p commonly seen in many cancers (and previously discussed in Section 1.2.4) which 
will confer a selective advantage for the slow acetylator genotype to become dominant. 
The impaired enzymatic function of the slow NAT2 alleles gives a strong argument for 
the association with this allelotype and bladder carcinogenesis. Studies have shown 
there is a higher preponderance of slow acetylators with bladder cancer compared to 
disease free individuals (Cartwright at al, 1982, Risch et al, 1995).
1.4.3 Summary
Research into the phenotypic and genotypic properties of the NATs has increased 
our understanding of their metabolic activity, although the precise genetic mechanisms 
by which NATl and NAT2 influence carcinogenesis remain unclear. Their chromosomal 
location on 8p suggests they could be potential tumour suppressor genes either through 
LOH or loss of functional carcinogen metabolising enzymes.
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1.5 Summary
The introductory chapter outlined the pathogenesis of transitional cell carcinoma 
of the bladder (TCC) and discussed difficulties of patient management which are 
exacerbated by the propensity of TCC to recur and to progress to muscle invasion. The 
molecular biology of cancer, and models for recurrence and progression in TCC were 
discussed and the reader’s attention was drawn to the strong association between 
environmental exposure to potential chemical carcinogens and carcinogenesis, 
specifically, the aromatic amines with bladder carcinogenesis. The N-acetyltransferase 
genes, NATl and NAT2, and their markedly polymorphic character, which may influence 
chemical carcinogenesis in the bladder, were discussed in detail.
The difficulty of identifying patients at greatest risk of recurring with bladder 
carcinoma makes additional tools for diagnosis and prognosis particularly desirable. 
The rapid development and constant refinement of molecular biology teclmiques has 
given researchers the opportunity to investigate the molecular mechanisms of 
carcinogenesis. Many genetic aberrations have been associated with cancer initiation 
and progression, with several genetic “hits” being necessary for cells to acquire the fully 
malignant phenotype. Against this background the time seems ripe to consider the rôle 
of molecular biology techniques as part of the clinical diagnosis and management of 
cancer patients.
The association between patient exposure to aromatic amines and bladder cancer 
gives us a clear “cause and effect” model within which to study carcinogenesis. Added 
impetus to the study of the genes NATl and NAT2 is given by their location to a region 
of frequent loss (on chromosome 8p) in many cancers including bladder cancer. The 
implied alteration of enzyme function in the aetiology of bladder cancer warrants further 
investigation.
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1.6 Study Aims
The aims were to determine the chromosome 8 and NAT2 status of patients 
presenting with transitional cell carcinoma, relating chromosomal aberrations to clinical 
course i. e. non recurrence, recurrence, recurrence and progression. This has the potential 
to increase the understanding of bladder carcinogenesis. For example: do patients with 
single episodes of non-detrusor-muscle invasive transitional cell carcinoma (TCC) have 
similar gene copy number to patients with a similar presentation but who subsequently 
develop detrusor-muscle-invasive TCC. To date this approach has been used by few 
researchers (Pycha et al, 1997, Bartlett et al, 1998).
There were two ways to address this question, using molecular biology, bearing 
in mind that the available material was formalin fixed and paraffin processed. Either by 
microdissecting tumour areas and using a method to investigate loss of heterozygosity 
such as restriction fragment length polymorphisms analysis (Elubbard et al, 1997), or 
using an in situ method such as fluorescent in situ hybridisation (FISH). An in situ 
method allows the tissue to be examined on a cell by cell basis, and avoids the problems 
encountered in trying to analyse homozygotes. FISH has been used extensively on many 
tumour types, including TCC, to determine gene and/or chromosomal copy number 
(Hopman et al, 1988, Sauter et al, 1995a, b, Wagner et al, 1997). Valuable data has 
been produced on the common genetic aberrations in TCC, but studies have tended to 
pick tumours from the archives or those presenting at clinic in a fixed period of time 
{e.g. Sauter et al, 1995c, Poddighe et al, 1996, Wagner et al, 1997). A larger amount of 
data would be obtained however if patients were followed sequentially, which could 
contribute to the elucidation of the mechanisms involved in recurrence and progression.
Thus the advantages of studying sequential tumours in situ from the same patient 
by FISH would allow the maximum amount of information to be gathered and therefore 
this method was chosen for the study. The study aims were therefore:
1. To develop a method to allow visualisation of chromosome 8 and NAT2 in archival 
bladder tissue using the technique of fluoresecence in situ hybridisation.
2. To apply the method to normal bladder tissue controls and to bladder carcinomas.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Patient Data
2.1.1 Materials and Methods
Patient notes were accessed, and allocation to four groups was made, based on 
clinical history.
“Non recurrent” (NR) patients had one superficial or minimally invasive transitional cell 
carcinoma (TCC), (pTa/pTl) with no subsequent recurrences at check cystoscopy. 
“Recurrent non progressive” (RNP) patients presented with several episodes of recurrent 
TCC following the index (primary) carcinoma but with no evidence of detrusor muscle 
invasion (stage pT2 and above).
“Recurrent progressive (RP) patients” presented with superficial or minimally invasive 
TCC and subsequent recurrences progressed to muscle invasion (pT2 and above). 
“Progressed at presentation” (PP) patients presented with muscle invasive TCC (at least 
pT2).
Where available information on treatment (chemotherapy or radiotherapy), smoking 
habits and previous occupational exposure to carcinogens was recorded.
Patients whose index tumour or first recurrence was treated by diathermy without 
sampling the tumour for pathology were excluded.
2.1.2 Statistical Analysis
Differences in age at diagnosis were analysed by one-way ANOVA; length of 
follow-up and number of cystoscopies by Kruskal-Wallis tests (Minitab for Windows 
package. Release 9.2). For the sex ratio and deaths due to bladder cancer, Fisher’s exact 
test (from SPSS for MS Windows, Release 6.1) was used.
2.1.3 Summary
Case notes were accessed, a patient cohort was identified, and all relevant details 
catalogued. Patients were categorised in four groups depending on the clinical course of 
their TCC.
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2.2 Histology
2.2.1 Materials
Inclusion in the study was dependant on the availability of adequate tissue. This 
consisted of:
a) small biopsies of clinically “suspicious” areas (e.g. mucosal reddening) and random 
biopsies of other sites in the bladder
b) bladder tumour obtained from a transurethral resection (TURT)
c) cystectomy specimens.
2.2.2 Methods
The haematoxylin and eosin histology slides for each of the individuals identified 
were retrieved and re-examined microscopically with a pathologist within the 
Department of Pathology. Tissue sections were then recut from paraffin blocks 
containing tumour. Structurally normal bladder tissue was also retrieved to act as a 
reference control.
Ten consecutive 5pm sections were cut onto silanised slides. 3-aminopropyl 
triethoxysilane (silane, Sigma, UK) acts as a section adhesive, essential to prevent the 
tissue from becoming detached from the slide during the FISH assay. The method 
followed was:
Place slides into racks.
Place slide rack in acetone for 5 minutes.
Place slides in 2% silane (take 2ml of silane, add to 98 ml of acetone) for 5 minutes. 
Wash under running tap water for 25 minutes.
Dry in fume hood.
Store in labelled and dated boxes.
The fifth section from each tissue block was stained with haematoxylin and eosin 
following the method outlined below:
Rehydrate sections through 2 changes of xylene and ascending grades of alcohol, from 
100% to 70%.
Wash under running tap water.
Stain in haematoxylin (GilTs, Surgipath, UK)
Rinse in tap water.
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Destain in 0.5% acid alcohol (99.5ml alcohol, 0.5ml ION hydrochloric acid (Bancroft & 
Stevens, 1996)) for up to 20 seconds.
Rinse in tap water and “blue” in Scott’s tap water substitute (2 g potassium bicarbonate, 
20 g magnesium sulphate, distilled water 1 litre (Bancroft & Stevens, 1996)) for up to 1 
minute.
Stain in 3% Eosin (3 g Eosin Y, 100 ml distilled water).
Rinse in tap water
Dehydrate through descending grades of alcohol, from 70% to 100%, then in 2 changes 
of xylene.
This protocol was performed on an automated system, the Stainette, E7751 (Miles 
Medical Laboratory Equipment Services, UK).
Care was taken to ensure there was as little wastage as possible between sections. 
Gloves were worn tliroughout and sections floated on a water bath containing distilled 
water. The haematoxylin and eosin sections of the bladder carcinomas were restaged and 
graded by the MRC reference pathologist for TOC, Dr K.M.Grigor (Edinburgh Royal 
Infirmary), using UICC guidelines (1978), whereby grade 3 and 4 are classified as grade
3.
2.2.3 Summary
Patients identified for the study were recruited if enough tumour material was 
available. Restaging and grading of the TCC’s by a MRC reference pathologist enabled 
consistency of pathological reporting to be achieved.
2.3 Labelling of Probes
2.3.1 Probe Preparation and Labelling
Probes for FISH were initially prepared as crude isolates of nucleic acids with 
radioactive labels. With the description of nick translation (Rigby et al, 1977), the 
synthesis of biotin UTP and recombinant DNA technology (Warford & Lauder, 1991), 
probe preparation became simpler. The nick translation method developed by Rigby et 
at, (1977) utilised a simple technique that incorporated radioactive label following the 
introduction of “nicks” into DNA by the enzyme DNase I; 25 to 50% of the unlabelled 
nucleotides subsequently could be replaced by labelled nucleotides with DNA 
polymerase I via excision repair. Centromeric and telomeric probes for many of the
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human chromosomes are available commercially, but for gene specific sequences probe 
generation is often carried out “in house”. Biotin was the first non-radioactive label to be 
used and was incorporated into the nucleic acid in the form biotin 11 dUTP (Leitch et al,
1994). Other modified nucleotides are now available, and biotin 14 dUTP and biotin 16 
dUTP are widely used. The label is incorporated at a position that does not interfere 
with hydrogen bonding between the probe and target DNA, containing a linker arm of at 
least 11 carbon atoms to minimise steric hindrance during hybridisation (Figure 10 
Leitch et at, 1994).
2.3.2 Source of DNA
Cosmid DNA prepared from Escherichia coli transfected with NAT2 cosmid 
(Franke et al, 1994) was kindly provided, together with the cosmid concentration, by the 
Department of Pharmacology, University o f Oxford. The clones were tested by NATl 
and NAT2 specific PCR. Clones that were positive for both were rejected. DNA was
received in TE (Tris-EDTA, Sambrook et al, 1989) buffer, pH 8.0.
2.3.3 Nick Translation
Enzymatic labelling kits are now available commercially and are used for in situ 
hybridisation (Hopman et al, 1991, Sauter et al, 1995a, b, c). The principles of the 
reaction are outlined as follows.
Two DNA enzymes, DNase I and Escherichia coli DNA polymerase I are used 
to incorporate labelled and unlabelled deoxynucleotide triphosphates (dNTP’s) into 
double stranded DNA, (Figure 11). DNase I introduces single strand breaks or “nicks” 
in the double-stranded DNA to expose free 3'-OH groups (step 2, Figure 11). The 5' to 
3' exonuclease activity of DNA polymerase I removes mononucleotides at the 5' side of 
the “nick” (step 3, Figure 11). The DNA polymerase I then catalyses the incorporation 
of labelled and unlabelled dNTP’s from solution at the 3'-OH end of the nick (step 4, 
Figure 11). The result is the synthesis of a new strand of uniformly labelled DNA, that 
includes labelled nucleotides (Leitch et al, 1994). The relative concentrations of DNase 
I and DNA polymerase I are altered to produce probes of between 200 to 600 base pairs
which are most suitable for using in in situ hybridisation assays.
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Figure 10 Biotin d-UTP
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The atomic structme of biotin enables it to be incorporated into the relevant nucleic acid 
at a position that does not interfere with hydrogen bonding.
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Figure 11: Nick translation
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The principles of the reaction are outlined in diagrammatic form and further discussed in 
the text
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2.3.3.1 The Nick Translation Method
The method employed was a modification of the Nick Translation System kit 
(Gibco BRL, UK) and is outlined as follows:
Combine the following: 
lpg(10|Lil)DNA
5pi dNTP mix, final concentration is 0.02mM each dATP, dCTP,dGTP (Gibco BRL, 
UK);
lOpl 5x biotin-16-dUTP (Boehringer Mannheim, UK), final concentration 0.004mM 
6.6pl ImM dTTP (Pharmacia Biotech, UK), final concentration 0.013 inM 
12.4pl sterile distilled water.
Giving a total volume of 44pl 
Microfuge.
Add Ip l DNase I (Boehringer Mannheim, UK), final concentration of 12pU/pl.
Add 5 pi enzyme mix (DNA polymerase I, DNase I, Gibco BRL, UK), final 
concentrations o f 0.08 U/pl and SmU/pl respectively.
Place on a PCR block (Biometra UN 0-Thermoblock, UK) pre-programmed to attain a 
temperature of 15°C for 90 minutes. Inactivate the enzymes by heating to 72°C for 10 
minutes.
2.3.3.2 Confirmation of Product Size from the Nick Translation Reaction:
Take 8pi of product, add to 2pi of gel loading buffer, (Sambrook et al 1989). Gel 
loading buffer consists of 0.25% bromophenol blue, 0.25% xylene cyanol FF and 30% 
glycerol in distilled water.
Take Ip l of 100 bp DNA ladder (Gibco BRL, UK), add to 2pl GLB.
Run on a 2% agarose gel. This concentration of agarose gel is recommended to 
resolve smaller DNA fragments (Sambrook et al, 1989) and is made up by adding Ig of 
agarose (Gibco, BRL) to 50ml 1 x Tris-acetate (TAB) buffer, from a stock of 50 x TAB 
buffer.
50 X TAB consists of: 242g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 Molal 
BDTA pH 8.0 dissolved in 1 litre of distilled water. Autoclave.
Heat the 2% agarose in a microwave to dissolve. Cool to approximately 50°C.
Add 2pl of 50mg/ml ethidium bromide (Sigma, UK).
Pour into a gel casting tray with a 12 lane comb and allow to set.
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Place the gel in a flat bed electrophoresis gel rig (Hoeffer Scientific Instruments) with 
sufficient IxTAE to cover the gel.
Run at 70V for 50-60 minutes.
View the size of the DNA fragment using an ultra violet light box. The product size is 
confirmed (it should be between 200 and 600 base pairs).
2.3.4 Suppression Hybridisation
Large DNA sequences such as a cosmid clone will often contain the sequences 
Alu and Kpn randomly dispersed approximately 900,000 and 100,000 times respectively, 
throughout the human genome (Gosden & Hanratty, 1991). Probes with Alu and Kpn 
sequences will hybridise to all chromosomes giving ambiguous results (Nisson et al, 
1991). To avoid this, a product called human COT-1 DNA was developed, which is 
human DNA enriched for the major classes of repetitive sequences (Gosden & Hanratty, 
1991). Unlabelled COT-1 DNA is combined with the labelled probe and the signal from 
repetitive sequences suppressed (Gosden & Hanratty 1991, Nisson et al, 1991). 
Hybridisation of the sequence of interest is then viewed against a low background of 
repetitive DNA sequences.
The addition of COT-1 DNA to nick translated DNA is a standard procedure to 
study genes by FISH either to establish loss or amplification. The presence of competitor 
DNA results in accurate hybridisation and increased sensitivity (Lichter et al, 1990). 
Therefore, the DNA probe labelled by nick translation was precipitated in the presence 
of COT-1 DNA as follows:
For every 5 pi (100 ng) of product, add 1 pi of 1 mg/ml COT-1 DNA (Gibco BRL, UK). 
Thus to 40 pi of product, add 8 pi of COT-1 DNA.
Add 1/10 volume 3 Molal sodium acetate pH 5.5 (Add 24.6 g to 100 ml distilled water. 
pH to 5.5) and 2 x volume cold 100% ethanol (stored at -20°C).
Precipitate the DNA at -20°C overnight or at -80°C for 20 minutes.
Microfuge for 15 minutes at 13000 rpm, decant the precipitant, wash in 80% ethanol, 
decant again and dry.
Reconstitute with 80 pi of hybridisation mix (from a stock of 5 ml formamide, 1 ml 20 x 
SSC, 0.5 ml 10 mg/ml salmon sperm DNA, 2 ml 50% dextran sulphate (All Sigma, UK) 
and 1.5 ml distilled water). Store at -20°C.
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2.3.5 Summary
Nick translation was used to label the NAT2 cosmid, to yield a probe of suitable 
length (200 to 600 base pairs) for in situ hybridisation assays. The labelled NAT2 probe 
was then precipitated in the presence of COT-1 DNA, thereby minimising ambiguous 
hybridisation results.
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2.4 Fluorescence in situ Hybridisation (FISH)
Double stranded DNA is held together by two hydrogen bonds between 
adenine/thymidine and three between cytosine/guanine base pairings. These bonds are 
relatively weak and it is possible to separate (denature) and reanneal (hybridise) strands 
of nucleic acid with relative ease. Therefore by attaching a label to a sequence of DNA, 
it is possible to hybridise this to a preparation containing a range of nucleic acids and 
specifically locate the target sequence containing the complementary base sequence 
(Figure 12, Herrington & McGee, 1992).
Jolm and co-workers in the UK and Gall & Pardue in the US described the first 
in situ hybridisation (ISH) experiments almost simultaneously in 1969 (Warford, 1994). 
Radioactively labelled RNA probes were used to localise specific DNA sequences 
within the nuclei of Xenopus laevis (John et ai, 1969). The resultant simplified 
technique o f ISH/FISH has been widely applied to study chromosomal rearrangements, 
in chromosome mapping and has also been used to study numerical chromosomal and 
genetic aberrations in several tumour types. The teclinique is widely recognised as a 
powerful tool with which to study such genetic anomalies (Price, 1993, Waldman et al, 
1991, Alcarez et al, 1994, Murphy et al, 1995, Nolle et al, 1996, Wolf et al, 1996, 
Bartlett et al, 1998 and many others).
2.4.1 Labels
Probes for FISH have been directly labelled with fluorochromes such as 
fluorescein isothoicyanate (FITC) and rhodamine (Leitch et al, 1994). Although this 
simplifies the technique, there is a resultant loss of sensitivity. This method is not 
recommended for the detection of low and single copy sequences (Leitch et al, 1994). 
However in cases of gene amplification, such as cerbB2 in breast carcinoma (Pauletti et 
al, 1996), FISH with a directly labelled probe has been successfully utilised. The 
commonest non-radioactive labels are the haptens biotin or digoxigenin. Biotin has 
limitations as it is present as an endogenous component o f many tissues (Warford & 
Lauder, 1991) and therefore non-specific binding of anti-biotin antibodies or streptavidin 
can be a problem,
Digoxigenin, a naturally occurring alkaloid derived from the foxglove (species 
Digitalis purpura and D. lanatd) was utilised to circumvent the problems encountered 
with biotin. Both digoxigenin and biotin are frequently used in FISH as dual labels to
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study the relationship between a unique sequence and the chromosome on which it 
resides (Han et al, 1994, Murphy et al 1995, Bell et al, 1996). This project used biotin 
as a label for NAT2 as, in our hands, the biotin labelled probe was more reliable, 
producing a bright signal. Also, the antibody steps used to visualise the copy number 
following hybridisation with biotinylated probes have greater flexibility than for 
digoxigenin labelled probes. An alpha satellite digoxigenin labelled probe for 
chromosome 8 was used.
59
Figure 12 An Outline of in situ Hybridisation, Incorporating the DNA 
Labelling and Signal Detection Systems
Paraffin blodt
Mounted section
Coated slides
Dewax and unmask 
nucleic acids
VcaoT
Insert
Labelling
Reaction
Accessible double 
stranded DNA target
Denature target 
and probe
Single stranded 
DNA target
Hybridise with 
labelled prolre
DE'mCTION SYSTCM
END PRODUCT
Figure 12: An outline of the principles of in situ hybridisation, further discussed in the 
text. Abbreviation: L= label;
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2.4.2 Hybridisation
Hybridisation is carried out under low stringency conditions to enhance hybrid 
formation (Mitchell et al, 1992). The hybridisation mix contains reagents to allow the 
hybridisation to proceed as efficiently as possible. 2 x SSC and 50% formamide allow 
matched hybrids to form but because this is a relatively low-stringency mix, some 
mismatched hybrids will also form. However they will be less strongly bound than the 
correctly matched hybrids, and can be largely eliminated by the post hybridisation wash 
(see below).
Other constituents of the hybridisation mix are dextran sulphate, a 
macromolecule (molecular weight of greater than 8000) which increases the effective 
probe concentration by molecular exclusion (Herrington & McGee, 1992) and salmon 
sperm DNA which may reduce non-specific staining by blocking possible interactions 
with the phosphate groups of the nucleotide chain (Mitchell et al, 1992).
2.4.3 Detection of Hybridisation
Efficient high-resolution detection systems are a prerequisite for any in situ 
hybridisation study (Mitchell et al, 1992). Reagents labelled with FITC and 
Indocarbocyanine, Cy3 (Cy3) were chosen for use in this project. FITC is a widely used 
fluorochrome, as it produces a bright green fluorescence easily distinguishable from an 
appropriate nuclear counterstain. Ideally, a fluorochrome which fluoresces at the 
opposing end of the colour spectrum will allow clear differentiation between the probes.
A label that fluoresces red is usually used to contrast with FITC. Rliodamine or 
Texas Red were the first to be used but these are being superseded by the cyanine dyes, 
which include Cy3. These dyes are much brighter, more photostable and give less 
background than the traditional fluorochromes. A nuclear counterstain that fluoresces 
blue (4,6-diamidino-2 phenylindole-2 hydrochloride, DAPI) affords sufficient contrast 
from FITC and Cy3 and was used in this study.
2.4.4 Verifying Probe Specificity
The labelled probe was tested for specificity by co-hybridising to metaphase 
cliromosomes with a probe for the centromeric region of chromosome 8. This was an 
essential preliminary step because the probe was then applied to interphase nuclei, which 
would give no indication of chromosomal specificity.
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Dual fluorescence in situ hybridisation (FISH) with probes for the centromere of 
the relevant chromosome (chromosome 8) and for the gene of interest {NAT2) were 
applied to metaphase spreads o f lymphocytes cultured from whole blood, prepared using 
conventional cytogenetic techniques, following a method based on Wlieater & Roberts 
(1987). Cells previously screened for normal karyotype, kindly supplied by the 
Department o f Medical Genetics, Yorkliill Hospital, Glasgow, were arrested in 
metaphase and fixed in 3:1 methanol:acetic acid. Slide preparation was carried out as 
follows:
Prepare the slides by soaking in 2% Decon 90 (Decon Laboratories Ltd., UK) overnight. 
Rinse for several hours in running tap water.
Dry, place in 70% ethanol for 5 minutes, rinse in running tap water, store in the fridge 
for up to 2 days.
Make the metaphase spreads by centrifuging the cell suspension at 800 to 1000 x g for 
10 minutes.
Remove the supernatant and resuspend in 3:1 methanol:acetic acid.
Take 20pl of the cell suspension and drop onto the top left hand corner of the slide. 
Allow it to run gently across the slide. Dry the slides and use the same day.
Confirm the presence of metaphases using phase contrast microscopy.
2.4.5 FISH
The principles of the technique are outlined in Figure 12 (Herrington & McGee, 
1992). The method followed in this study is outlined below:
2.4.5.1 FISH for Chromosome Spreads: Preparation of Tissue for Hybridisation:
Denature cell suspension on the slide with 70% formamide 2 x SSC at 72°C for 5 
minutes.
2 X SSC is a 1:10 dilution of 20 X SSC pH 7.0, consisting of 175.3g sodium chloride 
and 88.2g sodium citrate (both BDH, UK) added to 1 litre of distilled water, the pH 
verified and the solution autoclaved.
Dehydrate in ice cold 70% and 100% ethanol on ice and air dry.
Denature lOpl of biotin labelled NAT2 probe per slide at 72°C for 5 minutes, allow to 
reanneal for 30 minutes at 37°C. This step is known as suppression hybridisation as 
discussed in Section 2.3.4.
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Add Ipl o f digoxigenin labelled chromosome 8 probe (Appligene Oncor, UK), 
denatured at 72°C for 5 minutes and stored on ice, to lOpl of NAT2 probe. Cover with 
glass coverslips and seal with rubber cement (Halfords UK).
Hybridise for 16 hours at 37°C.
2.4.5.2 Post Hybridisation Wasb 
Peel off rubber cement.
Allow coverslips to fall off by immersing the slides in 2 x SSC for 15 minutes.
Place slides in 1 x SSC for 5 minutes at 72°C,
Rinse in PNT (phosphate buffer, pH 8.0 and 0.05% polyoxyethylenesorbitan (Tween 
20)).
Phosphate buffer is 6.8ml 1 Molal NaH2P0^, 93.2ml 1 Molal Na2HP0 4 , (both BDH, UK), 
and 0.5ml Tween 20 (Sigma, U.K.) made up to 1 litre with distilled water, and the pH 
verified.
2.4.5.3 Histocbemical Detection:
Block in PNTB ((PNT with 0.5% blocker) for 15 minutes.
The blocker is made up of 10% blocker (Boehringer UK) in maleic acid buffer, 
dissolved in the microwave The buffer consists of: 5.80g maleic acid (Sigma, UK), 
4.38g NaCl, 3.50g NaOH (solid) (both BDH, UK) in 400 ml distilled water. pH to 7.5 
and adjust final volume to 500ml.
Drain and cover with sheep anti-digoxigenin antibody (Ipg/ml, Boeluinger, UK) diluted 
in PNTB for 45 minutes.
Rinse in PNT for 10 minutes.
Rinse in 4 X SSCT (20ml 20 X SSC, 0.05ml Tween 20, 79.95ml distilled water)
Block in 4 X SSCTB (4 X SSCT with 0.5% blocker) for 10 minutes.
Drain and cover with FITC avidin (25pg/ml, Vectorlabs, UK) and rabbit anti-sheep 
(18pg/ml, Stratech, UK) diluted with 4 X SSCT for 40 minutes.
Rinse in 4 X SSCT for 10 minutes.
Drain and cover with Cy3 donkey anti-rabbit (3pg/ml, Stratech, UK) and biotinylated 
goat anti-avidin (5pg/ml, Vectorlabs, UK) diluted with 4 X SSCT for 30 minutes.
Rinse in 4 X SSCT for 10 minutes.
Drain and cover with FITC avidin (25pg/ml, Vectorlabs, UK) diluted with 4 X SSCT for 
30 minutes.
Rinse in 4 X SSCT for 20 minutes.
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Dehydrate through 70% and 100% ethanol, air dry and mount in Vectashield 
(Vectorlabs, UK) with 2pg/ml 4,6-diamidino-2 phenylindole-2 hydrochloride (DAPI) 
(Sigma, UK) added.
2.4.5.4 FISH for Formalin Fixed Wax Embedded Tissue Sections
Dewax and rehydrate sections:
xylene 2 x 1 0  minutes; methanol 2 x 5  minutes.
Air dry.
Treat with 30% sodium bisulphite (Sigma, UK) in 2 X SSC for 15 minutes at 45°C. 
Rinse in 2 X SSC.
Treat with 0.25% proteinase K (Sigma, UK) in 2 X SSC for 40 minutes at 45°C.
Rinse in 2 X SSC.
Dehydrate through 70% and 100% ethanol, mount in Vectashield with DAPI and check 
digestion microscopically. Nuclei that stain grey to grey/blue are underdigested and, 
once the coverslip is removed, can be reintroduced to a fresh batch of proteinase K for 
up to 15 minutes. Nuclei that stain blue with clearly visible nuclear borders are suitably 
digested. Where nuclear borders are lost these sections are over digested and are 
discarded. The digestion is repeated with different sections for 30 minutes.
Rehydrate, treat with Streck (“Streck” Molecular Biology Fixative ) (Alphalabs, UK)) 
for 10 minutes
Dehydrate through 70% and 100% ethanols.
Air dry.
Denature slides in 70% formamide 2 X SSC at 72°C for 5 minutes.
Dehydrate on ice in cold 70% and 100% ethanols.
Air dry.
Denature lOpl of NAT2 probe per section at 72°C for 5 minutes and allow to reanneal 
for 30 minutes at 37°C.
Add 1 pi of chromosome 8 probe, (denatured at 72°C for 5 minutes and stored on ice) to 
lOpl (lOOng) of the unique sequence probe for each section, cover with glass coverslips 
and seal with rubber cement
Hybridise for 16 hours at 37°C. Post hybridisation and immunocytochemical detection 
steps are carried out using the same method for chromosome spreads.
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2.4.6 Visualisation
Stokes discovered the principle of fluorescence in the 19'*' century. He formed Stokes’ 
Law that states that only short wavelengths of light can be used to excite fluorochromes, 
which then emit light energy of a longer wavelength. The emission of light energy 
enables the fluorochrome to be visualised. A fluorescence microscope is thus required, 
which is essentially a light microscope adapted by way of a specific illumination system, 
epi-illumination. Two types of filters are used to view the fluorescence; an exciter filter 
which selects short wavelength light and absorbs the radiation emitted by other 
wavelengths and a barrier filter, which allows only emitted light to pass to the viewer, 
absorbing the remainder. The filters need to be of high optical quality to enable the 
relatively small and faint areas of fluorescence to be viewed as clearly as possible 
against a dark background.
To view more than one label, incorporation of dual or triple band pass filters is 
required. In this study, a Leica DMLB microscope with a triple band pass filter system 
was used that allowed the combination of Cy3, FITC and DAPI to be visualised, 
excitation wavelength range, 420nm to 570nm; emission wavelength range 465nm to 
640nm (Table 1). A 100 Watt mercury arc lamp supplied the short wavelength blue 
light. Viewing and scoring were performed with either a 40x Leica PL Fluotar oil 
immersion objective or a lOOx Leica N PLAN oil immersion objective, and 
photomicrography performed using a Wild 48/52 photoautomat system (Leica, UK).
2.4.7 Control Sections
Morphologically normal bladder sections were cut for inclusion in the study to provide 
figures for normosomy. Initially 10 bladder sections were stained, and the results were 
the basis for normal values of chromosome 8 and NAT2. In all subsequent FISH 
experiments involving tumour slides, two normal bladder sections were also included, 
one following the FISH method (positive control), the other following the FISH method 
but excluding probe. At that stage, hybridisation buffer only was applied to the section 
(negative control). The positive control controlled for reproducibility and reliability of 
the teclinique, the negative control for non-specific staining generated by the 
hybridisation mix and antibodies.
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2.4.8 Quantitation of Hybridisation Signals
To obtain the maximum data using the technique of FISH, a method of evaluating the 
results is required. Essentially evaluation involves counting the number of signals 
observed per interphase nucleus or metaphase spread.
The method for quantifying hybridisation signals generated from the centromeric 
probe was as follows: identify regions for analysis by FISH using adjacent haematoxylin 
and eosin stained slides and mark areas to be scored on an enlarged photocopy (200%) 
of the section (Figure 13), Analyse one to tliree tumour areas, depending on the section 
size. Count signals generated from each probe in 200 non-overlapping nuclei per area in 
the control and carcinoma sections using a multichaiuiel counter. The number of signals 
(0 to >4) observed in each individual nucleus were recorded. Calculate mean copy 
number by dividing the total number of signals observed by total number of nuclei 
scored.
The mean copy number for chromosome 8 was then divided by the copy number 
for cosmid NAT2 for each area assessed. This gave a measure of the relative 
hybridisation efficiencies of each probe. The technique was first applied to control 
sections (with normosomy for NAT2 and 8) and a reference value was established. 
Subsequent analysis of tumour sections allowed comparison with this normal value and 
tumours with abnormal copy number were identified.
This study was carried out as a collaborative project with the Department of 
Pharmacology, University of Oxford, and two independent observers counted the 
signals.
2.4.9 Summary
FISH using biotinylated NAT2 and digoxigenin labelled chromosome 8 was applied to 
chromosome spreads to verify probe specificity and then to tissue sections. 
Hybridisation was detected with anti biotin or anti digoxigenin reagents and visualised 
with fluorochrome labelled systems. Control sections were included to establish 
normosomy for both probes, and to check for hybridisation efficiency. Tissue sections 
were evaluated using a rigorous scoring system, a percentage by two independent 
observers.
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Table 1 Fluorochromes Utilised
Fluorochrome Excitation wavelength 
(nm)
Emission wavelength 
(nm)
Fluorescein isothiocyanate (FITC) 492 520
Indocarbocyanine, Cy3 550 570
4,6-diamidino-2 phenylindole-2 
hydrochloride (DAPI)
355 450
The fluorocliromes used in this study to visualise the in situ hybridisation are shown in 
this table, together with the wavelengths required to produce the appropriate signal
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Figure 13: Haematoxylin & Eosin Stained TCC showing an area to be 
scored for FISH
Photomicrograph on the following page
This photomicrograph illustrates the identification of an area from an haematoxylin & 
eosin stained TCC, correlated with an adjacent FISH stained TCC to verify tumour areas 
for analysis; TCC pTaG2, magnification X 8, size bar=0.5mm.
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CHAPTER 3 RESULTS
3.1 Patient Data
Information from the patients’ notes was gathered to give a concise record of age at 
diagnosis, smoking and occupational history, the number of cystoscopies and other 
clinically relevant data. Nineteen patients were recruited into the study.
3.1.1 Data Derived from Patient Notes
3.1.1.1 Smoking and Occupational Histories
Twelve out of 13 (92%) patients, for whom the data was available, had a history of 
smoking. Six patients’ smoking histories were not recorded in the case notes. Ten 
patients had occupational histories; only one had possible occupational exposure to 
carcinogens, a foreman painter (RNPl).
3.1.1.2 Patient Demographics
There were no significant differences in age at diagnosis, sex ratio, the number of 
cystoscopies and length of follow-up. Table 2 summarises data derived from patient 
notes with information about the primary carcinomas.
Patients presented with TCC within a similar age range, regardless of their 
subsequent disease course. Median follow-up was between 37 and 79 months, the 
longest being in the NR group. Five patients had follow-up of less than 36 months; two 
were lost to follow-up, one moved to another hospital and two died.
The NR patient group had the largest median number of cystoscopies, reflecting 
the longest median follow-up. Patients who presented with or developed detrusor- 
muscle-invasive disease (such as the RP and PP groups shown here) were followed up 
more frequently, compared to patients with non-muscle-invasive disease (such as the NR 
and RNP groups represented here).
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Table 2 Patient Demographics
Patient group NR (n=6) RNP (n=4) RP (n=4) PP (n=5)
Age at 65.2 ±11.2 64.5+13.6 59.7+15.4 62.6±5.3
Diagnosis (51-78) (51-82) (43-80) (56-70)
Sex M:F 6:0 3:1 3:1 2:3
Follow-up 79.0 40.5 37.0 65.0
(months) (24-106) (18-135) (14-152) (24-151)
Number of 11 7 7 8
Cystoscopies (1-18) (4-20) (3-27) (3-20)
Stage at
diagnosis
pTa 5 2 2 0
pTl 1 2 2 0
pT2/24- 0 0 0 5
Grade at
diagnosis
1 3 2 1 0
2 2 1 2 0
3 1 1 1 5
This table summarises the information gathered from patient notes 
Abbreviations: NR = patients with non recurrent TCC
RNP = patients with recurrent TCC but which did not progress to detrusor-muscle 
invasion
RP = patients whose recurrences had progressed to detrusor-muscle invasion 
PP = patients with detrusor-muscle invasion at presentation 
n = number of patients per group
Age at diagnosis = mean in years ±  SD, The range is in parentheses.
Follow-up = median in months. The range is in parentheses.
Number of cystoscopies = median. The range is in parentheses.
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Regardless of clinical course, patients in the NR, RNP and RP groups had similar stage 
and grade at diagnosis. Stage or grade at diagnosis were not compared using any formal 
statistical analysis as the numbers were too small. The PP group was selected by muscle 
invasion (pT2 or above) at presentation.
3.1.1.3 Examples of Two Patients in the Study
Data obtained from one of the NR patients and one of the RP patients are shown 
in more detail (Table 3). Patient NR2 presented with a pTaGl lesion, and was followed 
up until his death nine years later; no recurrences were detected during this time. An 
example of one of the RPs, patient R Pl, presented with a pTaGl lesion. After his first 
recurrence, a pTlG3 lesion, the patient was given palliative radiotherapy. He was 
followed up for 152 months (nearly 13 years), reflecting a long history of superficial 
carcinomas prior to muscle-invasion, and a pT2G3 lesion was reported at the last 
cystoscopy. Three months later he died due to metastatic bladder cancer.
3.1.1.4 Deaths Due to Bladder Cancer
Comparing deaths in the recurrer progressor (RPs) and progressed at presentation 
(PPs) patients, two of four (50%) of RPs and one of five (20%) of PPs died due to 
metastatic bladder carcinoma. Two of six (33%) of non recurrer (NRs) and two of four 
(50%) recurrer non progressor (RNPs) patients died of unrelated causes and one 
progressed at presentation patient died of unspecified causes. This suggested a trend but 
in such small numbers no conclusions could be drawn.
3.1.1.5 Chemotherapy and Other Adjuvant Therapies
None of the NRs was treated with chemotherapy; two of four (50%) of RNP 
patients were treated with epirubicin, one in addition with photodynamic laser therapy; 3 
of 4 (75%) of RP patients had chemotherapy or radiotherapy; 2 of 5 (40%) of PP patients 
had radiotherapy, none had chemotherapy.
3.1.1.6 Summary
The information obtained from the case notes was collected and allowed the 
patients to be categorised depending on clinical outcome. This information was used to 
correlate the FISH experiments’ results with genetic and chromosomal abnormalities and 
clinical events.
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Table 3 Example of Two Patients in the Study
Patient group NR RP
Age at diagnosis 77 43
Sex M M
Follow-up (months) 106 152
Number of 
cystoscopies
11 27
Primary carcinoma pTaGl pTaGl
First recurrence pTlG3
Preinvasion
carcinoma
pTaG2
Postinvasion
carcinoma
pT2G3
This table details clinical and pathological information from two patients within this 
study
Abbreviations: NR = non recurrer; RP = recurrer progressor
Primary carcinoma = stage and grade of primary carcinoma
First recurrence = stage and grade of first recurrent carcinoma
Last recurrence = stage and grade of last documented recurrent carcinoma
Preinvasion carcinoma = stage and grade of preinvasion carcinoma
Post invasion carcinoma = stage and grade of post invasion carcinoma
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3.2 Pathology
Patient selection was followed by the identification of material from TCC 
specimens, stored in the pathology archives. Tissue blocks containing the maximum 
amount of representative tumour were selected for each TCC case in order that histology 
sections could be utilised to analyse tumour genetics by FISH.
3.2.1 Available Tumour Material
Three categories of available tumour material were included in the study:
3.2.1.1 Small Biopsies
For this investigation, a sub-group of patients were identified from a previous 
study, all of whom had sufficient material for analysis. Sometimes insufficient material 
remains within the paraffin block, as sections are routinely taken at several levels 
throughout a diagnostic biopsy thus ensuring that the possibility of missing tumour is 
minimised. In these cases, the remaining tumour biopsy material was inadequate for 
further study. Biopsies from all suspicious areas and any morphologically normal areas 
were included, (Figure 14B, pTaG2).
3.2.1.2 Bladder Tumour Obtained by TURT
Material from this category was not limited by sample size as two to six paraffin 
blocks were made from the resected tissue sent to the Department of Pathology. Tissue 
sections representing each block were examined microscopically, and those with the best 
preserved tumour included (Figure 14C, pTaGl). Some blocks contained predominantly 
muscle or inflammatory tissue and therefore were excluded.
3.2.1.3 Cystectomy Specimens
Inclusion of material from this category was again not limited by sample size, but 
by the amount of mucosa remaining on the cystectomy specimen. Cystectomy 
specimens received in the pathology department are usually opened to allow the fixative 
access to the tissues. The inner mucosal layers are susceptible to auto lysis if this 
procedure is not carried out promptly and delays between operating theatre and 
laboratory are not unusual. All cystectomy tissue sections were examined, and those 
containing tumour with the best mucosal preservation selected for study. (Figure 14D, 
pT4G3).
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Figure 14: H&E sections of Bladder Tissue
Photomicrographs are on the following page 
14A: Morphologically Normal Bladder
This photomicrograph represents normal bladder mucosa, used in the analysis of 
normosomic values, magnification X 32, size bar = 0.2mm.
14B: Bladder Biopsy
This photomicrograph represents a bladder biopsy, pTaG2; magnification X 25, size bar 
= 0.2mm.
14C: Transurethral Resection of Tumour
This photomicrograph represents a transurethral resection of tumour (TURT), pTaGl; 
magnification X 8, size bar = 0.5mm.
14D: Cystectomy
This photomicrograph represents a section from a cystectomy specimen, pT4G3; 
magnification X 8, size bar = 0.5mm.
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3.2.2 TCCs Analysed
For NR and PP patients, the tumours analysed were: the primary (index) 
carcinoma, (n=l 1) and for RNP patients, the primary (index) carcinoma, first recurrence 
and last documented recurrence, (n=12). For RP patients, the primary (index) 
carcinoma, first recurrence, last pre- and first post-muscle-invasive carcinomas, were 
analysed (n=14). The total number of carcinomas analysed was 37. Photomicrographs 
of morphologically normal bladder mucosa and representative bladder carcinomas are 
illustrated in Figure 14, A to D.
3.2.3 Pathology Review
All TCC tissue sections were reviewed by Dr K.M. Grigor, Department of 
Pathology, Edinburgh Royal Infirmary. Three carcinomas were restaged from pTx to 
pTa and two from pTa to pTl (as the base of the tumour was clearly seen at restaging): 
three were regraded from G1 to G2, and one from G2 to G3. In total, 24% (9/37) 
carcinomas were reported differently at review. Tissue sections were then prepared as 
outlined in Section 2.2.2.
3.2.4 Summary
Tissue blocks for inclusion in the study were those most representative of the 
patients’ carcinoma. These were sectioned and stored for use with the FISH protocol.
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3.3 Nick Translation
3.3.1 DNA
The DNA for NAT2 was accompanied by an image of the dot plate used to 
establish the concentration by comparing spots of known concentration with the 
unknown, (Figure 15, arrowed). lOOng/pl was received in 50pl o f TE, pH8.0 and stored 
at -20°C. For nick translation, Ipg (lOpl) of DNA was added to each reaction.
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Figure 15: Dot plate
A range of concentrations of DNA were spotted onto a Petri dish containing an agarose 
gel. The intensity of the spot was then compared with an unknown spot to give a rough 
estimation of the DNA concentration. This was more reliable than OD values for DNA. 
The arrowed spot was the unknown, and the row above from left to right were 
concentrations of 100, 50, 25 and 12 ng/pl.
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3.3.2 Investigation  o f  the N ick  T ranslation  M ethod
3.3.2.1 Assessment of the Existing Nick Translation Protocol
The nick translation method using a kit (Gibco BRL) was performed, and the 
product run on a 1.5% agarose gel without pre-precipitation. The method is outlined as 
follows:
Combine the following:
lOpl (Ipg) DNA; 5pi dNTP mix: lOpl 5x biotin-16-dUTP; 20pl sterile distilled water, 
total volume 45pl. Microfuge. Add 5pi enzyme mix (DNA polymerase I, DNase I). 
Then proceed as outlined in sections 2.3.3.1 and 2.3.3.2.
The result was uncut cosmid, suggesting a lack of DNase I activity. This is 
shown in Figure 16A. Two samples of nick translated NAT2 cosmid were run on the gel. 
Both show the characteristic intense bands at the top of the gel which represent high 
molecular weight cosmid. A 100 base pair ladder was run so that the fragment size 
could be estimated, and this is seen in the far right hand lane. The DNA ladder was run 
with each gel as an internal size marker. Bands of equal intensity were observed for 200 
to 500 base pairs and higher intensity bands represented 100, 600 and 1 k base pairs.
On storage there is a progressive loss of DNase I activity after 4 to 6 months 
(Rigby et al, 1977). At this juncture the kit had been used for 5 and a half months. A 
new kit was ordered and the experiment was repeated. Similar results were observed 
impyling that the DNase I concentration was too low, rather than it heing inactive.
3.3.2.2 Comparison of Two Nick Translation Methods
Two methods were thus compared, the nick translation protocol outlined in 
Section 3.3.2.1 and a non-kit protocol previously used to study NAT2 copy number using 
FISH in bladder washings and exfoliated bladder cells (Stacey et al, 1996, 1999). The 
essential differences were that the former method used a dNTP mix of 0.2mM each 
dATP, dCTP and dGTP dTTP whereas the latter incorporated two-thirds the amount of 
dTTP and one third the amount of biotin dUTP. The existing method used 40mU/pl of 
DNase I whereas the alternative used 60mU/pl of DNase I.
The first method was specifically designed for radiolabelled nucleotides, but 
could be adapted for labelling biotinylated probes by incorporating a 1:2 ratio of biotin 
dUTP: dTTP. The stock solution of 0.4mM A, C, G, and T was further diluted to the 
correct proportions of 0.2mM A, C and G and 0.132mM T with additional 0.068mM 
biotin dUTP. This proportion of biotin dUTP:dTTP allows for the most efficient
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incorporation of biotin into the DNA. At low concentrations, incorporation of 
biotinylated dUTP may be compromised by steric hindrance by the biotin molecule 
(Leitch et al, 1994).
The two methods were compared directly in one experiment. An identical 
amount of product (8pl, and 2pi of gel loading buffer) was run on a gel. The existing 
method showed a similar result to the gel picture in Figure 16A i.e. incut cosmid, 
whereas the product from the alternative could not be visualised (results not shown).
This implied that the enzyme had been too active in the latter method and had 
digested all the DNA. The conclusion was that a compromise between methods was 
needed, as there was not enough enzyme in existing method and excess in the 
alternative. It was now necessary to closely compare the concentration of enzyme 
required to produce fragments of optimal length. In order to simplify the results from 
these comparative experiments, control DNA (pBR322) was used and biotin dUTP 
omitted. The protocol outlined in section 3.4.2.1 was followed, the two variables to the 
original technique thus being DNase I concentration and nick translation reaction time.
3.3.2.3 Comparison of Nick Translation Times
The recommended time for nick translation is between 60 and 90 minutes (Leitch 
et al, 1994). However the alternative method stops the reaction at 90 minutes and if the 
fragments are not of correct size, the reaction is allowed to proceed for up to 20 minutes 
longer. Nick translation was carried out at 65, 90, 100, 110 minutes to establish whether 
the generation of fragments could be controlled by altering the time of the nick 
translation. The protocol outlined in section 3.3.2.1 was followed and the result was 
large fragments of equal size in each of the four lanes, 1 to 4, representing a reaction 
time of 65, 90, 100 and 110 minutes (see Figure 16B). The fifth lane in this gel 
contained the marker DNA. Lanes 6 to 9 contained duplicate results to lanes 1 to 4 
results of the nick translation reaction followed as above, the only difference was that 
DNA from another cosmid was used to compare the results. However they were 
identical and the conclusion from this comparison was that not only did an increase of 
nick translation time have no effect on the size of fragments produced, but different 
sources of DNA also did not affect the reaction.
3.3.2.4 Comparison of DNase I Concentrations (1)
Several nick translation reactions were carried out in parallel using a range of 
DNase I concentrations. The alternative teclinique used 20mU/pI more than the kit 
(40mU/pl). Four dilutions, 40mU/pl, 50mU/pl, 62.5mU/pl, and 75mU/pl were
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compared. Additional amounts of enzyme were added to the existing protocol as 
follows:
Take Ipl of stock DNase I, lOU/pl, dilute with 99pl sterile distilled water, giving a 
dilution of O.lU/pl. Take 5pi of O.lU/pl DNase I and add to 195pl sterile distilled water, 
giving a dilution of 0.0025 U/pl, or 2.5mU/pl.
Table 5 outlines the volume of DNase I and sterile distilled water added, to give 
a range of enzyme concentrations increasing by lOmU/pl. The enzyme was added, 
together with the existing enzyme mix after all the other constituents had been added. 
The reagents were placed on ice and added together also on ice. The result was uncut 
fragments with 40mU/pl lanes 1 and 2, and no evidence of DNA in the next 3 lanes, 
representing 50mU/pl, 62.5mU/pl and 75mU/pl respectively. (Figure 16C). The 100 
base pair DNA ladder is in lane 6 to the right hand side of the fragments illustrated. In 
conclusion 40mU/pl of DNase I was insufficient to produce fragments of the correct 
size, whereas 50mU/pl of DNase I was an excessive amount.
Table 4 Comparison of DNase I Concentrations (1)
Final enzyme 
concentration (mU/pl)
40 50 62.5 75
Additional DNase I (pi) 0 4 9 14
Distilled water (pi) 27.5 23.5 18.5 14.5
The DNase I enzyme added was at a concentration of 2.5mU/pl.
3.3.2.5 Comparison of DNase I Concentrations (2)
The experiment was repeated with a range of DNase I concentrations from 
40mU/pl to 49.6mU/pl with stepwise increases of 0.6 mU/pl, and two reaction times of 
90 minutes and 110 minutes. Thus the protocol in section in 3.4.2.1 was followed with 
the addition of extra DNase I as follows. By taking 50pl of 2.5m U/pl and adding this to 
150pl sterile water this gave a dilution of 0.6mU/pl. The volume of DNase I and sterile 
distilled water added to produce the stepwise dilutions is shown in Table 6.
The gel from this experiment is illustrated in Figure 16D. The far left hand lane 
(large arrow, lane 1), which incorporated a DNase I concentration of 42.4mU/pl 
produced fragments of optimal size, approximately 500 base pairs, after 90 minutes. 
When the reaction was allowed to proceed for another 20 minutes, fragments of
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approximately 250 base pairs (small arrow, lane 2) were produced. Lane 3 incorporated 
a DNase I concentration of 44.8mU/pl following a reaction time of 90 minutes. This 
produced fragments of approximately the same size as lane 2. Lane 4 shows a far 
smaller fragment of approximately 100 base pairs when the reaction proceeded for a 
further 20 minutes. Lanes 5 and 6 incorporated a DNase I concentration of 49.6mU/pl 
and as before the reaction in lane 5 was stopped after 90 minutes, whereas that in lane 6 
proceeded for a further 20 minutes (total of 110 minutes). Lane 5 shows DNA 
fragments of similar size to that in lanes 2 and 3 (250 base pairs), whereas lane 6 showed 
fragments of 50 base pairs. The results from the experiments that incorporated DNase I 
at concentrations of 40mU/pl to 41.2 mU/pl are not shown. The fragments produced by 
40mU/pl showed uncut cosmid, a similar result to gel picture 16B; 40.6 mU/pl large 
fragments of over 1Kb; there was little DNA seen when 41.2 mU/pl of DNase I had 
been incorporated into the gel. These were the results following nick translation of 90 
minutes.
When the reaction proceeded for a further 20 minutes, there was no change in the 
result for 40mU/pl, 40.6mU/pl produced fragments of about 600 base pairs and 
41.2mU/jul produced a similar result to that of 90 minutes. The lack of DNA present in 
the gel from the reaction incorporating 41.2mU/pl may have been due to a pipetting 
error. In conclusion, the result shown for 42.4mU/pl after 90 minutes (lane 1, large 
arrow) was considered optimal for the production of suitably sized fragments for FISH.
Table 5 Comparison of DNase I Concentrations (2)
Final enzyme 
concentration (mU/pl)
40 40.6 41.2 42.4 44.8 49.6
Additional DNase I (pi) 0 1 2 4 8 16
Distilled water (pi) 27.5 26.5 25.5 23.5 19.5 11.5
The DNase I enzyme added was at a concentration of 0.6mU/pl.
3.3.2.6 Repetition of Experiment with Biotin dUTP & NAT2
As control DNA without biotin dUTP had been used to explore the parameters of 
time and DNase I, the experiments were repeated using control DNA and biotin 16 
dUTP and dTTP in the recommended 1:2 ratio. Similar results to those in Figure 16D 
were obtained (results not shown). The experiment then incorporating the NAT2 cosmid
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instead of control DNA and the optimum concentration of DNase I of plus one either 
side. The reaction was carried out for 90 minutes. Figure 16E shows in lane 1 that 
incorporated 41.2mU/pl of DNase I which produced fragments of about 1500 base pairs, 
which was too large. Lane 2 (42.4mU/pl) produced fragments of about 600 base pairs, 
too large for in situ hybridisation experiments. This time, lane 3, (44.8mU/pl arrowed) 
produced DNA fragments of the correct size, of 400 base pairs. The 100 base pair DNA 
ladder is in lane 6.
The above modifications were incorporated into the nick translation procedure, 
and the results produced fragments of suitable length for use in FISH (Figure 16F). The 
probe was then used successfully in the FISH method as outlined in sections 2.4.4.1 and 
2.4.4.2.
3.3.3 Conclusion
The most critical parameter in the nick translation reaction was the activity of 
DNase 1 (Leitch et al, 1994). Although a commercial kit ideally should perform under a 
wide variety of conditions, in this laboratory the enzyme concentration was insufficient 
and an additional 4.8 mU/pl of DNase I was required to produce fragments of the 
appropriate size (200-600 base pairs). Thus the modified protocol as outlined in section
2.3.3.1 was followed for the remainder of the project.
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Figure 16: DNA Fragments Obtained after Nick Translation 
Experiments
Images are on the following page; a 100 base pair DNA ladder is included in each 
experiment.
16A: Assessment of Existing Nick Translation Protocol
In this gel image, two lanes of DNA, both of which show the intense bands characteristic 
of high molecular weight cosmid at the top of the gel. The far right hand lane contains 
the DNA ladder.
16B: Comparison of Nick Translation Times
In this gel image, large fragments of DNA of equal size in each of the four lanes, 1 to 4, 
representing a reaction time of 65, 90, 100 and 110 minutes. The fifth lane in this gel 
contained the marker DNA. Lanes 6 to 9 contained duplicate results to lanes 1 to 4 
results of the nick translation reaction followed as above, the only difference was that 
DNA from another cosmid was used to compare the results.
16C: Comparison of DNase I Concentrations (1)
In this gel image, uncut fragments of DNA are seen in lanes 1 and 2, and no evidence of 
DNA in the next 3 lanes. The 100 base pair DNA ladder is in lane 6 to the right hand 
side of the fragments illustrated.
16D: Comparison of DNase I Concentrations (2)
In this gel image, lane 1 (large arrow), illustrates fragments of optimal size, of 
approximately 500 base pairs; lane 2 illustrates fragments of approximately 250 base 
pairs and lane 3 illustrates fragments of approximately the same size as lane 2. Lane 4 
shows a DNA fragment of approximately 100 base pairs. Lane 5 shows DNA fragments 
o f similar size to that in lanes 2 and 3 (250 base pairs), whereas lane 6 showed fragments 
o f 50 base pairs. The differences between the lanes of DNA fragments are explained in 
the text.
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16E: Repetition of Experiment Including Biotin I6-dUTP and NAT2 
Cosmid
Lanes 1 to 3 show the different sizes of DNA fragments produced by altering the DNase 
I concentration, incorporating biotin 16-dUTP and NAT2. Lane 3, (arrowed) produced 
DNA fragments of the correct size, of 400 base pairs. The 100 base pair DNA ladder is 
in lane 6.
16F: Repetition of Experiment with Optimal DNase I Concentration
Recapitulation of the experiment shown in Figure 16E with the optimal DNase I 
concentration; DNA ladder on the right.
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3,4 FISH: Modification for Formalin Fixed, Paraffin
Processed Sections
The nick translated NAT2 cosmid had previously been hybridised to exfoliated 
bladder cells from urine (Stacey et al, 1996), and bladder barbotage cells (washings) 
(Stacey et al, 1999) using the FISH technique. The cosmid was received in the 
laboratory and nick translated with a commercial kit. This was the first time the cosmid 
had been applied to formalin fixed paraffin processed material therefore extensive 
modifications of a previous teclmique were required. Morphologically normal skin 
sections were used principally in the evaluation and refinement of the methodology, 
together with chromosome spreads and bladder carcinoma sections where indicated.
3.4.1 Initial Evaluation
The method in place for commercial alpha or classical satellite probes was used 
for the first experiments. Formalin fixed, paraffin wax embedded bladder tissue sections 
were digested with 0.4% pepsin in 0.2 N HCl for 45 minutes; (chromosome spreads 
followed the protocol outlined in 2.4.4.1). lOpl (200ng) of biotinylated NAT2 cosmid 
probe (supplied by M. Stacey) and alpha satellite chromosome 8 probe was applied per 
slide predenatured at 75°C for 5 minutes; the sections or spreads were denatured at 72°C 
for 4 minutes. Weak signal for both the alpha satellite (red) and NAT2 (green) probes 
and precipitate were observed as shown in the photomicrograph, Figure 17A. Poor 
probe accessibility or purity and insufficient post hybridisation washes were suggested 
as possible causes of the weak signal and precipitate.
The DNA was precipitated as outlined in section 2.3.3.1 to increase purity, 
different digestion protocols were compared to improve accessibility of the probe as 
were various post hybridisation washes to eliminate precipitate.
3.4.2 Digestion
The material used in this study had been fixed with 10% neutral buffered 
formalin to preserve tissue morphology, therefore a tissue digestion step to unmask 
nucleic acids was required to perform in situ hybridisation. The standard fixative in 
histology laboratories, neutral buffered formalin, is an aldehyde that cross-links proteins 
and nucleic acids. Unmasking is achieved with limited proteolysis and must be 
optimised for each experimental system (Herrington & McGee, 1992).
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Two digestion methods with paraffin embedded material and the NAT2 cosmid 
probe only were compared. The DNA was nick translated following the method in 
section 2.3.3.1. DNA was precipitated before use as outlined in section 2.3.4. The 
existing method, previously used in this laboratory, had less steps at the digestion stage 
compared to the alternative (Table 6). The inclusion of 0.2N HCl and Triton X are 
tissue permeabilisation steps (Hopman et al, 1992). Normal skin and bladder carcinoma 
sections were used to make the comparison: using the existing method and skin sections, 
very weak patchy hybridisation with non specific staining was observed. With the 
alternative, nuclei were better preserved compared to the existing method, probably due 
to the shorter digestion time. More non specific staining in the alternative was observed 
compared to the existing method; hybridisation signal was comparable in both methods.
Using bladder carcinoma sections, no hybridisation and some non-specific 
staining was observed with the existing method. More precipitate was seen with the 
alternative method, largely obscuring assessment of nuclear preservation and possible 
signal, as shown in Figure 17, B and C. The conclusion was that the existing method 
gave better probe accessibility as less precipitate (non specific staining) was observed 
although the very weak signal suggested the accessibility could be improved.
An alternative digestion protocol, for unique sequence probes (Pauletti et al, 
1996) includes a pretreatment step of 30% sodium metabisulphite followed by 0.25% 
proteinase K in 2 X SSC. Sodium metabisulphite is a strong reducing agent that 
destroys disulphide bridges in proteins (Ottaway & Apps, 1984). This step is 
particularly recommended with proteinase K and is thought to reduce autofluorescence 
and enhance the accessibility of target DNA (Lowery, 1998). Cosmid NAT2 probe was 
applied with the alpha satellite probe for chromosome 8. A simple comparison between 
two bladder carcinoma sections was made, vaiying only the tissue digestion. All other 
methodological steps were identical. More green precipitate was observed with pepsin 
digestion; the nuclei stained a deeper blue (DAPI), indicating improved digestion and 
the NAT2 signals (green) were more easily visualised with proteinase K digestion 
(Figure 18 A and B). In conclusion, the method for FISH was modified to incorporate 
sodium metahisulphite and proteinase K as the digestion steps. However the level of 
precipitate in the background was still high which led to an investigation of the probe 
purity.
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Table 6 Comparison of Two Digestion Protocols
Existing method Alternative method
0.4% pepsin in 0.2N HCl for 
45 minutes at 37°C
0.2N HCl 10 minutes, PBS 2 x 5  minutes: 
0.01% Triton X in PBS 3 minutes; PBS 2 x 5  
minutes; 0.4% pepsin for 20minutes at 37°C
The components of two digestion methods used in the evaluation of the FISH 
methodology
Abbreviations: PBS=phosphate buffered saline
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Figures 17-20: Evaluation of FISH Methodology
Photomicrographs are on the following four pages, red signal represents the 
chromosome 8 probe, green signal the NAT2 probe, size bars 20pm and magnification X 
320, unless otherwise stated.
17A: Normal Bladder using the Existing Protocol
Preliminary experiment with the existing FISH protocol, arrows to the NAT2 signal.
17B: Normal Bladder using the Existing Digestion Protocol
An exploration of the existing digestion protocol as a comparison with Figure 17C, 
magnification X 128.
17C: Normal Bladder using the Alternative Digestion Protocol
The alternative digestion protocol, showing excessive precipitate, magnification X 128.
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ISA: Skin Tissue Section Digested with Pepsin & 18B: Skin Tissue 
Section Digested with Proteinase K
A comparison of two digestion methods using differing proteolytic enzymes, in both 
photomicrographs the NAT2 hybridisation signal is arrowed.
18C: Normal Bladder Section Incorporating NICK Columns in the 
Technique & 18D: Normal Bladder Section Without NICK Columns in 
the Technique
A comparison of the FISH technique altering only the way in which the prohe was 
purified, NAT2 hybridisation signal is arrowed in Figure C.
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3.4.3 NICK Columns
NICK columns (Pharmacia) are prepacked disposable columns containing Sephadex 
G-50 grade to separate nick translated DNA from unincorporated label. The aim of 
running the nick translation product through a NICK column, in this project, was to 
eliminate the precipitate seen at the post hybridisation stage, thought to be 
unincorporated label. The protocol outlined below was followed:
1. Allow the equilibration buffer (Pharmacia) to completely enter the gel bed. Add 
100ml of 2.5% dextran sulphate and 2.5% eosin to the NICK column. Elute the 
solution followed by lOx 200pl 0.1 X SSC and 0.1% sodium dodecyl sulphate, SDS, 
(BDH, UK) and collect the fractions in a volume of 200pl. Note at which fraction 
the dextran sulphate (blue) and eosin (pink) are collected, Dextran sulphate has a 
high molecular weight similar to DNA; eosin a low molecular weight comparable 
with biotin. By noting at which fraction the two compounds are collected, this can be 
extrapolated to the nick translated DNA. Fraction 3 was blue and fraction 10 pink.
2. Allow the equilibration buffer (Pharmacia) to completely enter the gel bed. Add 
nick translated DNA to the NICK column. Elute the solution followed by 1 Ox 200pl 
0.1 X SSC and 0.1% SDS and collect the fractions. Fraction 3 was theoretically the 
DNA.
3. Precipitate DNA following the method in section 2.3.4.
DNA probe for NAT2 that had been prepared using the NICK column was 
subsequently compared with the unpurified NAT2 probe using the FISH method as 
outlined in section 3.3.1 and bladder sections. There was a distinct loss of signal 
following the use of the NICK column although the preparation was cleaner as 
demonstrated in bladder sections (Figure 18 C and D). The use of such columns is 
recommended for in situ hybridisation (Stickland, 1992), where less background was 
observed. However, the type of probe was not specified. A possible explanation for the 
lack of signal is that the biotin bound to the DNA was meshed in the Sephadex beads 
due to its shape. In conclusion, in these experiments, there was a lessening of 
hybridisation signal following the use of NICK columns. This step was therefore not 
incorporated into the methodology in this study based on the assessment o f a single copy 
gene. This methodology may be beneficial in larger probes or possibly those labelled 
with digoxigenin.
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3.4.4 Suppression Hybridisation
The addition of COT-1 DNA is recommended, when studying unique sequences 
(Lichter et al, 1990). The standard FISH method did not contain this step, and was thus 
compared with the addition of COT-1 DNA. Figure 19 illustrate the differences between 
the two conditions. Chromosome 8 is identified by the red hybridisation signal at the 
centromere. In the chromosome spread without the co-precipitation of COT-1 DNA 
(Figure 19A) weak cross reaction (red) with another two chromosomes was seen. No 
green signal {NAT2) was evident on the short arm of either chromosomes that had the 
red hybridisation signal. By contrast, the NAT2 cosmid’s signal was clearly seen in the 
chromosome spread on the p arm of chromosome 8 (Figure 19B, arrowed), when the 
cosmid DNA was co-precipitated with COT-1 DNA,
In the skin sections the hybridisation signal for chromosome 8 was clearly seen 
as two red dots in the nucleus. There was less precipitate when the cosmid DNA was 
co-precipitated with COT-1 DNA although the signal intensity was higher where the 
COT 1-DNA had been excluded, but it was difficult to pick out the hybridisation signal 
(Figures 19, A and B). Some laboratories pre-precipitate the DNA with COT-1 DNA, 
(Murphy et al, 1995), others add it to the hybridisation mix (Bell et al, 1996 and 
Kallioniemi et al, 1995). In this study it was convenient to add the cosmid and COT-1 
DNA preprecipitated to the hybridisation mix optimised for centromeric probes and thus 
the concentrations of either probe did not need to be altered. A recommended 
concentration of 10 times COT-1 DNA to cosmid DNA was used and found to be 
satisfactory (Lichter et al, 1990).
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19A: Chromosome Spread Without Incorporation of COT-I DNA & 
19B: Chromosome Spread With Incorporation of COT 1 DNA
A comparison of the FISH methodology without and with COT-1 DNA to improve the 
NAT2 probe purity, showing lack of NAT2 signal in the cliromosome spread without 
COT-1 DNA, NAT2 arrowed in Figure 19B.
19C: Skin Tissue Section Without Incorporation of COT-1 DNA & 
19D: Skin Tissue Section With Incorporation of COT-I DNA
A comparison of the FISH methodology without and with COT-1 DNA to improve the 
NAT2 probe purity, showing lack of NAT2 signal in the skin tissue section without COT- 
1 DNA, NAT2 arrowed in Figure 19D.
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3.4.5 Post Hybridisation Wash
Probes are hybridised under conditions of low stringency, to allow 
complementary DNA strands to reanneal correctly. This also results in weakly bound 
mismatched hybrids that can be removed by a post hybridisation wash. This must be 
more stringent than the hybridisation conditions and is achieved by increasing the 
concentration of monovalent cation i.e. N a \ increasing the concentration of formamide 
and/or increasing the washing temperature (Herrington & McGee, 1992). The 50% 
formamide 2 X SSC wash and 2 X SSC washes, both performed at 42°C for 20 minutes, 
used as the post hybridisation wash in the method for alpha and classical satellite probes, 
was directly compared to two other washes, a 2 X SSC or a 1 X S S C  wash, both 
performed at 72°C for 5 minutes. Skin sections were used in this analysis. The protocol 
for precipitation with COT-1 DNA, tissue digestion and prehybridisation steps was 
followed as outlined in the Methods chapter, sections 2.3.4 and 2.4.4.2.
Photomicrographs for each of the posthybridisation washes are shown in Figure 
20. The 50% formamide wash showed large green signals localised to the nucleus but 
also a high degree of green precipitate, but no red (chromosome 8) signal was evident 
(Figure 20A). The 1 X SSC and 2 X SSC washes both showed distinct signal for both 
the cosmid and centromeric probes (Figures 20 B and C, NAT2 hybridisation signals 
arrowed). However, the cleanest preparation was seen with the 1 X SSC wash, with the 
least preeipitate. High salt concentration solutions e.g. 2 X SSC are less stringent than 
low salt concentrations (such as 1 X SSC) (Mitchell et al, 1992) and are less likely to 
remove weakly bound non specific hybrids. For these particular probes, the higher 
stringency wash gave the most acceptable preparations, which allowed clear 
visualisation of the signal generated from the biotin labelled NAT2 probe. The scoring 
results were also included to compare signal intensity following the 1 X SSC and 2 X 
SSC post hybridisation washes. As shown in Table 7 there was a higher percentage of 
nuclei with 1 or 2 signals in the section following thel X SSC compared to the 2 X SSC 
wash. These data consolidated the choice of the 1 X SSC wash in the protocol.
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20A: Skin Tissue Section With Existing Post Hybridisation Wash
With the 50% formamide, 2 X SSC wash, excess green precipitate was seen, masking 
the NAT2 signals
20B: Skin Tissue Section With 2 X SSC Wash
A lessening of precipitate was seen with this wash compared to Figure 20A, NAT2 signal 
arrowed.
20C: Skin Tissue Section With 1 X SSC Wash
A lessening of precipitate was seen with this wash compared to Figure 20A, NAT2 signal 
arrowed.
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Table 7 Comparison of Scoring Results for Post Hybridisation Washes
PHW Probe 0 1 2 Total MCN NAT2:%
2 X SSC 8 1 45 54 100 1.53
2 X SSC NAT2 42 39 19 100 0.77 50.33%
1 X SSC 8 3 31 66 100 1.63
1 X SSC NAT2 26 20 54 100 1.28 78.23%
This table shows the results of scoring two skin tissue sections varying only the post 
hybridisation wash; the scoring results show a higher number of hybridisation signals for 
both NAT2 and chromosome 8 probes with the 1 X SSC wash.
Abbreviations: PHW = post hybridisation wash; 0, 1,2 = number of signals per nucleus; 
MCN = mean copy number;
NAT2\^ = mean copy number of NAT2 divided by chromosome 8
3.4.6 Summary of Modifications to the FISH Method
Vai'ious parameters of the FISH method were investigated, to attempt to 
overcome the presence of precipitate and to enhance the weak hybridisation signal. A 
eompetitior together with the NAT2 cosmid probe reduced preeipitate as did a proteolytic 
digestion step involving proteinase K as opposed to pepsin. A cleaner preparation was 
then observed with a 1 X SSC post hybridisation wash compared to any other wash. 
These modifications gave optimal results for the evaluation of the hybridisation signals 
and were adopted as the standard protocol.
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3.5 Fluorescence in situ Hybridisation (FISH)
3.5.1 Metaphase Spreads
The cosmid had previously been used to demonstrate NAT2 specificity (Stacey et 
al, 1996). The NAT2 probe was hybridised to chromosomes arrested in metaphase 
together with a probe for the 8 centromere (Figure 21 A) to identify clii'omosome 8. 
Hybridisation was seen on the p arm of chromosome 8 (arrowed) in the correct region 
for the NAT2 gene. No other hybridisation signals were seen thus confirming probe 
specificity.
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Figure 21: The FISH Protocol on a Chromosome Spread and a Range 
of Bladder TCC Sections,
The photomicrographs are shown in the following two pages, magnification X 320, size 
bars 20pm, unless otherwise stated.
21A: Chromosome Spread
This preparation shows NAT2 probe specificity, to the short arm of chromosome 8, 
identified by the strong red hybridisation signal for chromosome 8; NAT2 signals 
arrowed.
21B: Normosomy Chromosome 8 and NAT2
This TCC, pTlG2 is normosomic for chromosome 8 and NAT2 (arrowed).
21C: Polysomy Chromosome 8, Normosomy AWT2
This TCC, pTlG3 is polysomic for chromosome 8, normosomic for NAT2 (arrowed).
21D: Polysomy Chromosome 8 and NAT2
This TCC is polysomic for chromosome 8 and also shows multiple signals for NAT2 
(arrowed).
21E: Polysomy Chromosome 8 and NAT2
This TCC is polysomic for chromosome 8 and also shows multiple signals for NAT2.
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3.5.2 Assessment of Tissue for Adequate Digestion
As outlined in Section 3.3.2, proteolysis is required for in situ hybridisation on 
formalin fixed tissue, to access the DNA. However this must be achieved with minimal 
tissue damage, to enable morphology to be correlated with genetic aberrations. 
Optimum maintenance of cell and tissue morphology following unmasking of nucleic 
acids is achieved by assessment o f tissue sections following proteolytic digestion prior 
to hybridisation. Viewing the nuclear staining intensity due to the intercalation of DAPI 
with DNA is a reliable indicator of the extent of digestion. Areas from distinct regions 
of the tissue sections were assessed to control for variability in fixation effects and thus 
proteinase K digestion. If the digestion of at least two thirds of the tumour was optimal, 
then these slides were suitable for hybridising. Figure 22A shows an underdigested 
TCC, figure 22B an optimally digested TCC and Figure 22C an over digested section of 
TCC. As would be expected with the wide range of tissue included, from small biopsies 
to cystectomies there was variability in the digestion times because of fixation 
differences.
3.5.3 Assessment of Control Sections
In every control section, 200 nuclei were assessed, both in the initial evaluation 
and when controls were included in the assessment of the patients’ TCC’s. The data 
from one control section are shown in Table 8. The mean copy numbers for 
chromosome 8 and NAT2 were calculated as outlined in Section 2.4.8 and further 
explained in the accompanying legend. From this could be derived the data for each 
section and a mean value for normosomy established (Table 9).
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Figure 22: Digestion Profile
The photomicrographs illustrating the variability in digestion are shown on the following 
page, magnification X 128, size bars 50pm.
22A: Underdigested TCC Section
Although the nuclei can be discerned, protein remains which masks the preparation 
22B: Optimally Digested TCC
Nuclei are clearly seen in this preparation, and this represents an optimally digested 
tissue section.
22C: Overdigested TCC
The morphology of the specimen is beginning to disappear, and nuclear borders are 
irregular, representing an overdigested tissue section.
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Table 8 Data For One Control Section
Observer Probe Signal (%)
MCCN/
MGCN
Mean
MCCN/MGCN lOV (%) Mean
NAT2\^
(%)
0 1 2
A 8 11 30 59 1.48
1.45B 8 8 43 49 1.43
A NAT2 12 43 45 1.33
1.20 14.7 82.9B NAT2 26 41 33 1.08
Results of one control section assessed by two observers (A and B), independently 
Abbreviations: MCCN = mean chromosome copy number calculated by multiplying the 
number of nuclei with 0 signals by 0, the number of nuclei with one signal by 1 etc 
summing the number of signals and dividing by the number of nuclei counted. Therefore 
for observer A and the chromosome 8 probe, (11 X 0) + (30 X 1) + (59 X 2) = 148. 
Divide the number of signals by the number of nuclei (100) to give a value of 
1.48.
MCGN = mean gene copy number, calculated in the same way as MCCN; The 
mean value was calculated by adding the two values together and dividing by 
2 .
lOV = interobserver variation, the difference between observer for the values 
obtained per signal; mean NAT2\^ is calculated by dividing mean MGCN by 
mean MCCN and expressing this as a percentage.
Assessment of 10 control sections with two independent observers established 
normal values for chromosome and cosmid probes (Table 9). For cliromosome 8, the 
mean value o f the data for MCCN (mean chromosome copy number) were 1.49 ±_0.07 
(1.40-1.60), for MGCN (mean gene copy number) for NAT2 1.10 +0.20 (0.72-1.35); 
mean NAT2\^ ratio was 73.3 + 13.1 (51.1-89.7); +SD, range in parentheses. A loss of 8 
was defined as the MCCN minus 3 standard deviations i.e. 1.28, and a gain of 8 defined 
as the mean plus 3 standard deviations i.e. 1.70. The same calculation was applied to the 
MGCN for NAT2 copy number and a loss was calculated as less than 0.50, a gain as
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greater than 1.70. Once again the mean + 3 SD was applied to the NAT2\^ ratio. 
Therefore a normal ratio was between 33.9% and 112.7%. These values were compared 
with the results from the tumours. Eighty percent of the controls and thirteen (35.1%) of 
the 37 TCC’s were dual scored.
Table 9 Data for Ten Control Sections
Chromosome 8 
MCCN
Cosmid NAT2 
MGCN
NAT2:% ratio (%)
1.45 1.20 ■ 82.8
1.53 1.32 86.3
1.60 0.97 60.5
1.40 0.72 51.1
1.51 1.35 89.6
1.42 1.06 74.4
1.55 0.92 59.3
1.51 E27 84.4
1.51 1.03 67.6
1.40 1.08 77.1
The results of the evaluation of 5 control sections and two observers is shown in Table 
10. This exemplifies the methodology used, initially for control material and then 
applied to carcinomas in the patient series. Calculations were as previously outlined in 
Table 8 and in Section 2.4.8.
Abbreviations: MCCN/MGCN = mean chromosomal copy number/ mean gene copy 
number; mean NAT2:^ = mean ratio of NAT2\% (%)
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Table 10 Results of Evaluation of 5 Control Sections and Two 
Observers
Slide 1 2 3 4 5
Observer A B A B A B A B A B
MCCN 8 1.48 1.43 1.63 1.57 1.38 1.43 1.61 1.41 1.47 1.59
MGCN 
NAT2
0.94 1.13 0.95 0.98 0.77 0.67 1.33 1.38 0.94 1.13
Mean 8 1.53 1.60 1.40 1.51 1.53
Mean 
NAT2
1.03 0.97 0.72 1.35 1.03
IOV8 5.7 2.7 2.4 9.3 5.7
ION NAT2 13.0 2.5 10.2 2.6 13.0
Mean
NAT2\^
67.6 60.5 51.1 89.6 67.6
This table details the scoring information derived from the assessment of 5 bladder 
sections and two observers.
Abbreviations: MCCN, MCGN as previously defined inTable 8, IOV=interobserver 
variation (%); the ratio of NAT2\^ expressed as a percentage.
3.5.4 Inter Observer Variation
Inter observer variation (lOV), a measure of reproducibility of the technique, for 
controls was 6.97% + 6.05% for chromosome 8 and 11.79% + 6.04% for NAT2. lOV 
for the tumours for chromosome 8 was 5.75%± 4.41, for NAT2 10.95%+ 18.18. Figures 
represent the mean +SD (Table 11). High inter observer variation was noted when the 
NAT2 copy number was very low, but the scores were still eoncordant. The data from 
which these figures were derived is shown in the table below.
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Table 11 Figures for lOV in Controls and Tests
Section lOV chromosome 8 \OW NAT2
Control 2.4 10.2
Control 2.5 9.3
Control 15.9 20.5
Control 16.8 5.9
Control 5.7 13.0
Control 7.2 18.2
Test 9.6 63.1
Test 3.0 41.9
Test 3.5 27.9
Test 1.6 14.1
Test 3.2 6.3
Test 3.6 10.9
Test 5.1 4.5
Test 13.8 3.6
Test 13.6 20.8
Test 5.8 2.2
Test 1.0 23.9
This table shows the data obtained from the evaluation of tissue sections both in control 
and test sections from two observers. lOV (inter observer variation) is a measure of 
concordance between observers.
3.5.5 Evaluation of TCCs
Each TCC case was stained with haematoxylin & eosin, compared with the FISH 
stained section and specific tumour areas marked for analysis (Figure 13). The section 
was also assessed for variations in pathology. For example, where a TCC had been 
reported as superficial in part of the tissue but muscle-invasive in another, both areas 
were scored. If more than one tissue fragment was present in a biopsy specimen, each
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Table 13 Stage and Grade of Recurrent TCCs with FISH Results
Patient MCCN
Chromosomes
MGCN 
Cosmid A4 T2
A4T2:8 
ratio (%)
Stage 
and grade
RNP1(2) 1.67 1.18 70.8 pTlG3
RNP1(3) 1.51 0.88 58.3 Severe dysplasia
RNP2(2) 1.59 1.30 82.4 PTaGl
RNP2(3) 1.57 1.09 69.6 PTaGl
RNP3(2) 1.64 0.73 44.6 PTaG2
RNP3(3) 1.62 0.94 58.0 PTaG2
RNP4(2) 1.66 1.01 60.6 PTaG2
RNP4(3) 1.75 1.27 73.0 pTlG2
RP1(2) 2.13 1.38 65.0 pTlG3
RP1(3) 2.36 1.06 46.2 PTaG2
RP1(4) 3.17 2.69 84.8 pT2G3
RP2(2) 1.54 0.53 34.4 PTaG3
RP2(3) 1.64 0.68 41.5 pT2-4G3
RP3(2) 2.38 0.49 20.4 PTaG2
RP3(3) 2.49 2.03 81.5 pTlG3
RP3(4) 2.17 1.37 63.1 pT2G3
RP4(2) 3.61 1.72 47.6 pT2G3,CIS
RP4(3) 3.27 2.30 70.4 pT2G3,CIS
This table shows the results derived from assessment of FISH stained TCCs, together 
with stage and grade.
Abbreviations: MCCN= mean chromosomal copy number; MGCN= mean gene copy 
number; A477:8= the ratio of NAT2\% as a measure of hybridisation efficiency expressed 
as a percentage; RNP=recurrer non-progressor, number in parentheses refers to 
recurrence; RP=recurrer progresser, number in parentheses refers to recurrence (2, 3), 
progression (4); except for RP2 and 4 where recurrence 3 was also the progression event.
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3.S.5.3 Assessment of Mean Chromosome and Gene Copy Number
Seventeen tumours were normosomic by the definition of MCCN/MCGN outlined in 
section 3.5.3 (Figure 21B, NAT2 signals arrowed). Twenty tumours were abnormal for 
gene and/or chromosomal copy number (Tables 12 and 13). One (3%) had loss of NAT2 
and normosomy 8; two (6%) had loss of NAT2 with polysomy 8; ten (27%) had 
normosomy NAT2 and polysomy 8 (Figure 21C, NAT2 hybridisation signals arrowed) 
and seven (19%) had polysomy of both gene and chromosome (Figures 2 ID, NAT2 
arrowed, and 2 IE). Comparing grade with any abnormality, using the chi square test, 
two of eight grade 1 ,5  of 11 grade 2 and 14 of 17 grade 3 were abnormal (p=0.01). 
Comparing stage with any abnormality, 7 of 18 were pTa, 5 of 8 were pTl and 9 of 10 
were pT2 and above (p=0.03).
3.5.5A NAT2:S Ratio
The NAT2:^ ratio expressed as a percentage was also used in the assessment of the 
TCC’s.But there were only two tumours categorised as having loss of NAT2 over and 
above those defined by MGCN. But in some cases, A4 77:8 ratio may be a more 
accurate measure than mean gene copy number of gene dosage as it takes chromosome 
copy number into account in the analysis. That is, a polysomy 8 could have a “normal” 
gene copy number such as patient NR6 (Table 12) which is defined as a loss by gene to 
chromosome ratio. Both methods of analysis were included in this study; either gave 
valuable information which may have been missed by including one or the other in the 
assessment of gene copy number.
A normal ratio was defined as within the range 33.9% to 112.7%, following 
assessment of 10 tissue sections normosomic for chromosome 8 and A4 77 copy number 
(Table 9). Thirty two tumours had a normal ratio, 5 were abnormal, defined as loss of 
A477 copy number relative to chromosome 8 copy number. Two defined as 
normosomic for A477 (NR6 and PP3) had a loss of A477 by this method, the remaining 
3 had a loss of NAT2 defined either by mean gene copy number or mean ratio.
The tumour reported as severe dysplasia was normal for both gene and 
chromosome copy number using either MCCN/MGCN or ratio of A47’2:8 to define 
normosomy.
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Figure 23: Percentage of Abnormal TCCs in each Patient Group
This graph illustrates the percentage of abnormal tumours categorised by patient group 
and is shown on the following page.
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3.5.6 Assessment of Primary TCCs
Nineteen patients were included in the study (Table 12).
3.5,6.x Mean Copy Number For Chromosome 8
Nine patients were normosomic for chromosome 8 as previously defined. Ten 
patients had polysomy of chromosome 8. Comparing stage with copy number, 7 of 10 
pTa were normosomic, 3 were polysomic; 2 of four p T l’s were normosomic, two were 
polysomic; no pT2 or above were normosmic, 5 of 5 were polysomic for chromosome 8. 
Comparing grade with copy number, 4 of 6 grade 1 s were normosomic, 2 polysomic; 4 
of 5 grade 2s were normosomic, one was polysomic and 1 of 8 grade 3 patients were 
normosomic, 7 were polysomic (Table 14).
Table 14 The Number of Index TCCs Normosomic & Aneusomic for 
Chromosome 8
Stage/grade Chromosome 8
Normosomic Polysomic
pTa/pTl 9 5
pT2 and above 0 5
Grade 1 4 2
Grade2/3 5 8
The number of index (primary) TCCs normosomic and polysomic for cliromosome 8 
copy number categorised by stage and grade.
3,5.6.2 Copy Number îorNAT2  in Primary TCCs
Fourteen patients were normosmic for NAT2 copy number, five aneusomic, as 
previously defined. Two patients TCCs demonstrated a loss of NAT2, three showed an 
increase in NAT2 copy number. Comparing stage with copy number, 8 of 10 pTa TCCs 
were normosomic, two aneusomic, both showing a loss of NAT2 copy number; 3 of 4 
pTls were normosomic, one aneusomic, demonstrating an increase and 3 of 5 pT2 or 
above were normosomic, two aneusomic, both with an increase of gene copy number. 
Comparing grade with copy number, 5 of 6 were normosomic for grade 1, one had a loss 
of NAT2 copy number; 4 o f 5 were normosmic for grade 2 TCCs one demonstrated a 
loss; 5 of 8 grade 3 s were normosmic, 3 had a gain of copy number (Table 15).
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Table 15 The Number of Index TCCs Normosomic and Aneusomic For
NAT2 Copy Number
Stage/grade NAT2
Normosomic Aneusomic
pTa/pTl 11 3
pT2 and above 3 2
Grade 1 5 1
Grade2/3 9 4
The number of index TCCs normosomic and aneusomic for NAT2 copy number 
categorised by stage and grade.
3.S.6.3 Copy Number for Chromosome 8 and NAT2
Using the MCCN/MGCN to assess primary TCCs, eight were normosomic and 
11 aneusomic for chromosome and/or gene copy number (Table 16). Abnormalities of 
either chromosome or gene copy number were seen in 2/6 (33%) of grade 1 TCCs and 
9/13 (61.5%) of grade 2 or 3 TCC, There was an association with high stage and 
aneusomy, however, as 6/14 (36%) of pTa/pTl TCCs were abnormal whereas 5/5 
(100%) of pT2 or above were abnormal. The percentage of each patient group with 
genetically abnormal primary and recurrent TCCs is illustrated in Figure 23. 
Normosomy was observed in 4 of 6 NR patients, 3 of 4 RNP patients, 1 of 4 RP patients 
but in none of the PP patients.
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Table 16 The Number of Index TCCs Normosomic and Polysomic For
Chromosome 8 and NAT2 Copy Number
Stage/grade
pTa/pTl
pT2 and above
Grade 1
Grade2/3
Chromosome 8 &
NAT2
Normosomic Aneusomic
The number o f index TCCs normosomic and aneusomic for chromosome 8 and NAT2 
copy number categorised by stage and grade 
3.5.6.4A4J2:8 Ratio
Applying the ratio of A477:8 to categorise primary TCC’s, fifteen had a normal 
ratio, as previously defined, 4 were abnormal, of whom 1/6 were grade 1, 3/13 grade 2 
or 3. Four of 14 were pTa or pTl and 1 of 5 were pT2 or above. (Table 17).
Table 17 The Number of Index TCCs Normosomic and Aneusomic For 
7V47!2:8 Ratio
Stage/grade A4T2:8 Ratio
Normosomic Aneusomic
pTa/pTl 11 3
pT2 and above 4 1
Grade 1 5 1
Grade2/3 10 3
The number of index TCCs normosomic and aneusomic for A4 72:8 ratio categorised by 
stage and grade
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3.5.7 Recurrent Tumours
Eighteen recurrent TCCs from the patient groups, RNPs and RPs, were studied 
for abnormal NAT2 or chromosome 8 copy number (Table 13).
3.5.7.1 Copy Number of Chromosome 8
Nine of eighteen recurrent tumours were polysomic, as previously defined. Comparing 
stage to copy number, 6 pTas were normosomic, whilst 2 were polysomic; one of 4 pTls 
was normosomic, 3 polysomic; one of 5 pT2 and above was normosomic, 4 were 
polysomic. Comparing grade with copy number, 2 of 2 grade 1 tumours were 
normosomic; 3 of 6 grade 2s were normosomic, 3 were polysomic and 3 of 9 grade 3 
TCC’s were normosomic, 6 were polysomic (Table 18).
Table 18 The Number of Recurrent TCCs Normosomic and Polysomic 
For Chromosome 8 Copy Number
Stage/grade Chromosome 8
Normosomic Polysomic
pTa/pTl 7 5
pT2 and above 1 4
Grade 1 2 0
Grade2/3 6 9
The number of recurrent TCCs normosomic and polysomic for chromosome 8 copy 
number categorised by stage and grade
3.5.1.2 NAT2 Copy Number
Thirteen recurrent TCCs were normosomic for NAT2, five were aneusomic. 
Comparing stage to copy number, 7 of 8 pTas were normosmic, one showed a loss; 3 of 
4 pTls were normosomic, one showed an elevated copy number and 2 of five pT2 and 
above were normosomic, 3 were aneusomic, all showing an elevated copy number. 
Comparing grade to copy number, 2 grade Is were normosomic, none was aneusomic; 5 
grade 2 were normosomic, one aneusomic, showing a loss of NAT2 copy number and 5 
of 9 grade 3 s were normosmic, 4 aneusomic, all with an elevated copy number (Table 
19).
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Table 19 The Number of Recurrent TCCs Normosomic and Aneusomic
For NAT2 Copy Number
Stage/grade NAT2
Normosomic Aneusomic
pTa/pTl 10 2
pT2 and above 2 3
Grade 1 2 0
Grade2/3 10 5
The number of recurrent TCCs normosomic and aneusomic for NAT2 copy number 
categorised by stage and grade
3.S.7.3 Chromosome 8 and NAT2 Copy Number in Recurrent TCCs
Using the MCCN/MGCN to assess copy number, the last documented recurrence 
in RNP 4 showed increase of copy number for chromosome 8 although this was at the 
low end of polysomy (1.75); all other patients’ recurrences in the RNP group were 
normal for gene and chromosome copy number. Three of the four recurrer progressor 
patients (RP) were abnormal for either gene or chromosome copy number (Tables 13 
and 20). For example, patient RPl who had polysomy of chromosome 8 and loss of 
NAT2 in the primary TCC remained polysomic for 8, but first and premuscle-invasive 
events were normosomic for NAT2. The muscle-invasive tumour showed polysomy for 
8 and elevated copy number for NAT2.
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Table 20 The Number of Recurrent TCCs Normosomic and Aneusomic
For Chromosome 8 & NAT2 Copy Number
Stage/grade Chromosome 8 &
NAT2
Normosomic Aneusomic
pTa/pTl 7 5
pT2 and above 1 4
Grade 1 2 0
Grade2/3 7 8
The number of recurrent TCCs normosomic and aneusomic for chromosome 8 and 
NAT2 copy number categorised by stage and grade.
In summary, eight out of nine (89%) of patients with muscle-invasive transitional 
cell carcinoma (TCC) at presentation or who developed this pathology (RP and PP 
groups) had aberrant gene and/or chromosome copy number at some point in their 
progression from superficial TCC to locally invasive TCC to muscle-invasive TCC. 
Whereas 4/10 (40%) of patients with non-invasive disease or locally invasive TCC (NR 
and RNP groups) had aberrations.
3.5.7.4. Ratio of AC4T2:8
One recurrent tumour from patient RP3, already defined as having loss of NAT2, 
had loss with A477:8 ratio, therefore this calculation gave no additional information 
over and above mean gene copy number.
3.5.8 Tumour Heterogeneity
Five TCCs exhibited heterogeneity, and in those cases, the most aneusomic cell 
population was used in the final analysis. One of these was from the index TCC 
(pTaGl) of a RNP patient. This appeared to be a clone of aberrant cells amidst a 
normosomic population. Previously this patient’s TCC had been assessed with probes 
for other chromosomes (Table 21) and again this particular area had been abnormal. The 
other four TCCs were from patients with muscle-invasion at presentation (n=l) or who 
developed this pathology (n=3). In addition, two separate tissue sections analysed from
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one RP patient’s cystectomy specimen had different genetic profiles. One was 
normosomic, the other aneusomic, and again the most aneusomic cell population was 
used in the final analysis.
3.5.9 Association with Other Chromosomal Abnormalities
Some of the index TCCs in this study had previously been investigated for 
chromosomal abnormalities common in bladder cancer. The results were compared with 
those of chromosome 8 and NAT2. For simplicity, the combination of mean gene and 
chromosome copy number only was compared, as shown in Table 21. In the NR group, 
one patient with a loss of NAT2 as defined by mean gene copy number was normosomic 
for the other chromosomes. The NR with polysomy 8 in this study had been polysomic 
for all other chromosomes studied. This strongly suggests that polyploïdisation has 
occurred and that this was possibly the mechanism for carcinogenesis to occur. One of 4 
RNP patients had abnormalities in other chromosomes, RNP3 had polysomy of 8 in one 
tumour area only. This area had shown aneusomy in all of the other chromosomes 
analysed, whilst the remaining tumour areas demonstrated normosomy. This indicates 
development of a malignant clone within an essentially normosomic tumour for the 
chromosomes analysed. However monosomy of chromosome 9 was also present again 
within this one area which may be the initiating event in this patient’s TCC. All of the 
RP’s had abnormalities of at least one other chromosome, one of whom had 
abnormalities in 3 other chromosomes (RP4).
3.5.10 Summary
Figures for normal gene and chromosome copy number (MCCN/MGCN) and 
mean NAT2:S ratio were established with control sections. Thirty seven tumours were 
then assessed, from 19 patients. Using MCCN/MGCN, twenty were abnormal, whereas 
5 with mean NAT2:S ratio were abnormal. In either case a significant proportion of the 
TCCs studied were abnormal, and patients with muscle-invasive caicinoma at some 
point in their clinical history had a higher proportion of abnormalities that those who did 
not have this pathology.
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Table 21 Association with Other Chromosome Abnormalities
Patient Chromosome
7 ^!NAT2 9 10 11 17
NRl N N N N N N
NR2 N N N N N N
NR3 N N N N N N
NR4 N N/L N N/D N N
NR5 N N N N N N
NR6 G G/N G G G G
RNPl N N N N/D N/D N
RNP2 N N N N N N
RNP3 G G/N L N G G
RNP4 N N L N/D N/D N
RPl N G/L L N N/D N
RP2 N N N N N G
RP3 N G/N N N/D N/D G
RP4 G GIG N N/D G G
A comparison of genetic and chromosomal abnormalities observed in this study, in the 
index TCC’s compared to the results of previous research with DNA probes for 
chromosomes commonly abnormal in bladder cancer.
Abbreviations: NR = non recurrer, RNP = recurrer non progressor, RP= recurrer 
progressor, G = gain of chromosome copy number as previously defined (Watters et al, 
1999); N = normosomy, as defined in Section 3.5.3; L = loss (monosomy) as previously 
defined (Bartlett et al, 1998); N/D=not done.
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CHAPTER 4 DISCUSSION
4.1 Introduction
The rising incidence in the developed world for cancer reflects statistics for 
bladder carcinoma in Scotland (Figure 1), with no evidence that this trend will decrease 
well into the next century. The repeated observations that two primary TCCs with 
identical clinical and pathological profiles may have widely differing prognoses have led 
to the hypothesis that there are genetically distinct routes to recurrence and/or 
progression (reviewed by Foresman & Messing, 1997). Several genetic aberrations have 
been identified in TCC of the bladder and models for progression and to a lesser extent 
recurrence have been proposed (Dalbagni et al, 1993, Reznikoff et al, 1996). However 
few studies have emphasised the need for clinical follow-up of patients whose genetic 
aberrations have been studied, (for example those of Pycha et al, 1997 and Bartlett et al,
1998) therefore there is less known of the genetics of recurrence.
Several factors e.g. the depth of invasion, multifocality, high grade and size at 
presentation are associated with muscle invasion (Adshead et al, 1998). Currently 
pathologically determined factors (stage and grade) are the primary prognostic variables 
that dictate treatment strategies (Stein et al, 1998). However, there are still insufficient 
clinical and histological parameters to predict with accuracy which pTa or pTl 
carcinomas will progress to detrusor muscle invasion. Increasingly the potential for 
combining molecular profiling with pathological and clinical diagnoses is being realised 
(Adshead et al, 1998, Knowles, 1998). Facilitation of selection of patients who may 
benefit from less or more aggressive treatments depending on the combination of their 
clinical, pathological and biological profiles is the ultimate goal of an increasing number 
of diagnosticians.
4.1.1 Patient Management
Patients who present with non-muscle invasive (pTa/pTl) carcinoma routinely 
have the tumour removed surgically, but 50-70% of such patients will present with 
recurrent carcinoma within 1-2 years (van der Meijden, 1998). Many patients are in fact 
undertreated at presentation of their primary carcinoma. In an attempt to prevent this 
some centres treat adjuvantly with intravesical drugs, and reduced rates of recurrence 
have been reported (Oosterlink et 1993, Tolley et al, 1996). However, there remains a 
clinical dilemma as the patients who do not recur have had unnecessary chemotherapy;
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in this context a means of identifying patients who are at highest risk of recurring would 
be beneficial.
The accumulation of data supporting the theory that carcinogenesis is 
accompanied by several genetic anomalies (Nowell, 1976) has led to proposals of 
genetic mechanisms of recurrence (Pycha et al, 1997, Harnden et al, 1999, Watters et al,
1999). These changes give insight into potential ways to improve the targetting of 
patients for more aggressive treatment regimes. This aspect will be discussed in more 
detail with particular reference to the results of this study later in the discussion.
In this study only patients presenting with papillary TCC were included, as the 
molecular biology of CIS differs from papillary TCC (Reznikoff et al, 1995). Evidence 
is emerging that pTa and pTl are also genetically distinct (Richter et al, 1997, Sauter & 
Mithatsch, 1998). Foresman & Messing, (1997) in their review quote results of a study 
of 249 pTa or pTl carcinomas where patients were followed up for a median period of 
39 months. Four percent of pTa compared with 30% of pTI patients progressed and of 
grade 1 pTa/pTl lesions only 2% progressed to muscle invasive/metastatic disease 
compared with 11% of grade 2 and 45% of grade 3 carcinomas. Progression occurred 
within 25 months in most cases. Nearly 50% of pTlG3 carcinomas progressed over this 
interval. These results support the generally accepted view by urologists who treat 
pTaGl TCC as a completely distinct disease entity from pTlG3 TCC. pTaG3 and 
pT lG l carcinomas are unusual and pTl carcinomas tend to be more aggressive (of 
higher grade) than pTa lesions. As it is far more common to have a pTlG3 lesion than a 
pT lG l lesion, high grade may be the significant factor as this is known to be associated 
with aggressive tumours.
Rather than grade or stage being of greater import, the combination of the two 
may be the driving factor in tumour aggressiveness. Once a malignant cell has invaded 
the basement membrane the characteristics of a grade 3 tumour, by definition showing 
more features of malignancy than a grade 1 may drive the cell to become invasive. 
However the argument remains flawed as not every pTlG3 becomes detrusor muscle 
invasive and some pTaGl carcinomas do develop invasive profiles. This is borne out in 
the patient cohort used in this study as a diagnosis of a pTlG3 carcinoma at presentation, 
in the patient groups analysed here, did not affect disease outcome, as one “non 
recurrer”, one “recurrer non progressor” and one “recurrer progressor” had this 
diagnosis. Of those that died four were grade 1, two were grade 2 and one grade 3 at 
presentation. From assumptions made on disease course based on diagnosis at
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presentation, the higher grades should be associated with more deaths. However these 
patient groups were very small, precluding any statistical associations with stage, grade 
and clinical behaviour. In this small patient cohort, the stage and grade of the primary 
carcinoma was not associated with individual outcome, even if this was a pTl grade 3, 
despite reports such as that of Foresman and Messing (1997).
Within this study, 5 patients with pT2 or above (muscle invasion) at presentation 
were included. From previous research (Knowles, 1998) non-muscle invasive and 
muscle invasion at presentation have differing clinical and pathological outcomes. The 
latter is also associated with more genetic aberrations and other biological abnormalities 
(Knowles, 1998). A comparison of the genetic anomalies of chromosome 8 and NAT2, 
in pTa versus pTl versus pT2 and above, combined with non recurrent through to 
progressed at presentation disease has the potential to identify chromosome S/NAT2 
status as a biological marker of recurrence or progression.
4.1.2 Exposure to Chemical Carcinogens
4.1.2.1 Introduction
This study investigated the genetics of the aromatic amine metabolising enzyme, NAT2, 
thus industrial history or smoking was considered, both of which involve exposure to 
aromatic amines.
4.1.2.2 Industrial Exposure
The lack of information available on patients’ occupational history in this study 
reflects the low priority accorded to such documentation in routine clinical practice. Ten 
of the 19 patients had occupational histories documented at initial admission, but this 
was not necessarily recorded at the Urology clinic. This is surprising, as bladder cancer 
is one of the few neoplasms directly correlated with industrial exposure (Case et al, 
1954, Risch et al, 1995). A study to assess the accuracy of recording occupational 
history was carried out by McCahy et al, (1997). Despite using a specially designed 
questionnaire, accuracy was achieved in only 39% of cases. The researchers argue that 
this lack of information could lead to missed claims for compensation and under­
reporting of occupational mortality.
A five year field survey by Case et al, (1954) was the first study to connect the 
causal link of potential chemical carcinogens with bladder cancer, prompting studies 
relating bladder cancer aetiology with exposure to chemical carcinogens to be carried 
out. For example, Cartwright et al, (1982) studied a group of employees in dye
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manufacturing and found a high proportion with bladder cancer and the slow acétylation 
phenotype. With the decline in manufacture of dyes and other aromatic amines in 
Britain and other Western countries since the 1970’s, (Risch et al, 1995, Golka et al, 
1996), awareness of environmental exposure has lessened. However risk factors remain 
for those involved in textile, rubber and leather industries, and workers in dyestuff 
production still experience a relative bladder cancer risk of 2.4 to 2.6, even after 
adjustment for smoking and age (Sorlie et al, 1998).
Screening exists for workers in high-risk occupations, specifically urine 
screening programmes (Droller, 1985), that have a higher pick-up rate than the general 
population, despite the low sensitivity of this test. Regular cystoscopic monitoring in 
this high risk group has been suggested as they are approximately seven times more 
likely to develop TCC than the general population (Schulte et al, 1986). However, 
although this procedure may detect early cases of TCC, the latency of the development 
of TCC (Risch et al, 1995) means that individuals are subjected to many cystoscopies 
and anaesthetics before a positive result is detected. Individual anxiety would 
undoubtedly be heightened and the trauma involved would be uncomfortable. Also 
whether or not the resources exist to cope with the increased workload is questionable.
An alternative is to use a chemical reagent strip to test for haemoglobin, 
indicating haematuria (Goldstein & Messing, 1998). Almost all bladder cancers will 
cause haematuria at some point. In their review, Goldstein & Messing, (1998) reported 
results of two studies of the general population using haematuria home testing; in both 
studies, 15-20% of the screened populations had haematuria and 6 to 8% were found to 
have urothelial cancers. However, the disavantage of a home based test is that the 
responsibility is entirely on the patient, although the patient could be called to clinic, but 
this would considerably increase the clinician’s workload. As is the argument for many 
screening programmes, such as the USA program for detecting prostate cancer, the 
problem remains resource based in a country such as the UK where private health 
schemes are rare and costly. Thus at present, occupational screening remains a urine 
based procedure even though urine cytology has a low sensitivity.
4.1.2.3 Environmental Exposure
With respect to TCC, the only direct causal linlc with carcinogenesis and 
environmental factors is through smoking. The high proportion of patients with a 
smoking history in this study reflects the statistics for Western populations. Cigarette 
smoke accounts for at least 50% of bladder cancers, and in particular the use of black
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tobacco is more strongly associated with bladder cancer than lung cancer on a 
geographical basis (Vineis & Martone, 1996). In this study, twelve of 13 patients, for 
whom information was available, had a smoking history.
The two ways of curing tobacco change the colour of the resultant product. 
Black tobacco is air cured and blond tobacco is flue cured. Europeans tend to smoke 
black tobacco, in the USA the blond variety is more popular. Black tobacco has a higher 
concentration of carcinogens such as 4-aminobiphenyl and p naphthylamine compared 
to the blond variant. A significantly higher frequency of G:C to C:G transversions are 
found in bladder cancer compared to lung or colorectal carcinoma. These mutations 
may be induced by free oxygen radicals present in cigarette smoke (Knowles, 1998). 
Landman & Droller (1998) in their review suggest that the carcinogens caused by 
pyrolysis may act at a late stage in bladder cancer progression, perhaps by causing late 
chromosomal damage possibly by increased frequency of p53 mutations. This may be 
more pronounced in patients who smoke black tobacco, with its higher concentration of 
toxic metabolites.
A study of the epidemiology of bladder cancer patients (Vineis and Martone, 
1996) found that those who smoked black tobacco had a greater relative risk of 
developing bladder cancer compared to individuals who smoked blond tobacco (4.0 
versus 1.8). The relative risks of developing bladder cancer were lessened in individuals 
who stopped smoking 2 to 15 years previously, (0.63 compared with 1.0 in smokers; 
Morrison et al, 1984). However, there was still a 2-3 fold increase in bladder cancer 
incidence if an individual had ever smoked versus non-smokers, (Morrison et al, 1984), 
regardless of the type of tobacco used. Higher grade and more frequent recurrences are 
also associated with TCC patients who are smokers (reviewed by Landman & Droller, 
1998). Within this study no association with smoking and recurrence or grade was 
possible, however the high number of smokers in this cohort reflects previous research.
4.1.3 Follow-up
In four patients included in this study, length of follow-up available was reduced 
by factors such as the patient moving to another hospital or the original case notes being 
lost. Bladder cancer is characterised by recurrent disease over many years, requiring 
patients to attend clinic many times. This increases the risk of case notes going missing
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or patients moving to another treatment centre. Thus these findings are fairly typical of 
patients who have long term follow-up.
4.1.4 Deaths Due to Bladder Cancer
Deaths due to bladder cancer all followed either recurrent progressive disease or 
muscle invasion at presentation. These results reflect those of Bartlett et al, (1998) and 
Watters et al, (1999). Patients were categorised in a similar way and only those in the 
recurrent progressive category died of bladder cancer, although patients with muscle 
invasive disease at presentation were excluded in those studies. Pryor et al, (1973) 
looked at factors that influence the survival of patients with TCC. Depth of invasion 
(stage) and tumour grade (degree of tumour differentiation), lack of lymph node invasion 
and patients age were most important. Three year survival rate in a cohort of 691 
patients followed up over 10 years was 82% for T1 lesions, 48% for T2, 21% for T3 and 
4% for T4 carcinomas. Higher grade carcinomas also had a shorter 3 year survival rate. 
The outcome in this patient cohort thus reflects the general trend for patients with 
aggressive carcinomas.
4.1.5 Conclusion
The detailed data gathered from the patient notes provided a basis for assessment 
of the results generated by the FISH assays, the aim of which was to correlate genetic 
aberrations with the clinical course of TCC.
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4.2 Methodological Aspects
4.2.1 Introduction
Methodologies previously established in the laboratory for probe labelling and 
fluorescence in situ hybridisation were initially applied to the analysis of the TCCs in 
this study. However, there was limited experience in the use of a labelled unique 
sequence probe for FISH as applied to the study of genetic aberrations, especially in 
archival tissue sections. The preliminary experiments with nick translation to label the 
NAT2 cosmid clone to produce a probe for FISH were unsuccessful. Modifications of 
both techniques were required to evaluate copy number in archival material. Several 
factors influence the intensity and specificity of the hybridisation signal; in particular the 
purity of the DNA probe and the size of the probe fragments used in the hybridisation 
reactions (Lichter et al, 1990). Both these factors are discussed below.
4.2.2 Nick Translation
4.2.2.1 Probe Production
A cosmid clone containing the NAT2 sequence was synthesised following the 
method of Franke et al, (1994), The purity of the DNA probe was assumed to be 
acceptable, as the cosmid containing the NAT2 sequence had been previously been 
labelled and applied successfully to the study of exfoliated cells in urine (Stacey et al,
1996) and to bladder barbotage cells (Stacey et al, 1999). The isolation of cosmid 
clones containing the sequence of interest has been a standard method for synthesising 
probes for fluorescence in situ hybridisation (Franke et al, 1994). Recently the 
production of probes by a different method has been reported (Davidson et al, 1998) to 
circumvent the difficulties of studying unique sequences in thin tissue sections (5 
microns or less). Davidson et al (1998) constructed probes spanning the MYC and EWS 
regions, assembled from multimegabase contigs of yeast artificial chromosome clones 
(YAC) and removed Alu sequences by subtraction hybridisation. The probes were then 
labelled with biotin or fluorescein isothiocyanate and in subsequent hybridisation 
experiments yielded bright signals. Davidson et al (1998) also demonstrated the 
stability of the probes after multiple rounds of amplification by the polymerase chain 
reaction (PCR).
Probes have previously been produced by PCR as opposed to nick translation 
(Weier et al, 1994), by incorporating the label in the PCR, thus simultaneously
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amplifying and labelling the DNA sequence. However, PCR is capable of amplifying a 
single molecule, thus specificity of the labelled DNA can be compromised (Stickland, 
1992). In general the production of probes by nick translation is a simple procedure and 
the resulting fragments are of suitable size for in situ hybridisation. Methods such as 
that of Davidson and co-workers, (1998) claimed to produce an intense hybridisation 
signal but they were demonstrating chromosomal rearrangements flanking MYC  and 
EWS, not aberrations of the sequence specific probe. However, it would be possible to 
buy the relevant YAC contigs and apply the methodology to the NAT2 gene, and 
compare the results with the nick translation method. But for the purposes of this study, 
as will be discussed in the following section, with judicious modification of the existing 
nick translation protocol, probes were produced which were then successfully used in 
FISH.
4.2.2.2 Modifications of the Nick Translation Reaction
4.2.2.2.1 Introduction
Nick translation is an enzymatic labelling procedure that results in the uniform 
incorporation of label into DNA sequences which are of the appropriate size for in situ 
hybridisation (Leitch et al, 1994). The enzymes DNase I and DNA polymerase I 
incorporate labelled nucleotides into DNA. DNase I introduces single strand breaks 
(nicks) and DNA polymerase I catalyses the incorporation of new nucleotides. As the 
nicks are introduced at random into the double stranded DNA molecule, labelled 
fragments of different lengths and containing variable proportions of insert and vector 
are produced. There has been a suggestion made that the fragments anneal together via 
their overlapping portions to produce a probe network, thereby amplifying the target 
sequence in situ and enabling the nick translation method to achieve high sensitivity 
(Herrington & McGee, 1992). The end result is a DNA strand which has incorporated 
labelled nucleotide to produce a probe of between 200 and 600 base pairs, achieved by 
altering the relative concentrations of the two enzymes DNase I and DNA polymerase I 
(Leitch et al, 1994).
4.2.2.2.2 Optimising the Nick Translation Reaction
In order to ascertain the optimal nick translation reaction, several steps were 
taken to investigate ways in which the DNA fragment size could be altered within the 
reaction. Initially a simple comparison between two methods was made. The existing 
method produced unnicked cosmid whereas no product was visualised in the alternative 
protocol.
136
Comparison of enzyme concentrations revealed the alternative protocol 
contained a higher concentration of DNase I than the existing one. Titration of DNase I 
enzyme concentration produced fragments of acceptable length (Figure 16). Rigby et al 
(1977) noted that DNase I activity varies from different commercial sources. From the 
literature it appears that of the two enzymes DNA polymerase I and DNase I, DNase I is 
the more sensitive to factors such as prolonged storage, repeated freezing and thawing. 
It is also the enzyme required to initiate the nick translation reaction, therefore if the 
enzyme concentration is too low or the activity compromised, the reaction carmot 
proceed (Rigby et al, 1977). The extent of nucleotide replacement o f the template can 
be controlled by varying the amount of DNase I in the reaction (Sambrook et al, 1988). 
From this evidence, it appears that DNase I concentration is a crucial parameter in the 
nick translation reaction. This was borne out by the results of the titration experiments, 
which finally incorporated an additional 4.8 mU/pl of DNase I into the reaction (Figure 
16D).
4.2.2.2.3 Biotinylation
Biotinylated dUTP was added in the proportion 2:1 TTP:biotinylated dUTP. 
This allows for the most efficient incorporation of biotinylated dUTP into the DNA, as 
some steric hindrance is encountered due to the molecule’s size (Figure 10). 
Incorporation of the biotin molecule at Cl 1 or C l6 allows the most efficient 
incorporation of biotinylated dUTP (Leitch et al, 1994). Initially in this study the 
protocol for radio labelled probes was followed which recommended the addition of the 3 
unlabelled nucleotides in the same proportion as the labelled nucleotide. However, 
radiolabels are much smaller than biotin and therefore incorporation of label is not 
compromised by size. This may have contributed to the failure of the initial experiment, 
but this parameter was not investigated to any extent as the results of the experiments 
varying DNase I concentration were successful. However because of the steric 
hindrance of biotin, unlabelled DNA was used in the initial comparative experiments 
(Section 3.3.2.2) and then reintroduced when the experiments were successful (Section 
3.3.2.5). The experiment with biotinylated dUTP was then compared to the previous 
one without biotin; the addition of biotin did not appear to compromise the reaction. 
Therefore, no further modifications were undertaken.
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4.2.2.3 Conclusion
The success of the nick translation reaction was essential to enable the probe for 
NAT2 to be incorporated into FISH. A reliable, reproducible modification of a kit was 
developed which produced a DNA fragment of suitable size for FISH.
4.2.3 FISH
4.2.3.1 Preparation of the Tissue for FISH
Five micron tissue sections were cut from paraffin blocks. Contaminant DNA 
must be avoided, therefore gloves were worn throughout the section cutting and FISH 
technique. Nucleases present on the skin represented another possible source of 
contamination. Unfixed DNA or RNA can be degraded by nucleases, although this is 
less of a problem in formalin fixed material as fixed DNA or RNA are resistant to 
nuclease digestion (Warford, 1996). Intact tissue sections were used throughout the 
study, therefore areas of carcinoma could be assessed relative to non malignant regions 
within the same tissue section and regions of heterogeneity identified.
4.2.3.2 Modification of FISH Protocol for the Demonstration of Unique Sequence 
Probes in Paraffin Sections
4.2.3.2.1 Introduction
Fluorescent in situ hybridisation (FISH) is a technique involving the 
hybridisation of a known sequence of DNA or RNA into which is incorporated a suitable 
label (the probe) with target DNA or RNA. Aberrations of the gene or chromosome can 
then be evaluated following immunocytochemical detection with fluorescent labelled 
antibodies or directly if a fluorescent labelled probe is used. There are two
disadvantages to using a directly labelled probe: the sensitivity is reduced when 
compared to indirectly labelled probes and there is no flexibility at the detection stage 
e.g. if a signal is weak the option to reapply the immunocytochemical steps is not 
possible, although this can introduce undesirable background staining. The advantage is 
that the technique is performed rapidly and the signal produced may be more intense. In 
this study, whereby loss of a unique sequence probe was anticipated, it was essential to 
use a method with the highest degree of sensitivity i.e. an indirect technique.
The established FISH protocol for commercial centromeric probes was applied to 
5 micron tissue sections with the NAT2 and chromosome 8 probes. This preliminary 
experiment showed that the technique was not readily applicable to the demonstration of
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unique sequences in tissue sections as weak signal and precipitate (possibly non-specific 
binding of biotin) were observed. Therefore a number of modifications were introduced 
to increase signal intensity and decrease background staining. Throughout the changes 
introduced, emphasis on preservation of tissue morphology was maintained. One of the 
strengths of in situ hybridisation is that the conditions of pre and post hybridisation can 
be manipulated as necessary (Herrington & McGee, 1992).
4.2.3.2.2 Pretreatment and Proteolysis
Pretreatment and proteolysis of material enables the DNA to be accessed before 
in situ hybridisation can be performed and is essential for the success of the technique. 
Fixatives such as formalin are recommended for in situ hybridisation studies as these 
optimally preserve the tissue (Mitchell et al, 1992). Formalin is an aldehyde that forms 
cross links between protein molecules (Hopwood, 1996). For formalin fixed paraffin 
processed thin tissue sections, pretreatment and proteolysis involve dewaxing of the 
section, digestion with the appropriate proteolytic enzyme and denaturing of the target 
DNA. Pepsin or proteinase K are the most widely used enzymes for in situ 
hybridisation.
Several protocols for section pretreatment exist, before proteolysis, which are 
known as tissue permeabilisation steps. These include 0.2N HCl and Triton X (Hopman 
et al, 1992) or reducing agents such as sodium thiosulphate (Pauletti et al, 1996) and 
sodium thiocyanate, one of the strongest protein denaturing agents (Hopman et al, 
1991). Some protocols combine 0.2N HCl and a reducing agent, such as the 
Pathvysion™ HER-2 DNA probe kit, (Vysis,UK). 0.2N HCl is thought to increase the 
hybridisation signals, as acid deproteinases the tissue thus increasing probe penetration 
(Syrjanen, 1992). This is due to the pH dependent fixation reaction that proceeds more 
rapidly at higher pH (Hopwood, 1996) and presumably is reversed following the 
introduction of an acid, such as HCl. Reducing agents break the protein disulphide 
bonds formed by formalin (Ottoway & Apps, 1984) and allow greater nuclear 
accessibility. Generally the use of a permeabilisation step reduces the proteolytic step 
thus causing less tissue damage. The inclusion of sodium metabisulphite is also thought 
to reduce autofluorescence when combined with proteinase K (Lowery, 1998).
Pepsin is primarily used as the proteolytic step in the demonstration of genomic 
DNA and some mRNA (Herrington & McGee, 1992) although proteinase K has also 
been used successfully (Pauletti et al, 1996). Pepsin in HCl had been previously used as 
the only pretreatment step in the demonstration of alpha and classical satellite probes in
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formalin fixed paraffin processed thin sections (Watters, et al, 2000). This was not 
successful with the NAT2 probe which led to an investigation of an alternative method. 
The nuclei appeared larger with the sodium bisulphite/proteinase K protocol, probably 
due to the permeabilisation step compared to the pepsin digestion alone. The variation 
of methodology in the literature (Murphy et al, 1995, Pauletti et al, 1996, Wagner et al,
1997) would suggest that some adaptation of an existing protocol is necessary when a 
new probe is used. Adapting the protocol in this study resulted in increased hybridisation 
intensity and lower background staining. This improved result, without compromising 
tissue morphology, was then applied to the study of chromosomal aberrations in TCC.
The essential step at this part of the FISH technique is to allow permeabilisation 
of the tissue for probe accessibility, with preservation of tissue architecture. 
Undoubtedly part of the technical variability, with regard to routinely formalin fixed 
tissues, is that there is no control over fixation length. This in turn will affect the 
pretreatment time, which may also result in slight adjustments to the pretreatment 
protocol between cases.
4.2.3.2.3 NICK Columns
The use of nick columns is an additional step in some nick translation protocols 
(Syrjanen, 1992) to absorb unincorporated label that could result in increased 
background. However in the protocol followed in this study, there was a reduction in 
signal intensity, therefore this step was not incorporated into the methodology (Figures 
19C and D). This may have been due to a DNA precipitation step following the nick 
column protocol, as either nick columns or DNA precipitation are usually recommended 
for the removal of unincorporated nucleotides.
4.2.3.2.4 Suppression Hybridisation
COT-1 DNA is human DNA enriched for repetitive sequences (Gosden & 
Hanratty, 1991). The addition of COT-1 DNA, known as suppression hybridisation 
(Lichter et al, 1990) blocks repetitive sequences and is essential in the hybridisation of 
unique sequences for avoiding ambiguous signals. If the entire sequence from a cosmid 
clone is labelled and used as a probe, the interspersed repetitive sequences such as Alu 
and Kpn elements may confound the results (Nisson & Watkins, 1991). In this study the 
results were improved following the addition of COT-1 DNA (Figure 20). The 
incorporation of a subtractive hybridisation protocol at the probe production stage to 
quantitatively remove abundant repetitive sequences such as the Alu elements (Davidson 
et al, 1998) is an alternative but somewhat complex alternative to the simple addition of
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COT-1 DNA when the nick translation products are precipitated. In this study, COT-1 
DNA was precipitated with the cosmid DNA which gave acceptable results, that did not 
warrant further investigation.
4.2.3.2.S Dénaturation
Denaturing of both probe and target DNA renders the double stranded DNA 
single stranded thus enabling the probe and target to reanneal. Dénaturation can be 
performed by both chemical and physical means. Alkaline dénaturation, used in filter 
hybridisation, may lead to alkaline hydrolysis of the ester linkages that join the label 
molecule to the nucleic acid (Herrington & McGee, 1992). Most protocols use a 
combination o f heat, salt and formamide, all of which have the ability to break 
intramolecular hydrogen bonds, thus destabilise hybrids (Mitchell et al, 1992). In some 
situations, probe and target can be denatured simultaneously by diluting the probe in the 
hybridisation mix, which contains salt and formamide (Herrington & McGee, 1992), 
applying this to the section; hybridisation can then proceed by lowering the temperature 
from 72°C to 31°C. But this is not recommended for unique sequence probes into which 
a competitor such as COT-1 DNA has been incorporated (Gosden & Hanratty, 1991), 
because the preannealing step at 37°C for 30 minutes is necessary to allow repetitive 
sequences to reanneal thus excluding them from the hybridisation process.
In this study, the NAT2 probe was denatured for 5 minutes at 72°C then left for 
30 minutes at 37°C (suppression hybridisation, preannealing step), the chromosome 8 
probe was denatured for 5 minutes at 72°C and then added to the NAT2 probe following 
suppression hybridisation. However, the denaturing step used here has two 
disadvantages. It is time consuming and there is added exposure to formamide a highly 
toxic chemical which can cause foetal damage, even though this step was done in a fume 
hood. Some commercial sources of unique sequence probe e.g. the HER-2/neu probe 
(Vysis, UK) require simply the application of the ready diluted probe to the denatured 
target, and this produces excellent results (Bartlett et al, manuscript in preparation). For 
any future studies involving a unique sequence probe, the dénaturation step would be 
more closely evaluated to ascertain the necessity of separate dénaturation and 
hybridisation. Tissue sections were denatured with 70% formamide, 2 X SSC at 72°C 
and then probe applied.
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background. The previously used 50% formamide, 2 X SSC wash performed at 42°C 
was compared to 1 X SSC and 2 X SSC washes both performed at 72°C. The latter two 
have been used, although less frequently than the former with unique sequence probes. 
The lower temperature wash can be used with the destabilising effect of formamide, 
which will increase stringency; the high salt concentration washes alone give a higher 
stringency wash at the higher temperature. For the demonstration of the NAT2 and alpha 
satellite 8 probes used in this study, the cleanest preparation was seen with the 1 X SSC 
wash, with the least precipitate. The 1 X SSC wash is more stringent than 2 X SSC, 
probably due to the low salt concentration, as high salt concentration washes stabilise 
hybrids (Mitchell et al, 1992). The added advantage of using a high temperature wash is 
that it does not contain formamide. As already discussed this is a significant hazard. In 
conclusion, the 1 X SSC wash was the most suitable with these particular probes.
4.2.3.3 Conclusion
Several technical aspects were investigated to ensuie the hybridisation was 
specific and the signal produced unambiguous. Once this aim had been achieved, an 
assessment firstly of control material then test material was undertaken.
4.2.4 Comparison of FISH with other Molecular Biology Techniques
4.2.4.1 FISH versus ISH
Non-fluorescence in situ hybridisation (ISH) can be viewed with standard light 
microscopy thus tissue morphology is clearly seen, and direct comparison between ISH 
sections and other histology techniques can be made. This is an advantage over FISH, 
although with experience, tissue morphology can still be identified as, for example, 
elastin fibres autofluoresce. In this study the FISH stained sections were compared to 
sequential haematoxylin & eosin sections. Confirmation of tumour areas was made and 
regions of differing pathology assessed.
ISH has been widely applied to the study of numerical chromosomal aberrations 
(eg Hopman et al, 1991, Poddighe, 1996). Although colour separation is more difficult 
as chromogens are usually red and brown, dual labelling has been used successfully in 
conjunction with immunocytochemistry (Speel et al, 1994). However, the use of dual 
and triple band pass filters in FISH enables detailed analyses of chromosomal and 
genetic aberrations to be carried out not so easily done by ISH. By using a dual labelling 
FISH technique, with a probe for the centromere of the chromosome which houses the
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gene of interest additional information on the genetics of the carcinoma can be obtained. 
For example, Sauter et al, (1995c) using this approach defined amplification of c-myc 
copy number if more than 10% of cells had more c-myc signals than chromosome 8. In 
the study of Wagner and co-workers, (1997) also using dual FISH, they noted that 8p 
deletions were generally associated with an increased copy number of chromosome 8. 
These data cannot easily be achieved with ISH and therefore in this study, FISH was 
used to directly relate chromosome and gene copy number to tumour pathology.
4.2.4.2 FISH versus Flow Cytometry
Flow cytometry allows up to thousands of cells to be scanned per second 
(Camplejohn, 1992), the advantage is that the ploidy of large numbers of cells can be 
determined rapidly, compared to the more time-consuming analysis of cells on slides 
(Cajulis et al, 1994). Two parameters can be measured by flow cytometry-the presence 
of cells with abnormal amounts of DNA, the DNA aneuploid cells, and the S phase 
fraction, a crude index of cell proliferation (Camplejohn, 1992), and the technique can 
be used to segregate X and Y sperm.
The disavantage of this technique is that, if solid tumour is being analysed, 
unless the tumour is microdissected before flow cytometry is carried out, a dilution 
effect will occur, whereby tumour and normal tissue will be analysed together. In any 
event, small changes of ploidy are often missed e.g. in a slightly aneuploid population 
and tumour heterogeneity cannot be determined (Ramaekers & Hopman, 1993), due to 
the limitations of the technique. This is illustrated by the example of a common 
aberration in TCC, loss of chromosome 9. This is often an early event in the 
development of TCC and some researchers have suggested that this loss enhances 
susceptibility to other genomic changes (Ramaekers & Hopman, 1993). If subsequent 
genetic aberrations involve tetraploidisation, and flow cytometry is applied at that stage 
in the tumour’s development, the chromosome complement will be 4n, but specific 
chromosomal abnormalities will not easily be detected.
In conclusion flow cytometry is useful in giving an estimate of the total 
chromosome copy number in a cell (Cajulis, et al, 1994) but subtle genetic changes 
could be missed and these may be more profound in the analysis of tissue sections.
4.2.4.3 FISH and Comparative Genomic Hybridisation
Comparative genomic hybridisation (CGH) (Kallioniemi et al, 1995) has recently 
been developed to screen for chromosomal losses and gains. The method involves the 
comparative hybridisation of differentially labelled tumour and normal DNA to normal
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metaphase cells. This gives an advantage over methods such as FISH, which can only 
assess two or three chromosomes or genes in situ at one time, whereby the whole 
genome can be screened in one experiment (Mahdy et al, 1999). This methodology is a 
hybrid between flow cytometry and in situ hybridisation, and highlights genetic 
abnormalities, which can then be investigated further with e.g. FISH. However the 
technique is again limited if the analysis is performed on tissue sections.
DNA arrays on microchips are the latest technological development for assessing 
large panels of genes. This technology has been successfully applied to the 
simultaneous expression of thousands of genes and to large scale gene discovery 
(Ramsay, 1998). As with CGH the ability to screen many genes or chromosomes 
simultaneously is of enormous benefit, although at present DNA arrays on microchips 
can only be done on blood or lymphocyte preparations. Spectral karyotyping (SKY) 
combines the sensitivity and specificity of FISH with the global screening ability of 
conventional cytogenetics (Mark, 1998). This is another example of a technique that 
enables a high throughput of gene screening, but as with CGH and DNA arrays, the 
disadvantage is that expensive instrumentation is required, outwith the budget of most 
teaching hospitals and universities.
In conclusion, CGH and DNA arrays are very powerful tools in the 
screening of tumours for gross genetic changes, but subtle genetic aberrations may be 
missed especially if whole tissue sections are utilised. For example, CGH will not detect 
tumour suppressor gene inactivation that does not involve physical loss e.g. mitotic 
recombination and similarly activation of oncogenes by any other means than 
amplification is not detected (Kallioniemi et al, 1995).
4.2.4.4 Other Molecular Biology Techniques and FISH
RFLP (restriction fragment length polymorphism) analysis utilises specific 
restriction enzymes to study loss of heterozygosity (Yasui et al, 1992). This has been 
used in genotype analyses, for example to identify specific gene deletions (Risch et al, 
1995). A comparison of in situ hybridisation and RFLP analysis by Poddighe et al, 
(1996) acknowledged that RFLP analysis gave valuable information on specific allelic 
losses, that was not possible using in situ hybridisation. However, the detection of 
genetic aberrations on a cell by cell basis was only possible using the in situ approach.
Techniques such as Southern blotting give an overview of changes that dominate 
a tumour population (Poddighe et al, 1996) and indeed Southern blotting and 
polymorphic microsatellite analysis have been used to provide information about the
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genetic alterations which underly the development of solid tumours (Murphy et al, 
1995). But the overriding disadvantages with Southern blotting and RFLP analysis are 
that a dilution effect will occur, as whole tissue sections are used in the analysis. Thus 
there will be an admix of tumour and normal tissue, subsequently no information can be 
obtained on tumour heterogeneity, nor can tumour be directly compared to 
pathologically normal tissue.
4.2.4.5 Conclusion
None of the above techniques when compared to FISH can be used in situ. 
Although in theory they can all be applied to routinely formalin fixed and paraffin 
processed tissue if microdissection of tumour areas is initially carried out, the quality of 
the DNA is fragmented and may not be easily analysed. In addition, FISH analysis also 
avoids the problem of homozygosity encountered in LOH studies such as RFLP. FISH 
remains a powerful tool for studying genetic anomalies and will have a place in the 
molecular biology laboratory for some time to come.
The genetic aberrations most commonly associated with TCC, which have been 
initially characterised with CGH (Kallioniemi et al, 1995) and RFLP (Risch et al, 1995) 
can be further assessed with FISH and specific probes (Mahdy et al, 1999). Using an in 
situ technique on stored material from the pathology archives, genetic aberrations can be 
related to clinical outcome. As clinical material was used throughout the study, FISH 
was the most suitable technique to use in this study.
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4.3 Analysis of Results
4.3.1 Range of Tissue Used for Analysis
The assessment of tumour ploidy in situ is relatively recent (Hopman et al, 
1988), The advantages over flow cytometry, the existing technique for measurement of 
ploidy in interphase nuclei have already been discussed (Section 4.3.3.2).
Initial studies were made using metaphase spreads, using cells from a bladder 
cancer cell line and whole nuclei isolated from thick (50 micron) sections which were 
resuspended and dropped onto slides (Hopman et al, 1988). There are essentially two 
types of preparation that have been used to analyse the results of in situ hybridisation 
experiments: cells derived from cytology specimens or from paraffin wax tissue blocks 
or as intact sections from tissue imprints and frozen or paraffin wax embedded tissue 
blocks. The advantages and disadvantages of each type of methodology are discussed 
below.
4.3.1.1 Cytology
Bladder washings and urine samples are the simplest way of obtaining material 
for DNA analysis. However, urine is often acellular and DNA analysis cannot 
subsequently be performed. Bladder washings increase the cellular yield; FISH as 
applied to bladder washings was comparable to the detection of malignant cells by 
cytology with the advantage that the specimen was more cellular in terms of sensitivity 
and specificity (Cajulis et al, 1994). However this type of specimen may contain both 
tumour and normal cellular components.
4.3.1.2 Isolation of Nuclei
The dissociation of nuclei from 50 micron tissue sections cut from paraffin wax 
tissue blocks has been used to analyse several common genetic aberrations in bladder 
cancer (Hopman et al, 1988, 1991, Sauter et al, 1995 a-d). The single cell suspensions 
were dropped onto glass slides for further analysis. Although nuclear truncation in thin 
sections is avoided, the relationship between neoplastic and non-neoplastic tissue and 
correlation with pathology in haematoxylin and eosin sections is not possible. Two 
other disadvantages are that the resultant cell suspension is an admix of tumour and 
normal cells, which may be considerably more difficult to discriminate between than if 
assessment was performed in situ. In addition the analysis of a small biopsy may not be 
possible due to the limited material available. There is another disadvantage with this
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methodology as it incorporates another step in the FISH technique, which may prolong 
the protocol by a day.
However, in both methods outlined above, large numbers of nuclei would have to 
be assessed to be confident that any genetic abnormalities had not been missed. It may 
be difficult to differentiate tumour from normal or inflammatory tissue components. 
This also impinges on the methodology for assessing the preparations, further discussed 
in Sections 4.3.2 and 4.3.3.
4.3.1.3 Tumour Imprints
The use of tumour imprints from frozen or freshly excised tumour again enables 
whole nuclei to be analysed. However, the disadvantage is that tumour cells may have 
differing characteristics from normal cells. They may more readily detach from the 
tumour due to the increased production of degradation proteins. If frozen material is 
available, parallel studies using FISH, flow cytometry and comparative genetic 
hybridisation are more easily facilitated and direct comparisons of each technique can be 
made (Mahdy et al, 1999). All these studies have contributed to our knowledge of the 
genetics of bladder cancer. However, the practicalities in a clinical setting of obtaining 
fresh material become limited. If there is not a dedicated surgeon in the operating 
theatre, all tissue will follow the routine procedure, whereby tissue is placed in neutral 
buffered formalin for processing in the pathology laboratory. Assessment of the sections 
would follow the same protocol as for cytology specimens.
4.3.1.4 In situ Analysis of Frozen and Archival Tissue
Frozen sections are probably the most suitable type of preparation for assessing 
chromosome or gene copy number in situ as tissue will not have been placed in fixatives 
which can damage DNA (Williams et al, 1999). The limitation of frozen material is that 
long term storage may be problematic and the material is less easy to handle than 
formalin fixed and paraffin wax processed tissue. Stored archival material i.e. formalin 
fixed and paraffin wax processed tissue, is the most accessible, in terms of using tissue 
for further study. However, technically it is more difficult to work with archival tissue 
than cell spreads or imprints. Optimisation of the proteolytic digestion step is a 
prerequisite of the methodology. As discussed in Section 3.2.2, a compromise between 
optimal digestion and preservation of tissue architecture must be achieved.
The use of archival material, as thin sections, provides the greatest amount of 
information on ploidy using the technique of FISH, in a diagnostic setting. However, as 
outlined in more detail in Section 4.3.2, assessment of the sections requires careful
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evaluation, due to nuclear truncation artefact and there also needs to be strict quality 
control to ensure that accurate assessment of ploidy is achieved.
4.3.2 Evaluation Criteria
Hopman et al, (1988), used non-fluorescence in situ hybridisation (ISH) on 
interphase nuclei. These researchers outlined criteria for evaluation including avoidance 
of nuclear overlap, which would result in overestimation of the true copy number. The 
analysis of probe signal involved scoring spots of equal intensity, avoiding minor 
hybridisation signals, and if split spots (representing chromosomes about to enter “S” 
phase) very close together were seen again scoring these as one. All these criteria will 
bypass overestimation of copy number. Many researchers have produced papers using 
ISH and FISH since then, some referring to the criteria of Hopman et al, (1988), (for 
example, Cajulis et al, 1994). Others {e.g Sauter et al, 1995b and Pycha et al, 1997) refer 
to previous papers such as that of Waldman et al, (1991). The material used by all these 
researchers was whole nuclei, either as touch preparations (Waldman et al, 1991), 
barbotage specimens (Pycha et al, 1997) or dissociated nuclei (Hopman et al, 1988).
Once the definition of a true hybridisation signal is made, the number of nuclei to 
be assessed per tumour section must be determined. Two hundred to 500 nuclei were 
scored for each hybridisation and damaged and overlapping nuclei were ignored 
(Waldman et al, 1991). Variability remains in the number of nuclei assessed and in 
some studies the number is not specified (Misra et al, 1995). The exact number of 
nuclei that should be assessed per specimen will vary with the size of tumour.
Guidelines for accurate quantitation of copy number may include: initial 
evaluation of the whole tissue section, with reference to the haematoxylin and eosin 
stained tissue section, to identify tumour areas and avoid missing areas with different 
tumour pathology; distinct areas should be analysed and a minimum of 200 nuclei 
should give an accurate measure of copy number in a small biopsy. Larger tumours will 
require additional analysis of more nuclei to be representative of the specimen as a 
whole from different areas within the section. Previous studies within this laboratory 
(Bartlett et al, 1998, Watters et al, 1999) have shown that analysis of 200 to 600 nuclei 
(depending on section size) gives an accurate measure of copy number. Too few nuclei 
may miss a lesion but too many results in unnecessary analysis.
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4.3.3 D efinition o f  A neusom y
As discussed in Section 4.3.1, there are essentially two different types of cell 
preparations that have been used in the analysis of in situ experiments, either dissociated 
nuclei or intact tissue preparations, and the former preparation has been more widely 
used.
Assessment of chromosome copy number in dissociated nuclei, reflected the 
major (>50%) or dominant (20-50%) population present, if no aneusomic {i.e. other than 
2 copies/nucleus) subpopulation was present at >50% of the total, then the largest 
aneusomic population having >20% of total cells was used (Waldman et al, 1991). Thus 
a tumour was considered disomic if no other subpopulations had >20% of total cells. 
This is a cumbersome method of analysis and a simplified method would be preferable.
Variation in the cut off for aneusomy, from 5% (Cajulis et al, 1994) to 10% 
(Mahdy et al, 1999) to 20% (Waldman et al, 1991) has also been reported. Thus if 
between 5 and 20 nuclei per 100 were aneusomic this would give a diagnosis of 
aneusomy, depending on the study. The weakness with this type of analysis is that these 
preparations contain a mix of normal and abnormal cellular elements, and it may be 
necessary to assess many nuclei before an accurate genetic profile is achieved. As 
Figure 13 illustrates, an area is easily identified for analysis with an intact tissue section, 
but if the tissue section had been dissociated and analysed, at least 80% would be non­
tumour and may give a false result.
In previous studies of assessment of intact tissue sections, such as Pauletti and 
co-workers, (1996), 200 to 300 signals in randomly selected tumour nuclei were 
counted, less in cases of obvious gene amplification. Where the tumour can be 
identified unambiguously, assessment of as few as 100 or even 60 nuclei may be 
acceptable for an accurate genetic profile. In this study, two simple methods for 
assessment of aneusomy were developed. The first based on previous research (Bartlett 
et al, 1998, Watters et al, 2000) involved the summation of all signals observed then 
divided by the number of nuclei in a particular field, the mean chromosomal copy 
number (MCCN) or the mean gene copy number (MGCN). Established values reflecting 
normosomy were from 200 nuclei for both chromosome 8 and NAT2 over 10 control 
sections. Thus figures for loss or gain were defined taking into account the mean control 
values + 3 X SD i.e.99% confidence interval (Table 8). This was a stringent cut-off, but 
gave a robust method for accurate detection of genetic and chromosomal aberrations in
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situ in thin tissue sections. By following this method, confidence in the assessment of 
tumour sections in this study was afforded. In addition at least 200 nuclei were counted, 
from one area, and signals in up to 3 areas were counted where the material was plentiful 
i.e. to 600 nuclei were assessed.
Alternatively the mean NAT2:8 ratio was established and loss of NAT2 relative to 
chromosome 8 was defined. This was useful to detect losses of gene copy number, but 
information on polysomy or monosomy could not be derived. It was therefore necessary 
to take into account the copy number of chromosome and gene (Misra et al, 1995, 
Pauletti et al, 1996). The ratio of gene to chromosome copy number is also frequently 
used, {e.g. Pauletti et al, 1996).
In conclusion, unless the signals in a large number of nuclei in dissociated 
material are counted, the copy number may not be representative of the specimen being 
analysed. Assessing copy number in intact tissue sections avoids this problem, but the 
use of thin tissue sections requires analysis of normal copy number in several tissue 
sections to encompass variability in nuclear slicing.
4.3.4 Control Material
In this study, several tissue sections normosomic for chromosome 8 and NAT2 
were assessed before the tumour sections were analysed, and normosomic bladder tissue 
as controls were incorporated into each FISH run. Previously, researchers have reported 
using normal lymphocytes as controls for disomy (Sauter et al, a-d, 1995, Murphy et al, 
1995) or normal parenchyma from tumours to determine the background levels of 
trisomy and tetrasomy, (Corless et al, 1996). Correlation with other molecular biology 
methods was used to control for FISH reproducibility (Misra et al, 1995) but no direct 
reference to controls was made. The salient point in the use of control tissue is that a 
similar type should be used as the test. In that way conditions of pretreatment and 
hybridisation of material are standardised and a control is for the specificity of probe 
hybridisation only. This approach was used throughout this study and was a useful 
measure of technical reproducibility.
4.3.5 Quality Control
Eighty per cent of controls, to establish normal values, were dual scored, by 
observers from two different laboratories, as were 31% of tumours. This approach has 
previously been taken in this laboratory, (Bartlett et al, 1998, Watters et al, 2000). Good
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concordance of results meant that inter observer variation was established at <12%, 
which reflects a robust and reproducible technique.
4.3.6 Conclusion
In order for the molecular biology technique FISH to become part of a diagnostic 
service, clear and simple guidelines for assessment must be laid down, which must be 
unambiguous and reliable. The described method for analysis of the results in this study 
falls into these criteria and encompass the shortcomings of other methods previously 
reported.
4.4 Evaluation of TCCs
4.4.1 Range of Abnormalities Detected
Twenty of 37 TCCs were abnormal. Distinct patterns of abnormality were observed: 
normosomy 8 and loss of NÂT2, polysomy 8 and loss of NAT2 and polysomy 8 with 
retention of NAT2 copy number. These differing abnormalities are discussed in more 
detail as follows.
4.4.1.1 Normosomy 8 & Loss of NAT2
One TCC (from a non-recurrent patient) had this abnormality. This implies a 
loss of genes in the region 8p22, probably with loss of function of the retained copy 
indicative of a tumour suppressor gene (TSG) locus, which may play a role in the 
development of TCC (Knowles et al, 1993). Loss of heterozygosity (LOH) on 8p is 
frequent in many types of solid tumours, such as prostate, breast and bladder (Takle & 
Knowles, 1996). Several genes have been identified which could potentially act as 
tumour suppressor gene. The region of deletion at 8p21.3-p22 contains the MSR gene. 
Homozygous deletion of MSR (macrophage scavenger receptor gene) mapped to 8p22 
(MacGrogan et al, 1996) has been described in a metastatic prostate cancer sample 
(Takle & Knowles, 1996). The genes for the metabolic enzymes N-acetyItransferase 
{NATl and NAT2) have been mapped to 8p22 (Matas et al, 1997). The enzymes 
function to acetylate potential carcinogens. The increased incidence of slow acetylators 
who develop bladder cancer following occupational or smoking exposure (Cartwright et 
al, 1982, Risch et al, 1995) implies a loss of function of one of the alleles at this locus. 
However either MSR or NAT1/NAT2 are unlikely to be candidate tumour suppressor 
genes because of their specific functions that do not involve cell cycle regulation. They
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are most likely deleted through a mechanism such as méthylation silencing (MacGrogan 
et al, 1996)
A candidate tumour suppressor gene is homologous to an extracellular domain of 
the PDGF (platelet derived growth factor) receptor gene mapped to the region 8p21.3- 
22. PDGF-B is identical to the proto-oncogene protein Sis and controls the 'restriction 
point' in the cell cycle, at the GO or Gl/S transition (PDGF Home Page). Structural 
rearrangements and mutations have been found in a small number of tumours o f various 
types, although at lower frequency than would be expected on the known frequencies of 
8p LOH (Takle & Knowles, 1996).
Using 19 micro satellite markers on 8p, Ohagki, and co-workers, (1999) describe 
a common region of deletion which overlaps and narrows the 8p21.1-pter deletion 
described by Takle & Knowles (1996) in bladder cancer. Inactivation o f a tumour 
suppressor gene (s) at 8p22 is postulated to play an important carcinogenic role in 
prostate and other cancers including that of the urinary bladder, although the precise 
gene(s) have not been identified (Ohagki et al, 1999).
4.4.1.2 Polysemy 8 and Loss of NAT2
In the TCCs from two patients this abnormality was observed.This aberration 
suggests the formation of an isochromosome 8q, a common finding in many tumours 
including the bladder cancer cell line, RTl 12 (Stacey et al, 1999), whereby simultaneous 
8q gain occurs with 8p loss (Wagner et al, 1997). There may also be LOH occurring 
simultaneously as reports of 8p deletions and 8q gains are a frequent aberration in other 
tumours (Wagner et al, 1997). There has also been a suggestion that if a loss of 8p 
occurs, this then confers a selective advantage for whole chromosomal gain to occur in 
the following cell divisions (Sato et al, 1999).
4.4.1.3 Polysemy 8 with Retention of NAT2 Copy Number
The TCCs from ten patients had this abnormality. This implies duplication of 
chromosome 8 without major changes in NAT2, but in other regions on chromosome 8, 
such as amplification of c~myc or at the region 8pl2 (Wagner et al, 1997). Trisomy and 
polysomy 8 are associated with other carcinomas, including those of ovary, prostate and 
breast (Mark et al, 1997). Trisomy 8 was associated with higher stage disease in breast 
carcinoma and a gain of chromosome 8 was associated with systemic progression in 
prostate cancer (reviewed by Mark, et al, 1997). Chromosome 8 aberrations (losses and 
gains) are frequently observed in ovarian cancer, where it may be the lone abnormality, 
suggesting a role for abnormal chromosome 8 in carcinogenesis (Wolf et al, 1996).
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Aneusomy 8 is associated with an aggressive phenotype in bladder cancer (Knowles, et 
al 1993, Sauter et al, 1995c, Wagner et al, 1997), and in this study was more commonly 
observed in patients with muscle-invasive disease. This suggests that polysomy of 
chromosome 8, as observed in this study, is a later event in bladder carcinogenesis, 
possibly a marker of disease progression.
The oncogenes that might drive the process of polysomy in the absence of 
significant alteration of NAT2 copy number include c~myc at 8q24, and an as yet 
unidentified oncogene at 8ql2 both of which were associated with bladder cancer 
progression (Wagner et al, 1997).
4.4.1.4 Increase in Copy Number of Chromosome 8 and NAT2
Seven patients’ TCCs had this abnormality. This suggests that whole 
chromosomal duplication has occurred. Aberrations of chromosome 8 are common in 
many carcinomas and regions on both chromosome arms have been extensively mapped. 
Although the retention of NAT2 implies that the region 8p22 has not been lost, a deletion 
telomeric to this region may have occurred as 8p23.2 to 8p22 is thought to contain a 
tumour suppressor gene (Eydmann & Knowles, 1997).
4.4.1.5 Conclusion
Abnormalities of chromosome 8 and/or NAT2 were common in this group of 
tumours, although no losses of chromosome 8 copy number were observed. Complete 
chromosomal loss of 8 does not appear to be an aberration seen in epithelial derived 
tumours (Knowles et al, 1993, Sauter et al, 1995c).
4.4.2 Association of Stage & Grade with Genetic and Chromosomal
Aberrations
4.4.2.1 Polysomy 8
Nineteen of 37 tumours (51%) had polysomy 8 and this was associated with 
advanced stage (p=0.024) and grade (p=0.0056). Although the numbers are smaller, the 
results are similar to those of Sauter et al (1995c) who detected polysomy 8 in 41 of 87 
(47%) of bladder cancer cases, and this aberration was strongly associated with high 
stage and grade. Aneusomy is associated with a poorer prognosis as an accumulation of 
chromosomal aberrations leads to increased instability of the genome (Ried et al, 1999). 
Genes have been identified on chromosome 8 that may contribute to carcinogenesis and 
progression such as the oncogene myc located at 8q24 which was overexpressed in
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bladder tumours and associated with low grade bladder cancer (Sauter et al, 1995c). 
Gains at 8q24 were associated with higher stage bladder carcinomas by Wagner and co­
workers, (1997) by FISH which contradicts a previous study (Sauter et al, 1995c) by 
immunocytochemistry. The protein product of the myc oncogene when overexpressed, 
has been hypothesised to cause degradation of p27'"‘’’ leading to activation of 
cyclinE/cyclin dependent kinase 2 and cell proliferation (Sato et al, 1999). The 
amplification reported at 8pl2 has led to suggestions of a candidate oncogene on 8p, the 
heregulin gene coding for a ligand for the erbB2 oncogene and fibroblast factor 1 
(Wagner et al 1997).
In this study, the association of polysomy 8 with high stage and grade reflects 
previous research (Wagner et al, 1997 and Sato et al, 1999). Although there only 
appears to be two candidate regions for oncogenes, amplification at 8p24 and 8pl2 
(Wagner et al, 1997), 8p contains at least three regions of deletion, and at least two 
candidate tumour suppressor genes (Takle & Knowles, 1996) all o f which have the 
potential to exacerbate the propensity of a cell to become polysomic. Intriguingly, the 
region 8pl2 has been reported as amplified (Wagner et al, 1997) as well as deleted 
(Eydmann & Knowles, 1997), which may further confound the exact mechanisms 
whereby oncogenesis occurs.
In malignant cells, functional gain or loss of oncogenes and tumour suppressor 
genes is often mirrored by the acquisition of chromosomal aberrations (Ried et al, 1999). 
Thus, from previous studies, there would appear to be a confounding effect of polysomy 
possibly due to simultaneous loss of one region on chromosome 8 and gain of another, 
contributing to the increased stage and grade of tumours associated with this aberration, 
reflecting the results of this study.
4.4.2.2 Abnormalities 0ÎNAT2
Grade was associated with any abnormality of NAT2 (p=0.006) but not with 
stage in this study. A closer evaluation of the results, demonstrated that the pTa 
carcinomas had all lost the NAT2 gene whereas the pTl and pT2+ retained the gene with 
similar copy number to chiomosome 8. The grade 1 and 2 carcinomas had lost NAT2, 
the grade 3’s had retained NAT2.
Three different putative tumour suppressor regions on 8p have been localised to 
8p21.3-22 (Takle & Knowles, 1996) and at 8p23.2-22 (Eydmann & Knowles, 1997). 
The region 8p22 is a common region of deletion in many cancers including hepatic, 
colorectal and lung (Oghaki et al, 1999). The genes encoding the A-acetyltransferases
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(NATl and NATI) have been localised to 8p22 (Matas et al, 1997). Loss of 
heterozygosity (LOH) at 8p22 that encompasses the functional NAT  alleles will result in 
loss of function of these enzymes (Matas et al, 1997). Prostatic primary carcinomas 
show LOH at 8p22 in their métastasés (Oghaki et al, 1999). There has been a suggestion 
that the NAT2 genes are a marker for loss (Thygesen et al, 1999) as no other expressed 
sequences are known in this region.
NATl lies very close to NAT2 (Matas et al, 1997) in the region 8p22 and there is 
a strong possibility that not just NAT2 but both NATl and NAT2 genes will have been 
lost or retained (Thygesen et al, 1999). Where loss has occurred if both genes are 
involved, this may confer a selective advantage for bladder carcinomas to progress, as 
the functions of both NATl and 2 will have been lost. Although a low number of 
carcinomas showed loss of NAT2, 3 of 5 were in patients that had muscle-invasive 
disease at some point in their clinical history. NATl and NAT2 are polymorphic genes 
and vary in their ability to metabolise aromatic amines, potent carcinogens, as discussed 
in the introductory chapter and when lost may in part be responsible for the malignant 
potential of bladder cells. Immunohistochemical studies (Stanley et al, 1996) have 
demonstrated, using polyclonal antisera to NATl and NAT2, that NATl but not NAT2 
is expressed in the bladder and a diminution in NATl was detected in highly invasive 
tumours. There is thus a strong possibility that both enzymes are dysfunctional in the 
cases reported here and that this confers an increase in the potential for aromatic amines 
to be activated rather than detoxified.
4.4.2.3 Abnormalities of Chromosome 8 and AWT2
Fifty four percent (20/37) bladder carcinomas had abnormalities of either 
chromosome 8 or NAT2 or both chromosome and gene, and these were associated with 
high stage (p=0.03) and grade (p=0.01). The loss of NAT2 was more frequently seen in 
lower stage and grade carcinomas as discussed above, whereas a high copy number was 
observed with higher stage and grade. Sato and co-workers (1999) hypothesise in 
prostate cancer that accumulation of genetic aberrations occurs in 3 steps, first mutation 
or loss at 8p22, then whole chromosomal gain of chromosome 8, perhaps on the 
chromosome with a loss of 8p22 and thirdly 8q is gained, possibly as a result of 
isochromosome formation at 8q. Alternatively, the oncogene myc (at 8q24) may drive 
the process of progression. In pro static carcinoma, myc amplification was associated 
with poor prognosis, independently of other prognostic factors (Sato et al, 1999). From 
the results of this study, it would appear that loss of NAT2 occurs earlier than other
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aberrations in the development of bladder cancer thus supporting a previous report (Sato 
et al, 1999).
The gains observed in this study may represent whole chromosomal gain as they 
were always seen in tumours with polysomy 8, and the gene copy number reflected that 
of the chromosome. Two examples of tumours with similar NAT2 copy number to 
chromosome 8 are shown in Figure 21 D and E. These were observed in invasive (stage 
pT2 or above) tumours. This aberration, concomitant polysomy 8 with almost 
equivalent copy number of NAT2, was also reported by Stacey and co-workers (1999) 
using FISH to analyse copy number. These aberrations were more common in higher 
stage (pTl and pT2) tumours.
4.4.3 Aneusomy and Outcome
The NR patient with polysomy 8 was staged and graded as pTlG3, the remaining 
patients with polysomy 8 were muscle-invasive at presentation or developed this 
pathology. Two exceptions were the primary tumour from a patient (pTaGl) who had 
several recurrent non-invasive tumours, although this tumour did exhibit heterogeneity, 
known to be associated with an inherent genomic instability (Yokogi et al, 1996). This 
patient was normosomic for all subsequent events studied; one recurrent tumour from 
another patient in the RNP category was aneusomic for chromosome 8, although the 
copy number was at the low end of abnormal, with a mean copy number of 1.75.
Patients were followed through recurrence to progression and the copy number 
was compared to outcome. When assessing chromosome 8 or NAT2 by mean copy 
number, 8/9 (89%) of patients with muscle-invasive disease at presentation or who 
developed this pathology had aberrant gene and chromosome copy number, whereas 
only 4/10 (40%) of patients with non-invasive disease also had aberrations. There is an 
indication form these results that polysomy 8 may be a marker of progression. Sauter et 
al (1995c) observed that tumour cell proliferation, gain of c-myc copy number and 
polysomy of 7, 8 and 17 were strongly associated with a more aggressive phenotype, in 
his series of 87 tumours. The observation that patients with abnormal chromosome 
and/or gene copy number in their primary TCCs were predominantly from the group that 
progressed to muscle invasive disease (or had that phenotype at presentation) implies 
that these genetic aberrations are associated with an aggressive phenotype. This is
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largely in accordance with previous studies, (for example Knowles et al, 1993, Sauter et 
al, 1995c, Wagner et al, 1997).
4.4.4 Association with Other Chromosome Abnormalities
Previously alpha centromeric FISH probes for chromosomes commonly aberrant 
in TCC namely 1 ,9 , 10, 11 and 17 have been used to investigate abnormalities in some 
of the patients recruited into this study. Apart from the non-recurrer with normosomy of 
8 and loss of NAT2 (NR4) all the patients with abnormal %!NAT2 copy number had 
abnormalities of at least one other chromosome (Table 21). This is consistent with the 
genetic model for cancer progression discussed in Chapter I, whereby an accumulation 
of genetic aberrations is required to fully acquire a malignant phenotype. The high 
prevalence of abnormalities in patients in the RP and PP categories fits with the model 
proposed by Reznikoff and co-workers (1995), (Figure 6), whereby aberrations of 
chromosome 8 are associated with the later stages of bladder cancer progression.
4.4.5 Tumour Heterogeneity
Tumour heterogeneity was noted in 16.2% (6/37) of patient’s TCC events. This 
is a particular strength of an in situ technique, where different areas in one tissue seetion 
can be analysed, and as previously discussed, this characteristic cannot be detected in 
other molecular biology techniques such as flow cytometry and RFLP analysis. Of the 
six heterogeneous TCC’s, five were from patients with either muscle-invasive TCC at 
presentation or who subsequently developed this phenotype. Sauter et al, (1995d) 
demonstrated a high degree of aneusomy with heterogeneity and suggest that 
heterogeneity is a hallmark of genomic instability and that very heterogeneous tumours 
may represent an aggressive sub-type of bladder carcinoma. Yokogi et al (1996) also 
studied heterogeneity in bladder tumours and hypothesise that tumour heterogeneity 
could be a potential marker of progression as it was associated with a more aggressive 
phenotype.
4.4.6 Exposure to Carcinogenic Chemicals and Genetic Aberrations
Smoking is associated with slow NAT2 genotype, and 12/13 patients with 
smoking history in this study were smokers, associated with an increase risk of 
developing bladder cancer (Morrison et al, 1984, Sorlie et al, 1998). Risch et al, (1995),
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compared smokers versus non-smokers in the control and bladder cancer patients, and 
showed that nearly twice as many patients with bladder cancer and slow NAT2 genotype 
were smokers compared to non-smokers (Figure 9). In this study smokers were not 
associated with any particular clinical outcome, although previously an association with 
a more aggressive clinical course for bladder cancer has been made in smokers 
(reviewed by Landman & Droller. 1998). But this may be due to the small numbers 
included in this study.
No conclusion could be reached regarding occupational exposure and genetic 
aberrations as only one patient (a foreman painter) was in a high risk occupation for 
developing bladder cancer. This may reflect the geography of the region from which 
this patient cohort was selected, as industries such as dye factories have not been 
present, therefore there would be a smaller number of occupationally exposed bladder 
cancer patients as compared for example to previous research (Cartwright et al, 1982).
4.4.7 Conclusion
In the context of this study the results with FISH on archival sections of bladder 
carcinomas exemplifies the applicability of this approach to a diagnostic setting. No 
special procedure was involved in order for the fluorescence in situ hybridisation to be 
performed. The material was easily accessible from the pathology archives and as 
demonstrated even in this small patient cohort (n=19), a large amount of data was 
generated. This was related to pathological staging and grading and clinical disease 
course. Additionally, pathology could be directly related to FISH by carrying out the 
FISH in situ.
This study looked at the copy number of chromosome 8 and NAT2 in patients 
with clinical histories from those with non-recurrence following the primary TCC 
through to patients that recurred but did not develop muscle-invasive disease through to 
patients that did develop muscle-invasion and finally to those with muscle-invasion at 
presentation. A higher proportion of patients in the latter two categories had abnormal 
chromosome and/or gene copy number compared to those in the first two categories. 
Data from chromosome 8 in this study showed an association with polysomy and 
progression, the highest proportion of patients with this aberration had muscle-invasive 
disease. The high proportion of patients with aberrations of 8 and NAT2 (89%) with 
muscle invasion at presentation or who developed this aggressive phenotype strongly
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contrasts with only 40% from the two groups with non-invasive phenotype. This is in 
concordance with previous studies that have shown that deletions of 8p are more 
common in more advanced bladder cancer (Knowles et al, 1993, Wagner et al, 1997). 
The data from NAT2 also reflects the high proportion of LOH of 8p previously observed 
in patients with bladder cancer (Knowles et al, 1993).
The results of this study demonstrate that by studying the genetics of a disease 
entity, in this case TCC, by following a patient’s disease course over several years a 
substantial amount of clinically relevant data can be gathered. But it must be borne in 
mind that any test that challenges existing diagnostic methods, even as an adjunct, 
requires to be accurate and reproducible. Careful attention to quality control is essential 
and inter laboratory tests would need to be standardised. It would also be necessary to 
reproduce the results with large statistically significant numbers. However, in the future, 
for example, a radical cystectomy could be offered to a patient whose genetic profile on 
his primary carcinoma predicted progression, and we may not be many years away from 
a third arm to the diagnosis of TCC, in the form of molecular diagnostics.
An interesting review of genomic changes associated with progression from 
benign conditions such as a colorectal adenoma to adenocarcinoma was recently 
published (Ried et al, 1999). They brought together studies using comparative genomic 
hybridisation (CGH) to identify aberrations and associate them with tumour progression. 
This consolidates previous studies that have linked increasing aberrations with higher 
stage, more aggressive carcinomas and consequent poor prognosis. Specific aberrations 
are associated with initiation, such as loss of chromosome 9 in bladder cancer (Knowles, 
1995) and with progression such as gain of chromosome 13 in colorectal cancer (Ried et 
al, 1999). The specific changes associated with particular neoplasms warrant their 
translational application into diagnostics (Ried et al, 1999).
With regard to the results of this study, various aspects could be further 
investigated. The first is the link with polysomy 8 and progression. This could be done 
by recruiting more patients with complete follow-up, in the progressed groups and 
performing FISH with a probe for chromosome 8, possibly extending this to include a 
probe for 8q24. With respect to NAT2, it would be interesting to compare the results 
with NATl, and a probe has now been described (Stacey et al, 1999).
The region 8p is undoubtedly of interest in the progression of bladder cancer. 
Researchers such as Eydmann & Knowles, (1997) Oghaki and co-workers (1999) in
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mapping studies of chromosome 8 have identified areas that may contain tumour 
suppressor genes. This laboratory is currently recruiting more patients to expand the 
research into a link with progression and polysomy 8, with a probe for c-myc. Fine 
mapping of the 8pl2 region may begin to elucidate the area where the putative tumour 
suppressor lies.
In conclusion, the FISH technique is especially robust in a clinical setting and the 
presence or absence of specific genetic anomalies has the potential to predict the 
malignant potential of a carcinoma. In this context the emergence of molecular 
pathology as an additional diagnostic marker, together with clinical and pathological 
diagnoses becomes a realistic goal in patient management. Ultimately the contribution 
of a genetic profile can lead to refinement of treatments and improvement in survival.
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Appendix I: Patient Data
The table on the folowing page contains data obtained from patient notes, incorporated 
into the patient data
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